

GenCore version 5.1.6
 Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 1, 2004, 08:19:45 ; Search time 55 Seconds
 (without alignments)
 462.350 Million cell updates/sec

Title: US-09-989-293A-377
 Perfect score: 462
 Sequence: 1 MTFFLSLLLVLCEAIRSN.....DSRGLILGAEWGRGVKNT 90

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 206 summaries

Database : A_Geneseq_29Jan04:*

- 1: geneseqp1980s:*
- 2: geneseqp1990s:*
- 3: geneseqp2000s:*
- 4: geneseqp2001s:*
- 5: geneseqp2002s:*
- 6: geneseqp2003as:*
- 7: geneseqp2003bs:*
- 8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				Description	
Result No.	Score	Query Match	Length DB ID		
1	462	100.0	90	3	AAY66748 Membrane-
2	462	100.0	90	3	AB33469 Human PRO
3	462	100.0	90	4	AAU12408 Human PRO
4	462	100.0	90	4	AB50922 Human PRO
5	462	100.0	90	4	AB65271 Human PRO
6	462	100.0	90	6	ABU58086 Human PRO
7	462	100.0	90	6	ABU59164 Human PRO
8	462	100.0	90	6	ABU82676 Human PRO
9	462	100.0	90	6	ABU17852 Novel hum
10	462	100.0	90	6	ABU60595 Human PRO
11	462	100.0	90	6	ABU13977 Human PRO
12	462	100.0	90	6	ABU81106 Human PRO
13	462	100.0	90	6	ABU72562 Novel hum
14	462	100.0	90	6	ABU66806 Human PRO
15	462	100.0	90	6	ABU59887 Human PRO
16	462	100.0	90	6	ABU59887 Novel sec
17	462	100.0	90	6	ABU59311 Human PRO
18	462	100.0	90	6	ABO26008 Human PRO
19	462	100.0	90	6	ABO25077 Human PRO
20	462	100.0	90	6	ABU59017 Human PRO
21	462	100.0	90	6	ABU92395 Novel hum
22	462	100.0	90	6	ABU59460 Human PRO
23	462	100.0	90	6	ABU67082 Human PRO
24	462	100.0	90	6	ABU92226 Novel hum
25	462	100.0	90	6	ABU10932 Human PRO
	462	100.0	90	6	ABU81684 Novel hum

26	462	100.0	90	6	ABU88623 Human PRO
27	462	100.0	90	6	ABO34137 Human PRO
28	462	100.0	90	6	ADA45993 Novel hum
29	462	100.0	90	6	ADA76424 Human PRO
30	462	100.0	90	6	ADA19074 Human PRO
31	462	100.0	90	6	ADA61697 Homo sapi
32	462	100.0	90	6	ADB19482 Novel hum
33	462	100.0	90	6	ADB28023 Human PRO
34	462	100.0	90	6	ADA86502 Novel hum
35	462	100.0	90	6	ADB16066 Human PRO
36	462	100.0	90	6	ADA37888 Human PRO
37	462	100.0	90	6	ADA7852 Human PRO
38	462	100.0	90	6	ADA21574 Human PRO
39	462	100.0	90	6	ADA10361 Human PRO
40	462	100.0	90	6	ADA67647 Human PRO
41	462	100.0	90	6	ADB30654 Human PRO
42	462	100.0	90	6	ADA85950 Novel hum
43	462	100.0	90	6	ADA17905 Human PRO
44	462	100.0	90	6	ADA97162 Human PRO
45	462	100.0	90	6	ADA79466 Human PRO
46	462	100.0	90	6	ADA87605 Novel hum
47	462	100.0	90	6	ADB16807 Human PRO
48	462	100.0	90	6	ADA28013 Human PRO
49	462	100.0	90	6	ADA91899 Novel hum
50	462	100.0	90	6	ADB14962 Human PRO
51	462	100.0	90	6	ADB18923 Novel hum
52	462	100.0	90	6	ADA94138 Human PRO
53	462	100.0	90	6	ADB20034 Novel hum
54	462	100.0	90	6	ADB13346 Human PRO
55	462	100.0	90	6	ABO43385 Novel hum
56	462	100.0	90	6	ADA94593 Human PRO
57	462	100.0	90	6	ADA74600 Human PRO
58	462	100.0	90	6	ADB24833 Human PRO
59	462	100.0	90	6	ADA82357 Human PRO
60	462	100.0	90	6	ADA75320 Human PRO
61	462	100.0	90	6	ADA85398 Human PRO
62	462	100.0	90	6	ADA84846 Novel hum
63	462	100.0	90	6	ADB30102 Human PRO
64	462	100.0	90	6	ADA80630 Human PRO
65	462	100.0	90	6	ADA75872 Human PRO
66	462	100.0	90	6	ADA38818 Human PRO
67	462	100.0	90	6	ADA47097 Human PRO
68	462	100.0	90	6	ADB25393 Human PRO
69	462	100.0	90	6	ADA93569 Human PRO
70	462	100.0	90	6	ADB26919 Human PRO
71	462	100.0	90	6	ADB31206 Human PRO
72	462	100.0	90	6	ADA92939 Human PRO
73	462	100.0	90	6	ADA61134 Homo sapi
74	462	100.0	90	6	ADB24281 Human PRO
75	462	100.0	90	6	ADA96610 Human PRO
76	462	100.0	90	6	ADA81182 Human PRO
77	462	100.0	90	6	ADA96058 Human PRO
78	462	100.0	90	6	ADB26367 Human PRO
79	462	100.0	90	6	ADB21852 Novel hum
80	462	100.0	90	7	ADA77631 Human PRO
81	462	100.0	90	7	ADB18371 Human PRO
82	462	100.0	90	7	ADA87054 Novel hum
83	462	100.0	90	7	ADA88157 Human PRO
84	462	100.0	90	7	ADA46545 Novel hum
85	462	100.0	90	7	ADB28575 Human PRO
86	462	100.0	90	7	ADB29127 Human PRO
87	462	100.0	90	7	ABO53223 Human PRO
88	462	100.0	90	7	ADA77079 Human PRO
89	462	100.0	90	7	ADA22500 Human PRO
90	462	100.0	90	7	ADA88709 Novel hum
91	462	100.0	90	7	ADA97714 Human PRO
92	462	100.0	90	7	ADB27471 Human PRO
93	462	100.0	90	7	ADB22404 Novel hum
94	462	100.0	90	7	ABO22593 Human PRO
95	462	100.0	90	7	ADA06666 Human PRO
96	462	100.0	90	7	ADA39359 Human PRO
97	462	100.0	90	7	ADA67095 Human PRO
98	462	100.0	90	7	ADB22956 Human PRO

99	462	100.0	90	7	ADB23729	Human PRO	172	462	100.0	90	7	ADE22347	Human PRO
100	462	100.0	90	7	ADA92451	Novel hum	173	462	100.0	90	7	ADD79571	Human PRO
101	462	100.0	90	7	ADB15514	Human PRO	174	462	100.0	90	7	ADD42107	Human PRO
102	462	100.0	90	7	ADB38766	Novel hum	175	462	100.0	90	7	ADB17924	Human PRO
103	462	100.0	90	7	ADB96385	Human PRO	176	462	100.0	90	7	ADD92056	Human PRO
104	462	100.0	90	7	ADB38214	Novel hum	177	462	100.0	90	7	ADD93519	Novel hum
105	462	100.0	90	7	ADB66686	Novel hum	178	462	100.0	90	7	ADD34071	Novel hum
106	462	100.0	90	7	ADB89766	Human PRO	179	462	100.0	90	7	ADD80123	Human PRO
107	462	100.0	90	7	ADB90498	Human PRO	180	462	100.0	90	7	ADD93160	Human PRO
108	462	100.0	90	7	ADB39599	Human PRO	181	462	100.0	90	7	ADD19580	Human PRO
109	462	100.0	90	7	ADB47222	Novel hum	182	462	100.0	90	7	ADD19028	Human PRO
110	462	100.0	90	7	ADB86629	Human PRO	183	462	100.0	90	7	ADD96013	Human PRO
111	462	100.0	90	7	ADB77434	Novel hum	184	462	100.0	90	7	ADD96013	Human PRO
112	462	100.0	90	7	ADB34591	Human PRO	185	462	100.0	90	7	ADD96013	Human PRO
113	462	100.0	90	7	ADB35695	Human PRO	186	462	100.0	90	7	ADD96013	Human PRO
114	462	100.0	90	7	ADB34039	Human PRO	187	462	100.0	90	7	ADD96013	Human PRO
115	462	100.0	90	7	ADB35143	Human PRO	188	462	100.0	90	7	ADD96013	Human PRO
116	462	100.0	90	7	ADB36247	Human PRO	189	462	100.0	90	7	ADD96013	Human PRO
117	462	100.0	90	7	ADB46642	Novel hum	190	462	100.0	90	7	ADD96013	Human PRO
118	462	100.0	90	7	ADCS7857	Human PRO	191	462	100.0	90	7	ADD96013	Human PRO
119	462	100.0	90	7	ADCS5221	Human PRO	192	462	100.0	90	7	ADD96013	Human PRO
120	462	100.0	90	7	ADCS1208	Human sec	193	462	100.0	90	7	ADD96013	Human PRO
121	462	100.0	90	7	ADCS6510	Human PRO	194	462	100.0	90	7	ADD96013	Human PRO
122	462	100.0	90	7	ADCS07565	Human sec	195	462	100.0	90	7	ADD96013	Human PRO
123	462	100.0	90	7	ADCS11555	Human sec	196	462	100.0	90	7	ADD96013	Human PRO
124	462	100.0	90	7	ADCS0515	Novel hum	197	462	100.0	90	7	ADD96013	Human PRO
125	462	100.0	90	7	ADCS72062	Novel hum	198	462	100.0	90	7	ADD96013	Human PRO
126	462	100.0	90	7	ADCS6041	Novel hum	199	462	100.0	90	7	ADD96013	Human PRO
127	462	100.0	90	7	ADCS3048	Novel hum	200	462	100.0	90	7	ADD96013	Human PRO
128	462	100.0	90	7	ADCS7402	Novel hum	201	462	100.0	90	7	ADD96013	Human PRO
129	462	100.0	90	7	ADCS60593	Novel hum	202	462	100.0	90	7	ADD96013	Human PRO
130	462	100.0	90	7	ADCS1068	Novel hum	203	462	100.0	90	7	ADD96013	Human PRO
131	462	100.0	90	7	ADCS65595	Human PRO	204	462	100.0	90	7	ADD96013	Human PRO
132	462	100.0	90	7	ADCS4693	Novel hum	205	462	100.0	90	7	ADD96013	Human PRO
133	462	100.0	90	7	ADCS3654	Novel hum	206	462	100.0	90	7	ADD96013	Human PRO
134	462	100.0	90	7	ADCS59177	Novel hum							
135	462	100.0	90	7	ADCS9177	Novel hum							
136	462	100.0	90	7	ADCS6055	Novel hum							
137	462	100.0	90	7	ADCS58625	Novel hum							
138	462	100.0	90	7	ADCS14677	Novel hum							
139	462	100.0	90	7	ADCS08209	Novel hum							
140	462	100.0	90	7	ADCS03299	Novel hum							
141	462	100.0	90	7	ADCS02991	Novel hum							
142	462	100.0	90	7	ADCS2034	Human PRO							
143	462	100.0	90	7	ADCS69710	Human PRO							
144	462	100.0	90	7	ADCS48599	Human PRO							
145	462	100.0	90	7	ADCS10128	Human PRO							
146	462	100.0	90	7	ADCS07676	Novel hum							
147	462	100.0	90	7	ADCS04703	Novel hum							
148	462	100.0	90	7	ADCS2567	Human PRO							
149	462	100.0	90	7	ADCS0659	Human PRO							
150	462	100.0	90	7	ADCS11166	Human PRO							
151	462	100.0	90	7	ADCS48047	Human PRO							
152	462	100.0	90	7	ADCS08747	Novel hum							
153	462	100.0	90	7	ADCS0107	Novel hum							
154	462	100.0	90	7	ADCS06996	Novel hum							
155	462	100.0	90	7	ADCS09576	Human PRO							
156	462	100.0	90	7	ADCS83243	Human PRO							
157	462	100.0	90	7	ADCS41289	Novel hum							
158	462	100.0	90	7	ADCS52428	Human PRO							
159	462	100.0	90	7	ADCS5168	Human PRO							
160	462	100.0	90	7	ADCS3720	Novel hum							
161	462	100.0	90	7	ADCS5350	Human PRO							
162	462	100.0	90	7	ADCS6308	Human PRO							
163	462	100.0	90	7	ADCS1876	Human PRO							
164	462	100.0	90	7	ADCS02675	Human PRO							
165	462	100.0	90	7	ADCS02109	Human PRO							
166	462	100.0	90	7	ADCS4291	Novel hum							
167	462	100.0	90	7	ADCS4746	Human PRO							
168	462	100.0	90	7	ADCS2608	Human PRO							
169	462	100.0	90	7	ADCS1504	Human PRO							
170	462	100.0	90	7	ADCS04118	Human PRO							
171	462	100.0	90	7	ADCS26900	Novel hum							
					ADCS2415	Novel hum							

ALIGNMENTS

RESULT 1

AA66748 standard; protein; 90 AA.

XX AA66748;

AC AA66748;

XX AA66748;

DT 05-APR-2000 (first entry)

XX Membrane-bound protein PRO1159.

DE Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;

KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;

KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;

XX Homo sapiens.

OS Homo sapiens.

XX WO9963088-A2.

XX WO9963088-A2.

PD 09-DEC-1999.

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

XX 02-JUN-1999;

PR 05-JUN-1998; 98US-0088202P.
PR 08-JUN-1998; 98US-0088212P.
PR 09-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089601P.
PR 18-JUN-1998; 98US-0089607P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097210P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 16-SEP-1998; 98US-0098525P.
PR 12-JAN-1999; 99US-0115565P.
XX
PA (GETH) GENENTECH INC.
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX WPI; 2000-072883/06.
DR N-PSDB; AAZ65094.
XX
DR Membrane-bound proteins and related nucleotide sequences.
XX Claim 12; Fig 272; 822pp; English.
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors

CC of the relevant receptor/ligand interaction. The PRO encoding sequences
 CC are useful as hybridization probes, in chromosome and gene mapping and in
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will
 CC also be useful for the preparation of PRO polypeptides, especially by
 CC recombinant techniques

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 3; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDGRLLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDGRLLILGAEAWGRGVKNT 90

RESULT 2

AAB33469

ID AAB33469 standard; protein; 90 AA.

AC AAB33469;

XX 29-JAN-2001 (first entry)

XX Human PRO1159 protein UNQ589 SEQ ID NO:273.

XX Human; immune related disease; diagnosis; antiinflammatory; cardiant;
 KW dermatological; antiarthritic; antirheumatic; immunosuppressive;
 KW haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
 KW antianemic; hepatotropic; virucide; antiposrotic; antiallergic;
 KW antiaesthetic; systemic lupus erythematosus; rheumatoid arthritis;
 KW osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
 KW idiopathic inflammatory myopathy; Sjogren's syndrome thyroiditis;
 KW autoimmune thrombocytopaenia; immune-mediated renal disease;
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;
 KW inflammatory bowel disease; gluten-sensitive enteropathy;
 KW autoimmune disease; immune-mediated skin disease; allergic disease;
 KW immunological disease; transplantation associated disease;
 KW graft rejection; graft-versus-host-disease.

XX Homo sapiens.

XX WO200053758-A2.

XX 14-SEP-2000.

XX 02-MAR-2000; 2000WO-US0005841.

XX 08-MAR-1999; 99WO-US0005028.

XX 10-MAR-1999; 99US-0123618P.

XX 12-MAR-1999; 99US-0123957P.

XX 23-MAR-1999; 99US-0125775P.

XX 12-APR-1999; 99US-0128849P.

XX 20-APR-1999; 99WO-US0008615.

XX 28-APR-1999; 99US-0131445P.

XX 04-MAY-1999; 99US-0132371P.

XX 14-MAY-1999; 99US-0134287P.

XX 02-JUN-1999; 99WO-US012252.

XX 23-JUN-1999; 99US-0141037P.

XX 20-JUL-1999; 99US-0144758P.

XX 28-JUL-1999; 99US-0145698P.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.
 PR 29-OCT-1999; 99US-0162506P.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.

(GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;

PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;

PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Yan M;

XX WPI; 2000-572271/53.

DR N-PSDB; AAC58634.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Sixty four PRO polypeptides, useful in the diagnosis and treatment of
 immune related disorders, e.g. systemic lupus erythematosus, rheumatoid
 arthritis, osteoarthritis, thyroiditis and diabetes mellitus.

Claim 33; Fig 112; 309pp; English.

The present invention describes sixty four human PRO proteins which can
 be used in the treatment of immune related diseases. The human PRO
 proteins, anti-PRO antibodies, agonists and antagonists are useful for
 treating and diagnosing immune related disorders. The disorders are
 selected from systemic lupus erythematosus, rheumatoid arthritis,
 osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
 systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
 anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
 immune-mediated renal disease, demyelinating diseases, inflammatory
 peripheral nervous systems, hepatobiliary diseases, inflammatory bowel
 disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune
 diseases of the lung, and transplantation associated diseases including
 graft rejection and graft-versus-host-disease. AAC58397 to AAC58578
 represent PCR primers and hybridisation probes used in the isolation of
 human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477
 represent human PRO polynucleotide and protein sequences given in the
 exemplification of the present invention

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 3; Length 90;

Best Local Similarity 100.0%; Pred. No. 9,8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDGRLLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDGRLLILGAEAWGRGVKNT 90

RESULT 3

AAU12408

PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028565.
 PR 09-DEC-1999; 99US-0170262P.
 PR 20-DEC-1999; 99WO-US030911.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.

(GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski PJ;
 PI Gurney AL, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;
 PI Watanabe CK, Wood WI;
 XX
 DR WPI: 2001-025253/03.
 DR N-PSDB; AAC91481.
 XX

PT Thirty three nucleic acids encoding PRO polypeptides which are useful in
 PT the diagnosis and treatment of immune related disorders, e.g. systemic
 PT lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis
 PT and diabetes mellitus.

XX Claim 58; Fig 42; 218pp; English.

XX The present sequence is one of thirty three novel PRO polypeptides. The
 CC PRO polypeptides, anti-PRO antibodies, agonists and antagonists are
 CC useful for treating and diagnosing immune related disorders such as
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
 CC juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
 CC idiopathic inflammatory myopathies, Sjogren's syndrome, systemic
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 CC thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal
 CC disease, demyelinating diseases of the central and peripheral nervous
 CC systems (such as multiple sclerosis, idiopathic demyelinating
 CC polynuropathy or Guillain-Barre syndrome, and chronic inflammatory
 CC demyelinating polynuropathy), hepatobiliary diseases (such as
 CC infectious, autoimmune chronic active hepatitis, primary biliary
 CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis),
 CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's
 CC disease, autoimmune or immune-mediated skin diseases (such as bullous
 CC skin diseases, erythema multiforme, contact dermatitis, psoriasis),
 CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,
 CC food hypersensitivity and urticaria), immunological diseases of the lung
 CC (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and
 CC hypersensitivity pneumonitis), transplantation associated diseases
 CC including graft rejection and graft-versus-host diseases

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 4; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLVLCVIAWRSSGNTLNGYFLSKNKHNSQPTSSLEDSVTPTKAVKTT 60

DB 1 MTFPLSLLLVLCVIAWRSSGNTLNGYFLSKNKHNSQPTSSLEDSVTPTKAVKTT 60

QY 61 GKGVKGRNLDRLGILGAZAWGRGVKNT 90

Db 61 GKGVKGRNLDRLGILGAZAWGRGVKNT 90

RESULT 5

AAAB65271
 ID AAB65271 standard; protein; 90 AA.

AC AAB65271;

XX 02-APR-2001 (first entry)

XX Human PRO1159 (UNQ589) protein sequence SEQ ID NO:377.

XX Human; secreted and transmembrane protein; PRO; cytostatic; cell death;
 KW cancer; chromosomal mapping; gene mapping; tissue typing;
 KW diagnostic assay.

XX Homo sapiens.

XX WO2000073454-A1.

XX 07-DEC-2000.

XX 30-MAR-2000; 2000WO-US008439.

XX 02-JUN-1999; 99WO-US012252.

XX 23-JUN-1999; 99US-0141037P.

XX 07-JUL-1999; 99US-0143048P.

XX 20-JUL-1999; 99US-0144758P.

XX 26-JUL-1999; 99US-0145698P.

XX 28-JUL-1999; 99US-0146222P.

XX 17-AUG-1999; 99US-0149396P.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 08-OCT-1999; 99US-0158663P.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028301.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 22-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005841.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Denoyers L, Eaton DL;
 Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 Grimaldi CJ, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
 Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 Zhang Z;

WPI: 2001-032169/04.

N-PSDB; AAF44240.

PRO polynucleotides used to produce polypeptides used to target bioactive
 molecules such as toxins, radiolabels or antibodies, to specific cells,
 to cause targeted cell death.

Claim 12; Fig 272; 935pp; English.

The present invention describes human secreted and transmembrane PRO
 proteins. The PRO proteins have cytostatic activity. The PRO proteins can
 be used for targeted delivery of bioactive molecules, such as toxins,
 radiolabels or antibodies, that cause cell death. PRO nucleotide
 sequences, and their fragments, can be used as hybridisation probes, in

CC chromosomal and gene mapping, and in the generation of anti-sense RNA and
CC DNA. They may also be used to produce transgenic animals which are used
CC to develop and screen therapeutically useful reagents. The PRO nucleotide
CC and protein sequence can be used for tissue typing and in treating
CC cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to
CC AAF44470 represent PCR primers and hybridisation probes used in the
CC isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to
CC AAB65300 represent human PRO polynucleotide and protein sequences given
CC in the exemplification of the present invention
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 4; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRKNHNSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 6

ABU58086
ID ABU58086 standard; protein; 90 AA.

XX AC ABU58086;

XX DT 14-APR-2003 (first entry)

XX DE Human PRO polypeptide #118.

XX KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
XX horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
XX antibody-dependent enzyme mediated prodrug therapy.

OS Homo sapiens.

XX US2003027163-A1.

XX PD 06-FEB-2003.

XX PF 15-NOV-2001; 2001US-00997666.
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 27-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 22-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 01-JUL-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.

```
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0098949P.
PR 18-AUG-1998; 98US-0098950P.
PR 18-AUG-1998; 98US-0098959P.
PR 18-AUG-1998; 98US-0098960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098523P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 01-OCT-1998; 98US-0100858P.
PR 01-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 02-DEC-1998; 98US-0100858P.
PR 05-JAN-1999; 98US-0100858P.
PR 08-MAR-1999; 98US-0100858P.
PR 12-MAR-1999; 98US-0100858P.
PR 02-JUN-1999; 98US-0100858P.
PR 23-JUN-1999; 98US-0100858P.
PR 07-JUL-1999; 98US-0100858P.
PR 20-JUL-1999; 98US-0100858P.
PR 26-JUL-1999; 98US-0100858P.
PR 28-JUL-1999; 98US-0100858P.
PR 17-AUG-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 08-OCT-1999; 98US-0100858P.
PR 30-NOV-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 16-DEC-1999; 98US-0100858P.
PR 20-DEC-1999; 98US-0100858P.
PR 05-JAN-2000; 98US-0100858P.
PR 06-JAN-2000; 98US-0100858P.
PR 11-FEB-2000; 98US-0100858P.
PR 18-FEB-2000; 98US-0100858P.
PR 22-FEB-2000; 98US-0100858P.
PR 24-FEB-2000; 98US-0100858P.
PR 24-FEB-2000; 98US-0100858P.
PR 10-MAR-2000; 98US-0100858P.
PR 12-MAR-2000; 98US-0100858P.
PR 15-MAR-2000; 98US-0100858P.
PR 20-MAR-2000; 98US-0100858P.
PR 30-MAR-2000; 98US-0100858P.
PR 15-MAY-2000; 98US-0100858P.
PR 17-MAY-2000; 98US-0100858P.
PR 22-MAY-2000; 98US-0100858P.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023522.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKNHNSOPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKNHNSOPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIYKGRNLDLSRGLILGAEAWGRGVKNT 90
Db 61 GKGIYKGRNLDLSRGLILGAEAWGRGVKNT 90

RESULT 7
ABU59164
ID ABU59164 standard; protein; 90 AA.
XX
AC ABU59164;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO1159.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
FN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00990442.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
```


KW cardiac insufficiency disorders; angiogenesis; wound healing;
KW cancerous tumour; immune response; retinal disorder; sight loss;
KW retinitis pigmentosa; age-related macular degeneration; AMD;
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;
KW Crohn's disease; sports injury; arthritis.
OS Homo sapiens.
XX
XX US2003032023-A1.
XX
XX 13-FEB-2003.
XX
XX 14-NOV-2001; 2001US-00990711.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US02006P.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088214P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088734P.
XX 10-JUN-1998; 98US-0088739P.
XX 10-JUN-1998; 98US-0088742P.
XX 10-JUN-1998; 98US-0088810P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088858P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089440P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089532P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089599P.
XX 17-JUN-1998; 98US-0089600P.
XX 17-JUN-1998; 98US-0089603P.
XX 18-JUN-1998; 98US-0089801P.
XX 18-JUN-1998; 98US-0089907P.
XX 19-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089947P.
XX 19-JUN-1998; 98US-0089948P.
XX 19-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 23-JUN-1998; 98US-0090349P.
XX 23-JUN-1998; 98US-0090355P.
XX 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.

PR 16-SEP-1998; 98WO-0100634P.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-0100858P.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 01-DEC-1998; 98WO-US025108.
 PR 22-DEC-1998; 98WO-0113296P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 12-MAR-1999; 99US-0123957P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 23-JUN-1999; 99US-0141037P.
 PR 07-JUL-1999; 99US-0143048P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 28-JUL-1999; 99US-0146222P.
 PR 17-AUG-1999; 99US-0149396P.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 08-OCT-1999; 99US-0158663P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 15-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLLVEATWRSNGSGNTLENGYFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60
 Db |||||||
 QY 1 MTFPLSLLLLLVEATWRSNGSGNTLENGYFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60
 Db |||||||
 QY 61 GKGIKGRNLDLSGLILGAAGRGVKNT 90
 Db 61 GKGIKGRNLDLSGLILGAAGRGVKNT 90

RESULT 9
 AB017852
 ID AB017852 standard; protein; 90 AA.
 AC AB017852;

XX DT 26-AUG-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
 KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
 KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
 KW TNF-alpha release; cell proliferation; cell differentiation;

KW gene expression modulator; proteoglycan release; cytokine release;
 KW tumour; inflammatory disease; organ failure; atherosclerosis;
 KW cardiac injury; infertility; birth defect; premature aging; AIDS;
 KW acquired immunodeficiency syndrome; cancer; diabetic complication;
 KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
 KW bioreactor; tissue typing.

XX Homo sapiens.

OS US2003032156-A1.

XX 13-FEB-2003.

XX 06-MAY-2002; 2002US-00140474.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 14-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 23-NOV-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US031243.

PR 05-JAN-2000; 2000WO-US031274.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006319.

PR 20-MAR-2000; 2000WO-US006884.

PR 21-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US007532.

PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US030873.
PR 10-NOV-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX

(GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-341980/32.

N-PSDB; ACD24089.

XX New secreted and transmembrane PRO nucleic acids, for treating

PT inflammation, organ failure, atherosclerosis, cardiac injury,

PT infertility, birth defects, premature aging, acquired immunodeficiency

PT syndrome (AIDS), or cancer.

XX

PS Claim 12; Fig 474; 660pp; English.

XX

CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate the
CC uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression.
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIa, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,

CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLVCEAIRWSNCSNTLENGYFLSRNKNHSQPTQSLEDVPTTAVKTT 60

Db 1 MTFFLSLLLVCEAIRWSNCSNTLENGYFLSRNKNHSQPTQSLEDVPTTAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 10

ABU60595

ID ABU60595 standard; protein; 90 AA.

XX AC ABU60595;

DT 01-MAY-2003 (first entry)

XX DE Human secreted/transmembrane protein, #154.

XX KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;

XX KM diagnostic; therapeutic; gene therapy.

XX OS Homo sapiens.

XX PN US2002160384-A1.

XX PD 31-OCT-2002.

XX PF 14-NOV-2001; 2001US-00925598.

XX PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 13-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.


```
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 10-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 16-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006684.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX XX
XX (GETH ) GENENTECH INC.
PI Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AJ, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX XX
```

WPI; 2003-288106/28.
N-P8DB; ABX90341.
New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes.
Claim 12; Fig 272; 650pp; English.
The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and the isolated nucleic acids may be used for recombinantly expressing those markers. The PRO polypeptides and nucleic acids may also be used in tissue typing. Anti-PRO antibodies are useful in diagnostic assays for PRO, and in affinity purification of PRO from recombinant cell culture or natural sources. The sequences presented in ABU60478-ABU60624 are the PRO polynucleotides of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKKN 90
DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKKN 90

RESULT 11
ABU13977
ID ABU13977 standard; protein; 90 AA.
XX AC ABU13977;
XX 26-FEB-2003 (first entry)
XX Human PRO1159 polypeptide.
XX Human; PRO polypeptide; secreted protein; transmembrane protein;
XX genetic disorder; antibacterial; immunosuppressive.
XX Homo sapiens.
XX US2002103125-A1.
XX 01-AUG-2002.
XX 20-NOV-2001; 2001US-00989731.
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089601P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH) GENENTECH LTD.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2003-102117/09.
DR N-PSDB; ABX64187.
XX Novel secreted and transmembrane polypeptide for modulating biological
PI activity of cell expressing the polypeptide, identifying agonists or
PI antagonists of polypeptide, and as molecular weight markers.
XX Claim 12; Fig 272; 649pp; English.
PS The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. ABU13860-
CC ABU14006 represent the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/paipsdEntry.html
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHSHSQTSLSLEDSVPTKAVKTT 60
|||
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHSHSQTSLSLEDSVPTKAVKTT 60
|||
QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKXNT 90
|||
DB 61 GKGIVKGRNLDRLGILGAEAWGRGVKXNT 90
|||
RESULT 12
ABU81106
ID ABU81106 standard; protein; 90 AA.
XX AC ABU81106;
XX DT 23-JUN-2003 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO polypeptide; secreted and transmembrane protein;

KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
 KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
 KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
 KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;
 KW antidiabetic; anorectic; vulnerability; antiarthritic; osteopathic;
 KW antirheumatic; auditory; cerebroprotective; angiogenic.
 XX Homo sapiens.
 XX US2003004311-A1.
 XX 02-JAN-2003.
 XX 19-DEC-2001; 2001US-00028072.
 XX 18-JUN-1997; 97US-0049911P.
 XX 26-AUG-1997; 97US-0056974P.
 XX 17-SEP-1997; 97US-0059113P.
 XX 17-SEP-1997; 97US-0059115P.
 XX 17-SEP-1997; 97US-0059117P.
 XX 17-SEP-1997; 97US-0059122P.
 XX 17-SEP-1997; 97US-0059184P.
 XX 18-SEP-1997; 97US-0059263P.
 XX 18-SEP-1997; 97US-0059352P.
 XX 19-SEP-1997; 97US-0059588P.
 XX 19-SEP-1997; 97US-0059836P.
 XX 17-OCT-1997; 97US-0062250P.
 XX 17-OCT-1997; 97US-0062285P.
 XX 17-OCT-1997; 97US-0062287P.
 XX 17-OCT-1997; 97US-0063755P.
 XX 24-OCT-1997; 97US-0062814P.
 XX 24-OCT-1997; 97US-0063045P.
 XX 24-OCT-1997; 97US-0063082P.
 XX 24-OCT-1997; 97US-0063127P.
 XX 27-OCT-1997; 97US-0063327P.
 XX 27-OCT-1997; 97US-0063329P.
 XX 28-OCT-1997; 97US-0063550P.
 XX 28-OCT-1997; 97US-0063561P.
 XX 29-OCT-1997; 97US-0063704P.
 XX 29-OCT-1997; 97US-0063733P.
 XX 29-OCT-1997; 97US-0063735P.
 XX 29-OCT-1997; 97US-0063738P.
 XX 03-NOV-1997; 97US-0064248P.
 XX 07-NOV-1997; 97US-0064809P.
 XX 12-NOV-1997; 97US-0065186P.
 XX 17-NOV-1997; 97US-0065846P.
 XX 21-NOV-1997; 97US-0066364P.
 XX 24-NOV-1997; 97US-0066453P.
 XX 24-NOV-1997; 97US-0066511P.
 XX 24-NOV-1997; 97US-0066770P.
 XX 11-DEC-1997; 97US-0069212P.
 XX 11-DEC-1997; 97US-0069278P.
 XX 11-DEC-1997; 97US-0069334P.
 XX 16-DEC-1997; 97US-0069694P.
 XX 23-JAN-1998; 98US-0072320P.
 XX 04-FEB-1998; 98US-0073612P.
 XX 09-FEB-1998; 98US-0074086P.
 XX 09-FEB-1998; 98US-0074092P.
 XX 12-MAR-1998; 98US-0077791P.
 XX 20-MAR-1998; 98US-0078910P.
 XX 25-MAR-1998; 98US-0079294P.
 XX 27-MAR-1998; 98US-0079663P.
 XX 27-MAR-1998; 98US-0079728P.
 XX 31-MAR-1998; 98US-0080165P.
 XX 12-JUN-1998; 98WO-US012456.
 XX 14-JUL-1998; 98WO-US014552.
 XX 28-AUG-1998; 98WO-US017888.
 XX 10-SEP-1998; 98WO-US018824.
 XX 14-SEP-1998; 98WO-US019093.
 XX 14-SEP-1998; 98WO-US019094.
 XX 14-SEP-1998; 98WO-US019177.
 XX 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 16-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforke L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-352836/33.
 DR N-PSDB; ACA67230.
 XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid
 PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
 PT heart attack.
 XX Claim 12; Fig 474; 643pp; English.
 XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the treatment of diabetes, bone and/or cartilage disorders
 CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
 CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
 CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
 CC assays for PRO, by detecting its expression in specific cells, tissues or
 CC serum, and for affinity purification of PRO from recombinant cell culture
 CC or natural sources. ABU08070-ABU81144 represent the human PRO
 CC polypeptides of the invention. Note: The sequence data for this patent
 CC was obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipsDIDEntry.html
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGSLTLENGYFLSRKNKHSQPTQSLSLDSVPTTKAVKTT 60
 |||||
 Db 1 MTFFLSLLLLVCEAIWRNSGSLTLENGYFLSRKNKHSQPTQSLSLDSVPTTKAVKTT 60
 |||||

QY 61 GKGIYKGRNLDGRGLILGAEAWGRGVKKNT 90
 |||||
 Db 61 GKGIYKGRNLDGRGLILGAEAWGRGVKKNT 90
 |||||

RESULT 13

ABU72562

ID ABU72562 standard; protein; 90 AA.

XX AC ABU72562;

DT 17-JUN-2003 (first entry)

XX DE

XX Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; cytostatic; anti-HIV;

KW virucide; hepatotropic; antiinflammatory; neuroprotective; Gene therapy;

KW PRO; pharmaceutical; diagnostic; biosensor; bioindicator; malignancy;

KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;

KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;

KW drug screening.

XX OS Homo sapiens.

XX US2003003531-A1.

XX PD 02-JAN-2003.

XX PF 19-NOV-2001; 2001US-00989734.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 13-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087759P.

PR 02-JUN-1998; 98US-0087827P.

PR 03-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 10-JUN-1998; 98US-0088858P.

PR 10-JUN-1998; 98US-0088861P.

PR 10-JUN-1998; 98US-0088876P.

PR 10-JUN-1998; 98US-00889105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 16-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089588P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 02-JUN-1999; 99WO-US012252.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 02-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US008439.

PR 15-MAY-2000; 2000WO-US013358.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 01-DEC-2000; 2000WO-US032678.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-JUN-2001; 2001WO-US017800.

PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.

PR 03-JUL-2001; 2001WO-US021735.

PR 28-AUG-2001; 2001US-00941992.

XX (GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DL;

XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Kljavin LJ, Napier MA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;

XX Zhang Z;

XX WPI; 2003-352829/33.

DR N-PSDB; ACA64409.

XX New genes and secreted and transmembrane polypeptides (e.g. PRO183 or

PT

PT PRO184}, useful for treating or diagnosing e.g. ovarian cancer, Kaposi's
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's
PT disease.

XX PS Claim 12; Fig 272; 663pp; English.

XX CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,
CC 209439, 203335, etc); or a sequence with at least 80% identity to a DNA
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These
CC are particularly useful for detecting or treating e.g. malignancies or
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's
CC disease in mammals. The PRO polypeptides are useful in drug screening,
CC particularly as targets for therapeutic intervention in these diseases,
CC and in the diagnostic determination of the presence of these diseases.
CC The PRO polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQPTQSSLEDVPTPKAVKIT 60
Db 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNKHSQPTQSSLEDVPTPKAVKIT 60
Qy 61 KGKIVKGRNLSRGLILGAEWGRGVKKNT 90
Db 61 KGKIVKGRNLSRGLILGAEWGRGVKKNT 90

RESULT 14
ABU66806
ID ABU66806 standard; protein; 90 AA.

XX AC ABU66806;

XX DT 23-MAY-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic.

XX OS Homo sapiens.

XX PN US2003036180-A1.

XX PD 20-FEB-2003.

XX PF 09-MAY-2002; 2002US-00143114.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854288.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00862636.
 PR 19-JUN-2001; 2001US-00863342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-332040/31.
 DR N-PSDB; ACA03839.
 XX
 PT New secreted and transmembrane PRO nucleic acids, useful for gene
 PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
 PT typing, and in chromosome identification.
 XX
 PS Claim 12; Fig 474; 660pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for linking
 CC bioactive molecules to cells expressing PRO polypeptides, for modulating
 CC biological activities of cells expressing PRO polypeptides, and for
 CC identifying agonists or antagonists. The PRO polypeptides are useful for
 CC for stimulating the release of tumour necrosis factor (TNF)-alpha from
 CC human blood, for stimulating the proliferation or differentiation of
 CC chondrocytes, and detecting the presence of tumours. The polynucleotide
 CC sequences encoding PRO polypeptides are useful as hybridisation probes,
 CC in chromosome and gene mapping, in the generation of antisense RNA and
 CC DNA, in the preparation of PRO polypeptides, for generating transgenic
 CC animals or knockout animals, for the genetic analysis of individuals with
 CC genetic disorders, and in gene therapy. ABU6570-ABU6684 represent the
 CC human PRO polypeptides of the invention. Note: The sequence data for this
 CC patent was obtained in electronic format directly from the USPTO web site
 CC at seqdata.uspto.gov/psipdIDEntry.html
 XX
 SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLILLIVCAIRWSNGSNTLNGYFLSRNKENHSOPTQSSLEDSVTPTKVKT 60
 Db 1 MTFPLSLILLIVCAIRWSNGSNTLNGYFLSRNKENHSOPTQSSLEDSVTPTKVKT 60
 QY 61 KGKIVKGRNLDRLGILGAEMWGRGVKNT 90
 Db 61 KGKIVKGRNLDRLGILGAEMWGRGVKNT 90
 RESULT 15
 ABUS9887
 ID ABUS9887 standard; protein; 90 AA.
 XX
 AC ABUS9887;
 XX
 DT 13-MAY-2003 (first entry)
 XX

DE Novel secreted and transmembrane protein PRO1159.
 XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disease;
 KW mammalian kidney mesangial cell proliferation; Crohn's disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis.
 XX Homo sapiens.
 OS
 XX US2003017563-A1.
 PN
 XX 23-JAN-2003.
 PD
 XX 07-MAY-2002; 2002US-00140808.
 PF
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 17-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98WO-US019437.
 PR 29-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 20-NOV-1998; 98WO-US022992.
 PR 01-DEC-1998; 98WO-US024855.
 PR 05-JAN-1999; 98WO-US025108.
 PR 08-MAR-1999; 98WO-US025106.
 PR 10-MAR-1999; 99WO-US005028.
 PR 20-APR-1999; 99WO-US005190.
 PR 14-MAY-1999; 99WO-US008615.
 PR 02-JUN-1999; 99WO-US010733.
 PR 01-SEP-1999; 99WO-US012252.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 05-OCT-1999; 99WO-US021547.
 PR 29-NOV-1999; 99WO-US023089.
 PR 30-NOV-1999; 99WO-US028214.
 PR 01-DEC-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 20-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 22-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 03-JAN-2000; 99WO-US031274.
 PR 06-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US0063119.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-148238/14.
XX N-PSDB; ABX89377.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.

XX Claim 12; Fig 474; 659pp; English.

XX The invention describes an isolated human PRO polypeptide. The PRO
XX polypeptides are useful in detecting PRO polypeptides in a sample, in
XX linking a bioactive molecule to a cell expressing a PRO polypeptide, and
XX in modulating at least one biological activity of a cell expressing a PRO
XX polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
XX useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
XX stimulate adrenal cortical capillary endothelial growth, and PRO536,
XX PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
XX PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
XX useful for treating conditions or disorders where angiogenesis would be

CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein

XX Sequence 90 AA;

XX Query Match 100.0%; Score 462; DB 6; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTTKAVKTT 60
Db 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTTKAVKTT 60
Qy 61 GKGIKGRNLDRLGLILGAEGRGVKKNT 90
Db 61 GKGIKGRNLDRLGLILGAEGRGVKKNT 90

RESULT 16

ABUS9311
ID ABUS9311 standard; protein; 90 AA.
XX AC ABUS9311;
XX XX
XX 22-APR-2003 (first entry)
XX Human secreted/transmembrane protein, #154.
XX Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
XX biosensor; bioeffector; tumour; therapeutic; gene therapy;
XX tumour-associated antigenic target; TAT; ADEPT;
XX antibody-dependent enzyme mediated prodrug therapy; cytostatic.

XX Homo sapiens.

XX US2003027162-A1.

XX 06-FEB-2003.

XX 15-NOV-2001; 2001US-00997428.

XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087108P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088022P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088328P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 16-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 26-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.

PR	22-FEB-2000;	2000WO-US004414.	PR	04-JUN-1998;	98US-0088030P.
PR	24-FEB-2000;	2000WO-US004914.	PR	04-JUN-1998;	98US-0088033P.
PR	02-MAR-2000;	2000WO-US005004.	PR	05-JUN-1998;	98US-0088126P.
PR	10-MAR-2000;	2000WO-US005841.	PR	05-JUN-1998;	98US-0088202P.
PR	15-MAR-2000;	2000WO-US006319.	PR	05-JUN-1998;	98US-0088212P.
PR	20-MAR-2000;	2000WO-US006884.	PR	05-JUN-1998;	98US-0088217P.
PR	30-MAR-2000;	2000WO-US007377.	PR	09-JUN-1998;	98US-0088655P.
PR	15-MAY-2000;	2000WO-US013358.	PR	10-JUN-1998;	98US-0088734P.
PR	17-MAY-2000;	2000WO-US013705.	PR	10-JUN-1998;	98US-0088738P.
PR	22-MAY-2000;	2000WO-US014042.	PR	10-JUN-1998;	98US-0088742P.
PR	30-MAY-2000;	2000WO-US014941.	PR	10-JUN-1998;	98US-0088810P.
PR	02-JUN-2000;	2000WO-US015264.	PR	10-JUN-1998;	98US-0088824P.
PR	23-JUN-2000;	2000US-0213637P.	PR	10-JUN-1998;	98US-0088836P.
PR	28-JUL-2000;	2000WO-US020710.	PR	11-JUN-1998;	98US-0088858P.
PR	11-AUG-2000;	2000WO-US022031.	PR	11-JUN-1998;	98US-0088861P.
PR	23-AUG-2000;	2000WO-US023522.	PR	11-JUN-1998;	98US-0088876P.
PR	24-AUG-2000;	2000WO-US023328.	PR	12-JUN-1998;	98US-0089105P.
			PR	16-JUN-1998;	98US-0089440P.
			PR	16-JUN-1998;	98US-0089512P.
			PR	16-JUN-1998;	98US-0089514P.
			PR	17-JUN-1998;	98US-0089532P.
			PR	17-JUN-1998;	98US-0089538P.
			PR	17-JUN-1998;	98US-0089598P.
			PR	17-JUN-1998;	98US-0089599P.
			PR	17-JUN-1998;	98US-0089600P.
			PR	17-JUN-1998;	98US-0089653P.
			PR	18-JUN-1998;	98US-0089801P.
			PR	18-JUN-1998;	98US-0089907P.
			PR	18-JUN-1998;	98US-0089908P.
			PR	16-SEP-1998;	98WO-US019330.
			PR	17-SEP-1998;	98WO-US019437.
			PR	07-OCT-1998;	98WO-US021141.
			PR	01-DEC-1998;	98WO-US025108.
			PR	05-JAN-1999;	99WO-US000106.
			PR	08-MAR-1999;	99WO-US005028.
			PR	02-JUN-1999;	99WO-US012252.
			PR	15-SEP-1999;	99WO-US021090.
			PR	15-SEP-1999;	99WO-US021547.
			PR	30-NOV-1999;	99WO-US028313.
			PR	01-DEC-1999;	99WO-US028634.
			PR	16-DEC-1999;	99WO-US030095.
			PR	20-DEC-1999;	99WO-US030911.
			PR	06-JAN-2000;	2000WO-US000219.
			PR	06-JAN-2000;	2000WO-US000376.
			PR	11-FEB-2000;	2000WO-US003565.
			PR	18-FEB-2000;	2000WO-US004341.
			PR	22-FEB-2000;	2000WO-US004414.
			PR	24-FEB-2000;	2000WO-US004914.
			PR	24-FEB-2000;	2000WO-US005004.
			PR	02-MAR-2000;	2000WO-US005841.
			PR	10-MAR-2000;	2000WO-US006319.
			PR	15-MAR-2000;	2000WO-US006884.
			PR	20-MAR-2000;	2000WO-US007377.
			PR	30-MAR-2000;	2000WO-US008439.
			PR	15-MAY-2000;	2000WO-US013358.
			PR	17-MAY-2000;	2000WO-US013705.
			PR	22-MAY-2000;	2000WO-US014042.
			PR	30-MAY-2000;	2000WO-US014941.
			PR	02-JUN-2000;	2000WO-US015264.
			PR	28-JUL-2000;	2000WO-US020710.
			PR	11-AUG-2000;	2000WO-US022031.
			PR	23-AUG-2000;	2000WO-US023522.
			PR	24-AUG-2000;	2000WO-US023328.
			PR	01-DEC-2000;	2000WO-US032678.
			PR	28-FEB-2001;	2001WO-US006520.
			PR	01-JUN-2001;	2001WO-US017800.
			PR	20-JUN-2001;	2001WO-US019692.
			PR	29-JUL-2001;	2001WO-US021066.
			PR	09-JUL-2001;	2001WO-US021735.
			PR	28-AUG-2001;	2001US-00941992.

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSVTPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDGRLGLGAEAMGRGVKKNT 90
 Db 61 GKGIVKGRNLDGRLGLGAEAMGRGVKKNT 90

RESULT 17
 ABO26008
 ID ABO26008 standard; protein; 90 AA.
 XX
 AC ABO26008;
 XX
 DT 10-SEP-2003 (first entry)
 XX
 DE Human PRO1159 polypeptide.
 XX
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW genetic disorder; antibacterial; immunosuppressive.
 XX
 OS Homo sapiens.
 XX
 XX US2002127576-A1.
 XX
 PD 12-SEP-2002.
 XX
 XX 14-NOV-2001; 2001US-00991073.
 XX
 XX 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-US020069.
 PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

XX PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;

XX PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;

XX PI Zhang Z;

XX WPI: 2003-340824/32.

XX N-PSDB; ACD44377.

XX Novel isolated PRO polypeptides e.g., PROB26, PRO1184, PRO1346

XX and PRO1375, which stimulate proliferation of stimulated T-lymphocytes

XX and are therapeutically useful for enhancing immune responses.

XX Claim 12; Fig 272; 661pp; English.

XX The present invention relates to the isolation of novel human PRO

XX polypeptides, and the polynucleotide sequences encoding them. The PRO

XX polypeptides are secreted and transmembrane proteins. The PRO

XX polypeptides are useful for detecting other PRO polypeptides, for linking

XX bioactive molecules to cells expressing PRO polypeptides, for modulating

XX biological activities of cells expressing PRO polypeptides, and for for

XX identifying agonists or antagonists. The polynucleotide sequences

XX encoding PRO polypeptides are useful as hybridisation probes, in

XX chromosome and gene mapping, in the generation of antisense RNA and DNA,

XX in the preparation of PRO polypeptides, for generating transgenic animals

XX or knockout animals, to construct hybridisation probes for mapping the

XX gene which encodes the PRO polypeptide, and for the genetic analysis of

XX individuals with genetic disorders, in gene therapy, for chromosome

XX identification, as chromosome markers, and for generating probes for PCR,

XX Northern analysis, Southern analysis and Western analysis. ABO25891-

XX ABO26037 represent the human PRO polypeptides of the invention. Note: The

XX sequence data for this patent was obtained in electronic format directly

XX from the USPTO web site at seqdata.uspto.gov/psipd1Entry.html

XX Sequence 90 AA;

XX

XX Query Match 100.0%; Score 462; DB 6; Length 90;

XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;

XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSVTPTKAVKIT 60

Db 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSVTPTKAVKIT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 18

ABO25077

ID ABO25077 standard; protein; 90 AA.

AC ABO25077;

XX ABO25077;

XX

DT 05-SEP-2003 (first entry)

XX

XX Human secreted/transmembrane protein (PRO) #237.

XX

XX Human; PRO; secreted protein; transmembrane protein; tumour; cytostatic;

XX gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;

XX proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;

XX PBMC; Glucose uptake; FFA; skeletal muscle cell; adipocyte cell;

XX chondrocyte cell proliferation; chondrocyte cell differentiation;

XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell; A-peptide; factor VIIA.

XX

XX Homo sapiens.

XX

XX US2003036179-A1.

XX PD 20-FEB-2003.

XX

XX 10-MAY-2002; 2002US-00142431.

XX

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 25-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 18-FEB-2000; 2000WO-US004342.

XX 22-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005746.

XX 02-MAR-2000; 2000WO-US005841.

XX 10-MAR-2000; 2000WO-US006319.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX 30-MAY-2000; 2000WO-US014941.

XX 02-JUN-2000; 2000WO-US015264.

XX 28-JUL-2000; 2000WO-US020710.

XX 11-AUG-2000; 2000WO-US022031.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 08-NOV-2000; 2000WO-US030952.

XX 10-NOV-2000; 2000WO-US030873.

Wed Jun 2 08:28:01 2004

01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00742959.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854280.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
23-MAY-2001; 2001US-00866028.
23-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-466355/44.

N-PSDB; ACD42031.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 12; Fig 474; 659pp; English.

The invention relates to an isolated nucleic acid comprising at least 80%
sequence identity to a PRO (secreted and transmembrane protein) cDNA
comprising a nucleic acid (a) encoding a PRO polypeptide, or its
extracellular domain (with or without its associated signal peptide),
which comprises any of the 275 120-850 residue amino acid sequences,
given in the specification; (b) comprising any of the 275 300-3500
nucleotide sequences, given in the specification; or (c) comprising the
full-length coding sequence of the nucleotide sequences given in the
specification, or of the DNA deposited under any of the American Type
Culture Collection (ATCC) Accession Numbers listed in the specification.
Also included are a vector comprising the novel nucleic acid, a host cell
comprising the vector, producing a PRO polypeptide, the isolated PRO
polypeptides detailed above, a chimeric molecule comprising the PRO
polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
antibody, detecting a PRO polypeptide in a sample suspected of containing
the PRO polypeptide, linking a bioactive molecule to a cell expressing a
PRO polypeptide, modulating at least one biological activity of a cell
expressing a PRO polypeptide, stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
modulating the uptake of glucose or FFA by skeletal muscle cells or
adipocyte cells, stimulating the proliferation or differentiation of
chondrocyte cells (or proliferation of or gene expression in pericyte
cells), stimulating the proliferation of inner ear utricular supporting
cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
binding of A-peptide to factor VIIA, or differentiation of adipocyte

cells, detecting the presence of a tumour in a mammal and an
oligonucleotide probe derived from any of the nucleotide sequences given
in the specification. The polynucleotide is useful in molecular biology,
including uses as hybridisation probes, in chromosome and gene mapping,
in generating antisense RNA and DNA, and in gene therapy. The
polynucleotide may also be used in preparing PRO polypeptides by
recombinant techniques, and in generating either transgenic animals or
knock-out animals which, in turn, are useful in the development and
screening of therapeutically useful reagents. The PRO polypeptide or the
antibody is used in preparing a medicament for treating a condition
responsive to the polypeptide or antibody, such as tumours, and in
various diagnostic assays. The present sequence represents a PRO
polypeptide

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60
Qy 61 KGIVKGRNLDLSRLILGAEAWGKVKNT 90
Db 61 KGIVKGRNLDLSRLILGAEAWGKVKNT 90

RESULT 19

ABUS9017
ID ABUS9017 standard; protein; 90 AA.
XX AC ABUS9017;
XX DT 16-APR-2003 (first entry)
XX DE Human secreted/transmembrane protein, #154.

Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
diagnostic; biosensor; bio-reactor; tumour; therapeutic; colon cancer;
lung cancer; breast cancer; cancer; gene therapy.

Homo sapiens.

US2002142961-A1.

03-OCT-2002.

19-NOV-2001; 2001US-00989721.

16-JUN-1997; 97US-0049787P.

17-OCT-1997; 97US-0062250P.

05-NOV-1997; 97WO-US020069.

12-NOV-1997; 97US-0065186P.

13-NOV-1997; 97US-0065311P.

24-NOV-1997; 97US-0066770P.

25-FEB-1998; 98US-0075945P.

20-MAR-1998; 98US-0078910P.

28-APR-1998; 98US-0083322P.

07-MAY-1998; 98US-0084600P.

28-MAY-1998; 98US-0087106P.

02-JUN-1998; 98US-0087609P.

02-JUN-1998; 98US-0087759P.

03-JUN-1998; 98US-0087827P.

04-JUN-1998; 98US-0088021P.

04-JUN-1998; 98US-0088025P.

04-JUN-1998; 98US-0088026P.

04-JUN-1998; 98US-0088028P.

04-JUN-1998; 98US-0088029P.

04-JUN-1998; 98US-0088030P.

04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088739P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 12-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089908P.
PR 18-JUN-1998; 98US-0090193P.
PR 16-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 07-OCT-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 05-JAN-1999; 98WO-US005028.
PR 08-MAR-1999; 98WO-US012252.
PR 02-JUN-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 15-SEP-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 16-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 2000WO-US000219.
PR 05-JAN-2000; 2000WO-US000376.
PR 06-JAN-2000; 2000WO-US003565.
PR 11-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004414.
PR 22-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX XX (GETH) GENENTECH INC.

XX ASHENAZI AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrata N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;
PI Zhang Z;
DR WPI; 2003-155950/15.
XX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX
XX Claim 12; Fig 272; 647pp; English.
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABUS6900-ABUS9046 are the PRO polypeptides of the invention
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
RESULT 20
ABUS2395
ID ABUS2395 standard; protein; 90 AA.
XX
XX AC ABUS2395;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;
KW PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;
KW PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;
KW radiolabel; antibody; cell death; tissue typing; gene therapy;
KW cytosolic; chromosome mapping; gene mapping; transgenic animal;
KW knockout animal; immunohistochemical staining.
XX
XX Homo sapiens.
XX
XX US2003022187-A1.
XX
XX 30-JAN-2003.
XX
XX 14-NOV-2001; 2001US-00993667.
XX
XX

PR	16-JUN-1997;	97JUS-0049787P;
PR	17-OCT-1997;	97JUS-0622500P;
PR	02-NOV-1997;	97NOV-0502006P;
PR	03-NOV-1997;	97JUS-0065186P;
PR	13-NOV-1997;	97JUS-0065311P;
PR	24-NOV-1997;	97JUS-0066770P;
PR	28-FEB-1998;	98JUS-0075945P;
PR	20-MAR-1998;	98JUS-0078910P;
PR	28-APR-1998;	98JUS-0083322P;
PR	07-MAY-1998;	98JUS-0084500P;
PR	02-JUN-1998;	98JUS-0087106P;
PR	02-JUN-1998;	98JUS-0087607P;
PR	02-JUN-1998;	98JUS-0087609P;
PR	02-JUN-1998;	98JUS-0087759P;
PR	03-JUN-1998;	98JUS-0087827P;
PR	04-JUN-1998;	98JUS-0088021P;
PR	04-JUN-1998;	98JUS-0088025P;
PR	04-JUN-1998;	98JUS-0088026P;
PR	04-JUN-1998;	98JUS-0088028P;
PR	04-JUN-1998;	98JUS-0088030P;
PR	04-JUN-1998;	98JUS-0088033P;
PR	04-JUN-1998;	98JUS-0088326P;
PR	04-JUN-1998;	98JUS-0088367P;
PR	05-JUN-1998;	98JUS-0088402P;
PR	05-JUN-1998;	98JUS-0088412P;
PR	05-JUN-1998;	98JUS-0088421P;
PR	09-JUN-1998;	98JUS-0088455P;
PR	09-JUN-1998;	98JUS-0088734P;
PR	10-JUN-1998;	98JUS-0088738P;
PR	10-JUN-1998;	98JUS-0088742P;
PR	10-JUN-1998;	98JUS-0088810P;
PR	10-JUN-1998;	98JUS-0088824P;
PR	10-JUN-1998;	98JUS-0088826P;
PR	11-JUN-1998;	98JUS-0088858P;
PR	11-JUN-1998;	98JUS-0088861P;
PR	11-JUN-1998;	98JUS-0088876P;
PR	11-JUN-1998;	98JUS-0089105P;
PR	12-JUN-1998;	98JUS-0089440P;
PR	16-JUN-1998;	98JUS-0089512P;
PR	16-JUN-1998;	98JUS-0089514P;
PR	17-JUN-1998;	98JUS-0089532P;
PR	17-JUN-1998;	98JUS-0089536P;
PR	17-JUN-1998;	98JUS-0089598P;
PR	17-JUN-1998;	98JUS-0089599P;
PR	17-JUN-1998;	98JUS-0089600P;
PR	17-JUN-1998;	98JUS-0089603P;
PR	17-JUN-1998;	98JUS-00896801P;
PR	18-JUN-1998;	98JUS-0089907P;
PR	18-JUN-1998;	98JUS-0089908P;
PR	19-JUN-1998;	98JUS-0089947P;
PR	19-JUN-1998;	98JUS-0089948P;
PR	19-JUN-1998;	98JUS-0089952P;
PR	22-JUN-1998;	98JUS-0090246P;
PR	22-JUN-1998;	98JUS-0090252P;
PR	22-JUN-1998;	98JUS-0090254P;
PR	22-JUN-1998;	98JUS-0090282P;
PR	23-JUN-1998;	98JUS-0090343P;
PR	23-JUN-1998;	98JUS-0090355P;
PR	24-JUN-1998;	98JUS-0090431P;
PR	24-JUN-1998;	98JUS-0090444P;
PR	24-JUN-1998;	98JUS-0090445P;
PR	24-JUN-1998;	98JUS-0090472P;
PR	24-JUN-1998;	98JUS-0090535P;
PR	24-JUN-1998;	98JUS-0090540P;
PR	24-JUN-1998;	98JUS-0090557P;
PR	24-JUN-1998;	98JUS-0090676P;
PR	25-JUN-1998;	98JUS-0090678P;
PR	25-JUN-1998;	98JUS-0090690P;
PR	25-JUN-1998;	98JUS-0090694P;

```
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLIVCBIRWSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFPLSLLLIVCBIRWSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 21
ABUS9460
ID ABUS9460 standard; protein; 90 AA.
XX
AC ABUS9460;
XX
DT 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO1124.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disease;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
FN US2003027985-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990562.

XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 28-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088033P.
XX 04-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088734P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088742P.
XX 10-JUN-1998; 98US-0088810P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088858P.
XX 11-JUN-1998; 98US-0088861P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089440P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089532P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089599P.
XX 17-JUN-1998; 98US-0089600P.
XX 17-JUN-1998; 98US-0089653P.
XX 18-JUN-1998; 98US-0089801P.
XX 18-JUN-1998; 98US-0089907P.
XX 18-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089947P.
XX 19-JUN-1998; 98US-0089948P.
XX 19-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 23-JUN-1998; 98US-0090349P.
XX 23-JUN-1998; 98US-0090355P.
XX 24-JUN-1998; 98US-0090429P.
XX 24-JUN-1998; 98US-0090431P.
XX 24-JUN-1998; 98US-0090435P.
XX 24-JUN-1998; 98US-0090444P.
XX 24-JUN-1998; 98US-0090445P.
XX 24-JUN-1998; 98US-0090472P.
XX 24-JUN-1998; 98US-0090535P.
XX 24-JUN-1998; 98US-0090540P.
XX 24-JUN-1998; 98US-0090542P.
XX 24-JUN-1998; 98US-0090557P.
XX 25-JUN-1998; 98US-0090676P.
XX 25-JUN-1998; 98US-0090678P.
XX 25-JUN-1998; 98US-0090690P.
XX 25-JUN-1998; 98US-0090694P.
```

PR	25-JUN-1998;	98US-0090695P.	PR	20-JUL-1999;	99US-0144758P.
PR	25-JUN-1998;	98US-0090696P.	PR	26-JUL-1999;	99US-0145698P.
PR	26-JUN-1998;	98US-0090862P.	PR	28-JUL-1999;	99US-0146222P.
PR	26-JUN-1998;	98US-0090863P.	PR	17-AUG-1999;	99US-0149396P.
PR	01-JUL-1998;	98US-0091360P.	PR	15-SEP-1999;	99WO-US021090.
PR	01-JUL-1998;	98US-0091544P.	PR	18-SEP-1999;	99WO-US021547.
PR	02-JUL-1998;	98US-0091478P.	PR	08-OCT-1999;	99US-0158663P.
PR	02-JUL-1998;	98US-0091519P.	PR	30-NOV-1999;	99WO-US028313.
PR	02-JUL-1998;	98US-0091626P.	PR	01-DEC-1999;	99WO-US028301.
PR	02-JUL-1998;	98US-0091628P.	PR	16-DEC-1999;	99WO-US030095.
PR	02-JUL-1998;	98US-0091633P.	PR	20-DEC-1999;	99WO-US030911.
PR	02-JUL-1998;	98US-0091646P.	PR	05-JAN-2000;	2000WO-US000219.
PR	02-JUL-1998;	98US-0091673P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-JUL-1998;	98US-0091978P.	PR	11-FEB-2000;	2000WO-US003565.
PR	07-JUL-1998;	98US-0091982P.	PR	18-FEB-2000;	2000WO-US004341.
PR	09-JUL-1998;	98US-0092182P.	PR	22-FEB-2000;	2000WO-US004414.
PR	10-JUL-1998;	98US-0092472P.	PR	24-FEB-2000;	2000WO-US004914.
PR	20-JUL-1998;	98US-0093339P.	PR	24-FEB-2000;	2000WO-US005004.
PR	30-JUL-1998;	98US-0094651P.	PR	02-MAR-2000;	2000WO-US005841.
PR	04-AUG-1998;	98US-0095282P.	PR	10-MAR-2000;	2000WO-US006319.
PR	04-AUG-1998;	98US-0095285P.	PR	15-MAR-2000;	2000WO-US006884.
PR	04-AUG-1998;	98US-0095301P.	PR	20-MAR-2000;	2000WO-US007377.
PR	04-AUG-1998;	98US-0095302P.	PR	30-MAR-2000;	2000WO-US008439.
PR	04-AUG-1998;	98US-0095318P.	PR	15-MAY-2000;	2000WO-US013358.
PR	04-AUG-1998;	98US-0095321P.	PR	17-MAY-2000;	2000WO-US013705.
PR	10-AUG-1998;	98US-0095916P.	PR	22-MAY-2000;	2000WO-US014042.
PR	10-AUG-1998;	98US-0095929P.	PR	30-MAY-2000;	2000WO-US014941.
PR	10-AUG-1998;	98US-0096012P.	Query Match 100.0%; Score 462; DB 6; Length 90;		
PR	11-AUG-1998;	98US-0096143P.	Best Local Similarity 100.0%; Pred. No. 9.8e-49;		
PR	11-AUG-1998;	98US-0096146P.	Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
PR	12-AUG-1998;	98US-0096329P.	QY	1	MTFFLSLLILLVCEAIWRSNCGSSNTLENGYFLSRNKENHSGPTOSSLEDSVTPTKAVKTT 60
PR	17-AUG-1998;	98US-0096757P.	Db	1	MTFFLSLLILLVCEAIWRSNCGSSNTLENGYFLSRNKENHSGPTOSSLEDSVTPTKAVKTT 60
PR	17-AUG-1998;	98US-0096766P.	QY	61	KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90
PR	17-AUG-1998;	98US-0096768P.	Db	61	KGKIVKGRNLDNRGLILGAEAWGRGVKNT 90
PR	17-AUG-1998;	98US-0096773P.	RESULT 22		
PR	17-AUG-1998;	98US-0096791P.	ABU67082		
PR	17-AUG-1998;	98US-0096867P.	ID	ABU67082 standard; protein; 90 AA.	
PR	17-AUG-1998;	98US-0096891P.	XX	AC ABU67082;	
PR	17-AUG-1998;	98US-0096894P.	XX	DT 27-MAY-2003 (first entry)	
PR	17-AUG-1998;	98US-0096895P.	XX	DE Human secreted/transmembrane, PRO, protein SEQ ID 474.	
PR	17-AUG-1998;	98US-0096897P.	XX	KW Human; secreted protein; transmembrane protein; PRO;	
PR	18-AUG-1998;	98US-0096949P.	KW	inflammatory disease; organ failure; atherosclerosis; cardiac injury;	
PR	18-AUG-1998;	98US-0096950P.	KW	infertility; birth defects; premature aging; AIDS; biosensor;	
PR	18-AUG-1998;	98US-0096959P.	KW	acquired immunodeficiency syndrome; cancer; diabetic complication;	
PR	18-AUG-1998;	98US-0096960P.	XX	bioreactor; tumour.	
PR	18-AUG-1998;	98US-0097022P.	OS	Homo sapiens.	
PR	19-AUG-1998;	98US-0097141P.	XX	PN US2003032155-A1.	
PR	20-AUG-1998;	98US-0097218P.	XX	PD 13-FEB-2003.	
PR	24-AUG-1998;	98US-0097661P.	XX	PF 03-MAY-2002; 2002US-00137865.	
PR	26-AUG-1998;	98US-0097952P.	XX	PR 31-MAR-1997; 97WO-US005230.	
PR	26-AUG-1998;	98US-0097954P.	PR	12-JUN-1998; 98WO-US012456.	
PR	26-AUG-1998;	98US-0097955P.	PR	14-JUL-1998; 98WO-US014552.	
PR	26-AUG-1998;	98US-0097971P.	PR	28-AUG-1998; 98WO-US017888.	
PR	26-AUG-1998;	98US-0097974P.	PR	10-SEP-1998; 98WO-US018824.	
PR	26-AUG-1998;	98US-0097978P.	PR	14-SEP-1998; 98WO-US019093.	
PR	26-AUG-1998;	98US-0097979P.	PR	14-SEP-1998; 98WO-US019094.	
PR	26-AUG-1998;	98US-0097986P.			
PR	26-AUG-1998;	98US-0098014P.			
PR	31-AUG-1998;	98US-0098525P.			
PR	16-SEP-1998;	98US-0100634P.			
PR	16-SEP-1998;	98WO-US019330.			
PR	17-SEP-1998;	98US-0100858P.			
PR	17-SEP-1998;	98WO-US019437.			
PR	07-OCT-1998;	98WO-US021141.			
PR	01-DEC-1998;	98WO-US025108.			
PR	22-DEC-1998;	98US-0113296P.			
PR	05-JAN-1999;	99WO-US000106.			
PR	08-MAR-1999;	99WO-US005028.			
PR	12-MAR-1999;	99US-0123957P.			
PR	02-JUN-1999;	99WO-US012252.			
PR	23-JUN-1999;	99US-0141037P.			
PR	07-JUL-1999;	99US-0143048P.			

PR 14-SEP-1998; 98WO-US0191177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 27-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 30-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US000208.
 PR 10-MAR-1999; 98WO-US000519.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028401.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 03-JAN-2000; 98WO-US031274.
 PR 08-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US047259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001US-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 16-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-331925/31.
 DR N-PSDB; ACA04260.
 XX New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.
 XX Claim 12; Fig 474; 659pp; English.
 PS The invention relates to an isolated nucleic acid comprising, or which is
 CC at least 80% identical to, or the full-length coding sequence of, any of
 CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
 CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
 CC comprises the full-length coding sequence of the DNA deposited under
 CC American Type Culture Collection (ATCC) accession number in a list given
 CC in the specification. Also included are vectors and host cells for
 CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
 CC extracellular domains and mature sequences, methods of detecting PRO
 CC proteins, methods for stimulating the release of TNF-alpha (tumour
 CC necrosis factor alpha) from human blood, (and the proliferation of, or gene
 CC expression in pericyte cells, the release or proteoglycans from
 CC cartilage, proliferation of inner ear utricular supporting cells, the
 CC proliferation of T-lymphocyte cells, the release of a cytokine from
 CC peripheral blood mononuclear cells (PBMC), or the proliferation of
 CC endothelial cells), a method for modulating the uptake of glucose or free
 CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
 CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
 CC cells, a method for detecting the presence of a tumour in a mammal and an
 CC oligonucleotide probe derived from any of the nucleotide sequences cited
 CC above. The nucleic acids and polypeptides are useful for treating
 CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
 CC infertility, birth defects, premature aging, AIDS (acquired
 CC immunodeficiency syndrome), cancer, or diabetic complications. The
 CC nucleic acids are useful as hybridisation probes, in chromosome and gene
 CC mapping, and in generating antisense RNA or DNA. The polypeptides are
 CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
 CC are useful in tissue typing. The present sequence represents a PRO
 CC protein of the invention
 XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. NO. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MTFFLSLLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT	60
Db	1	MTFFLSLLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT	60
Qy	61	GKGIVGKRNLDLDRGLILGAEWGRGVKKNT	90
Db	61	GKGIVGKRNLDLDRGLILGAEWGRGVKKNT	90
RESULT 23			
ABU92226	ID	ABU92226 standard; protein; 90 AA.	
XX	AC	ABU92226;	
XX	DT	16-JUN-2003 (first entry)	
XX	XX	Novel human secreted and transmembrane protein PRO1159.	
XX	KW	Human; secreted and transmembrane protein; PRO; nootropic;	
XX	KW	neuroprotective; antiparkinsonian; cytotstatic; gene therapy;	
XX	KW	chromosome mapping; gene mapping; transgenic animal; knock-out animal;	
XX	KW	neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.	
OS	OS	Homo sapiens.	
XX	XX	US2003017476-A1.	
XX	XX	23-JAN-2003.	
XX	XX	20-NOV-2001; 2001US-00989724.	
XX	XX	16-JUN-1997; 97US-0049787P.	
PR	PR	17-OCT-1997; 97US-0062250P.	
PR	PR	05-NOV-1997; 97WO-US020069.	
PR	PR	12-NOV-1997; 97US-0065186P.	
PR	PR	13-NOV-1997; 97US-0065311P.	
PR	PR	24-NOV-1997; 97US-0066770P.	
PR	PR	25-FEB-1998; 98US-0075945P.	
PR	PR	20-MAR-1998; 98US-0078910P.	
PR	PR	28-APR-1998; 98US-0083322P.	
PR	PR	07-MAY-1998; 98US-0084600P.	
PR	PR	28-MAY-1998; 98US-0087106P.	
PR	PR	02-JUN-1998; 98US-0087607P.	
PR	PR	02-JUN-1998; 98US-0087609P.	
PR	PR	02-JUN-1998; 98US-0087759P.	
PR	PR	02-JUN-1998; 98US-0087827P.	
PR	PR	04-JUN-1998; 98US-0088021P.	
PR	PR	04-JUN-1998; 98US-0088025P.	
PR	PR	04-JUN-1998; 98US-0088026P.	
PR	PR	04-JUN-1998; 98US-0088028P.	
PR	PR	04-JUN-1998; 98US-0088029P.	
PR	PR	04-JUN-1998; 98US-0088030P.	
PR	PR	04-JUN-1998; 98US-0088033P.	
PR	PR	04-JUN-1998; 98US-0088326P.	
PR	PR	05-JUN-1998; 98US-0088167P.	
PR	PR	05-JUN-1998; 98US-0088202P.	
PR	PR	05-JUN-1998; 98US-0088212P.	
PR	PR	05-JUN-1998; 98US-0088217P.	
PR	PR	09-JUN-1998; 98US-0088655P.	
PR	PR	10-JUN-1998; 98US-0088734P.	
PR	PR	10-JUN-1998; 98US-0088738P.	
PR	PR	10-JUN-1998; 98US-0088742P.	
PR	PR	10-JUN-1998; 98US-0088810P.	
PR	PR	10-JUN-1998; 98US-0088824P.	
PR	PR	10-JUN-1998; 98US-0088826P.	
PR	PR	11-JUN-1998; 98US-0088858P.	
PR	PR	11-JUN-1998; 98US-0088861P.	
PR	PR	11-JUN-1998; 98US-0088876P.	
PR	PR	12-JUN-1998; 98US-0089105P.	
PR	PR	16-JUN-1998; 98US-0089440P.	
PR	PR	16-JUN-1998; 98US-0089512P.	
PR	PR	16-JUN-1998; 98US-0089514P.	

PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149386P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000376.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000WO-US0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MTFLLSLLLVCFAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDVPTKAVKTT 60
1 MTFLLSLLLVCFAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDVPTKAVKTT 60

QY 61 GKGIYKGRNLDNRGLILGAEAWGRGVKXNT 90
DB 61 GKGIYKGRNLDNRGLILGAEAWGRGVKXNT 90
RESULT 24
ABU10932
ID ABU10932 standard; protein; 90 AA.
XX AC ABU10932;
XX DT 04-FEB-2003 (first entry)
XX DE Human PRO polypeptide #118.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;
KW radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
antibacterial.
XX OS Homo sapiens.
XX US2002123463-A1.
XX PD 05-SEP-2002.
XX PF 19-NOV-2001; 2001US-00989732.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004414.
PR 22-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.

(GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;

XX WPI: 2003-066810/06.
DR N-PSDB; ABX17151.

XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.

XX Claim 12; Fig 272; 655pp; English.

XX The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying

CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9, 8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRKNHSGPTOSLSDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGVFLSRKNHSGPTOSLSDSVTPTKAVKTT 60

Qy 61 KGIVKGRNLDNRGLLIIGAEAWGRGVKNT 90

Db 61 KGIVKGRNLDNRGLLIIGAEAWGRGVKNT 90

RESULT 25

ABU81684

ID ABU81684 standard; protein; 90 AA.

XX AC ABU81684;

XX DT 24-JUN-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;

XX KW PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;

XX KW PRO1114; PRO3301; PRO9940; PRO1181; PRO170; PRO361; PRO846;

XX KW bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;

XX KW autoimmune disease; chromosome mapping; gene mapping; transgenic animal;

XX KW knockout animal; septic shock.

XX OS Homo sapiens.

XX PN US2002177164-A1.

XX PD 28-NOV-2002.

XX PF 20-NOV-2001; 2001US-00989293.

XX PR 16-JUN-1997; 97US-0049787P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

XX PR 02-JUN-1998; 98US-0087759P.

XX PR 03-JUN-1998; 98US-0087827P.

XX PR 04-JUN-1998; 98US-0088021P.

XX PR 04-JUN-1998; 98US-0088025P.

XX PR 04-JUN-1998; 98US-0088026P.

[illegible]

PD 26-DEC-2002.
XX 16-NOV-2001; 2001US-00991181.
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 18-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US000434.
PR 22-FEB-2000; 2000WO-US000444.

PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941592.
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gertsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Garney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX WPI; 2003-370792/35.
DR N-PSDB; ACA88455.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for the preparation of a medicament for treating a
PT condition that is responsive to the PRO polypeptide. e.g., cancer.
XX Claim 12; Fig 272; 647pp; English.
XX The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC for the preparation of a medicament for treating a condition that is
CC responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC molecular biology including being used as hybridisation probes, in
CC chromosome and gene mapping and in the generation of anti-sense RNA and
CC DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC cancer, retinal disorders, wound healing and kidney disorders. The
CC present sequence represents the amino acid sequence of a human secreted
CC and transmembrane PRO polypeptide of the present invention. Note: the
CC sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX Sequence 90 AA;
SQ Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLLVCEAIWRSNCSGNTLENGYFYSRNKENHSQPTQSLEDSVPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRSNCSGNTLENGYFYSRNKENHSQPTQSLEDSVPTKAVKTT 60
QY 61 GKGIWVGRNLDGRGLLGAIAWGRGVKNT 90
DB 61 GKGIWVGRNLDGRGLLGAIAWGRGVKNT 90
RESULT 27
AB034137

ID ABO34137 standard; protein; 90 AA.
XX AC ABO34137;
XX DT 19-SEP-2003 (first entry)
XX DE Human PRO1159 polypeptide.
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW biosensor; bioindicator; tumour; cancer; diabetes; ALS; ulcer;
KW rheumatoid arthritis; amyotrophic lateral sclerosis; cystostatic;
KW antidiabetic; antiarthritic; antirheumatic; antiulcer.
XX OS Homo sapiens.
XX US2003017981-A1.
XX PD 23-JAN-2003.
XX PF 20-NOV-2001; 2001US-00989728.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 10-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089593P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089949P.
PR 19-JUN-1998; 98US-0089950P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090446P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090577P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 30-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.

PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 20-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006566.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00860628.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 03-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-584997/55.
 N-PSDB; ADA45992.

Novel secreted and transmembrane polypeptide for modulating biological
 activity of cell expressing the polypeptide, identifying agonists or
 antagonists of polypeptide, and as molecular weight markers.

Claim 12; Fig 474; 659pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and
 transmembrane) polypeptides (I). (I) is useful for stimulating the
 release of TNF-alpha from human blood, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating the proliferation or differentiation of chondrocyte cells,
 for stimulating the proliferation of or gene expression in pericyte
 cells, for stimulating the release of proteoglycans from cartilage, for
 stimulating the proliferation of inner ear utricular supporting cells,
 for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSGPTQSSLEDSVPTTKAVKT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSGPTQSSLEDSVPTTKAVKT 60
 QY 61 GKGIYKGRNLDGRLLGAEAWGRGVKNT 90
 Db 61 GKGIYKGRNLDGRLLGAEAWGRGVKNT 90

RESULT 29

ADA76424

ID ADA76424 standard; protein; 90 AA.

XX AC ADA76424;

XX AC ADA76424;

DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS

XX OS Homo sapiens.

XX OS

XX PN US2003073212-A1.

XX PN

XX PD 17-APR-2003.

XX PD

XX PF 16-APR-2002; 2002US-00123903.

XX PF

XX PR 31-MAR-1997; 97WO-US005230.

XX PR

XX PR 12-JUN-1998; 98WO-US012456.

XX PR

XX PR 14-JUL-1998; 98WO-US014552.

XX PR

XX PR 28-AUG-1998; 98WO-US017888.

XX PR

XX PR 10-SEP-1998; 98WO-US018824.

XX PR

XX PR 14-SEP-1998; 98WO-US019093.

XX PR

XX PR 14-SEP-1998; 98WO-US019094.

XX PR

XX PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024955.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US074729.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001WO-US0082706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 23-JUN-2001; 2001WO-US021066.
PR 03-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-687639/65.
DR N-PSDB; ADA76423.
XX
XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear uricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSOPTOSSLEDSVTPKAVKTT	60
DB	1	MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRKNHNSOPTOSSLEDSVTPKAVKTT	60
QY	61	GKGIYKGRNLDNRGHLGAEAWGRGVKNT	90
DB	61	GKGIYKGRNLDNRGHLGAEAWGRGVKNT	90
RESULT 30			
ADAI9074			
ID	ADAI9074	standard; protein; 90 AA.	
XX			
AC	ADAI9074;		
XX			
DT	20-NOV-2003	(first entry)	
DE		Human PRO polypeptide #237.	
XX			
KW		Human; PRO; secreted polypeptide; transmembrane polypeptide;	
KW		tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;	
KW		colon; breast; prostate; rectum; cervix; liver; tumour; cancer;	
KW		glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;	
KW		cartilage; inner ear utricular supporting cell; cytokine; A-peptide;	
KW		factor VIIA; endothelial cell.	
OS		Homo sapiens.	
XX			
PN	US2003054517-A1.		
PD			
XX	20-MAR-2003.		
PF			
XX	08-MAY-2002; 2002US-00141755.		
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019177.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US020211.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	10-MAR-1999;	99WO-US005190.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028401.	
PR	01-DEC-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028534.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028564.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	

PR	22-DEC-1999;	99WO-US030720.	
PR	30-DEC-1999;	99WO-US031243.	
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	18-FEB-2000;	2000WO-US004342.	
PR	24-FEB-2000;	2000WO-US004414.	
PR	24-FEB-2000;	2000WO-US004914.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	01-MAR-2000;	2000WO-US005601.	
PR	02-MAR-2000;	2000WO-US005746.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	10-MAR-2000;	2000WO-US006319.	
PR	15-MAR-2000;	2000WO-US006884.	
PR	20-MAR-2000;	2000WO-US007377.	
PR	21-MAR-2000;	2000WO-US007532.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	11-AUG-2000;	2000WO-US022031.	
PR	23-AUG-2000;	2000WO-US023522.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	08-NOV-2000;	2000WO-US030952.	
PR	10-NOV-2000;	2000WO-US030873.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000US-00747259.	
PR	20-DEC-2000;	2000WO-US034956.	
PR	28-FEB-2001;	2001US-00796498.	
PR	28-FEB-2001;	2001WO-US006520.	
PR	01-MAR-2001;	2001WO-US006666.	
PR	09-MAR-2001;	2001US-00802706.	
PR	14-MAR-2001;	2001US-00808689.	
PR	22-MAR-2001;	2001US-00816744.	
PR	05-APR-2001;	2001US-00828366.	
PR	10-MAY-2001;	2001US-00854208.	
PR	10-MAY-2001;	2001US-00854280.	
PR	18-MAY-2001;	2001US-00860216.	
PR	25-MAY-2001;	2001US-00866028.	
PR	25-MAY-2001;	2001US-00866034.	
PR	25-MAY-2001;	2001WO-US017092.	
PR	01-JUN-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001WO-US019692.	
PR	21-JUN-2001;	2001US-00887879.	
PR	22-JUN-2001;	2001WO-US020116.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2001WO-US021735.	
PR	18-JUL-2001;	2001US-00938827.	
PR	06-AUG-2001;	2001US-00924419.	
PR	09-AUG-2001;	2001US-00927796.	
PR	16-AUG-2001;	2001US-00931836.	
PR	19-DEC-2001;	2001US-00028072.	
XX		(GETH) GENENTECH INC.	
PA			
XX			
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX			
DR	WPI; 2003-521854/49.		
XX	N-PSDB; ADA19073.		
DR			
XX			
PT	New PRO nucleic acid, useful for preparing a composition for treating		
PT	e.g., tumors.		

XX PS Claim 12; Fig 474; 660pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and

XX CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC CC invention also relates to an antibody which specifically binds to a PRO

CC CC polypeptide, a method for stimulating the release of tumour necrosis

CC CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC CC proliferation or differentiation of chondrocyte cells and a method for

CC CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,

CC CC prostate, rectal, cervical and liver tumours). The polynucleotides are

CC CC useful in molecular biology, including uses as hybridisation probes, in

CC CC chromosome and gene mapping, in generating antisense RNA and DNA and in

CC CC gene therapy. The polynucleotides may also be used in preparing PRO

CC CC polypeptides by recombinant techniques and in generating either

CC CC transgenic animals or knock-out animals which are useful in the

CC CC development and screening of therapeutically useful reagents. The PRO

CC CC polypeptides or antibodies are used in preparing a medicament for

CC CC treating a condition responsive to the polypeptides or antibodies, such

CC CC as tumours, for modulating the uptake of glucose or FFA by adipocyte

CC CC cells, for stimulating the proliferation of or gene expression in

CC CC pericyte cells, for stimulating the release of proteoglycans from

CC CC cartilage, for stimulating the proliferation of inner ear utricular

CC CC supporting cells, for stimulating the release of cytokines from PMEC

CC CC cells, for inhibiting the binding of A-peptide to factor VIIa, for

CC CC inhibiting the differentiation of adipocyte cells and for stimulating the

CC CC proliferation of endothelial cells. This sequence represents a human PRO

CC CC polypeptide of the invention. Note: The sequence data for this patent is

CC CC also available in electronic format from USFTO at

CC CC seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGSSNTLENGYFLSRKNHNSQPTSSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGSSNTLENGYFLSRKNHNSQPTSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 31

ADA61697

ID ADA61697 standard; protein; 90 AA.

XX AC ADA61697;

XX DT 20-NOV-2003 (first entry)

XX DE Homo sapiens.

XX KW Human; secreted and transmembrane protein; PRO;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; PFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX OS Novel.

OS human.

OS secreted.

OS and.

OS transmembrane.

OS protein.

OS PRO1159.

XX

PN XX US2003049816-A1.

XX PD 13-MAR-2003.

XX XX

XX PF 15-APR-2002; 2002US-00123262..

XX XX

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 23-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030311.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006894.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007552.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 03-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GENTECH INC.

XX (GENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-695892/66.

XX N-PSDB; ADA61696.

XX New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.

XX Claim 12; Fig 474; 660pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEALWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 32

ADB19482

ID ADB19482 standard; protein; 90 AA.

XX AC ADB19482;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine releas.

XX OS Homo sapiens.

XX PN US2003069796-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123261.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00736498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00815744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00896342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR N-PSDB; ADB28022.
PI

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695927/66.
DR N-PSDB; ADB19481.
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX Claim 12; Fig 474; 660pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte
XX Sequence 90 AA;
SQ

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. NO. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLIVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPKAVKTT 60
Dd 1 MTFPLSLLLIVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPKAVKTT 60
QY 61 GKGIKGRNLDNRGLIILGAEAWGRGVKNT 90
Dd 61 GKGIKGRNLDNRGLIILGAEAWGRGVKNT 90

RESULT 33
ADE28023
ID ADB28023 standard; protein; 90 AA.
XX ADB28023;
XX 20-NOV-2003 (first entry)
XX Human PRO polypeptide #237.
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003082704-A1.
XX 01-MAY-2003.
XX 24-APR-2002; 2002US-00131819.
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR N-PSDB; ADB28022.
DR

XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
XX
XX Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 6; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLRNKNHNSQPTQSSLEDSVTPTKAVKT 60
XX DB 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLRNKNHNSQPTQSSLEDSVTPTKAVKT 60
XX QY 61 GKGIKVRNLDRLGLILGAEWGRGVKNT 90
XX DB 61 GKGIKVRNLDRLGLILGAEWGRGVKNT 90
XX
XX RESULT 34
XX ADA86502
XX ID ADA86502 standard; protein; 90 AA.
XX AC ADA86502;
XX DT
XX 20-NOV-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.
XX OS
XX US2003082711-A1.
XX PN
XX 01-MAY-2003.
XX PD
XX 16-MAY-2002; 2002US-00147508.
XX PF
XX 02-JUL-1998; 98US-0091519P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 07-JUL-1999; 99US-0143048P.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-786914/74.
XX N-PSDB; ADA86501.
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This is the amino
XX acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.
XX
XX Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 6; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLRNKNHNSQPTQSSLEDSVTPTKAVKT 60
XX DB 1 MTFLLSLLLLVCEATWRNSGNTLENGVFLRNKNHNSQPTQSSLEDSVTPTKAVKT 60
XX QY 61 GKGIKVRNLDRLGLILGAEWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 35
ADBI6066
ID ADBI6066 standard; protein; 90 AA.
XX
AC ADBI6066;
XX
XX 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003087350-A1.
XX
XX 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127821.
XX
XX 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;
XX
DR WPI; 2003-786941/74.
DR N-PSDB; ADBI6065.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90
DB 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90
RESULT 36
ADA37888
ID ADA37888 standard; protein; 90 AA.
XX
XX ADA37888;
AC
XX 20-NOV-2003 (first entry)
DT
XX
DE Human secreted/transmembrane protein PRO1159.
XX
XX PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
XX Homo sapiens.
XX
XX US2003008297-A1.
XX
XX 09-JAN-2003.
XX
XX 15-NOV-2001; 2001US-00997653.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0086770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087108P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087593P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0089810P.
PR 10-JUN-1998; 98US-00888224P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089399P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 17-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 03-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen WE, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WJ;
PI Zhang Z;
XX
XX WPI; 2003-531419/50.
DR DR N-PSDB; ADA37887.
XX
XX New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT transmembrane polypeptides, useful as targets for the diagnosis and
PT treatment of cancers, such as lung and breast cancers.
XX
PS Claim 12; Fig 272; 660pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule comprising the
CC full-length coding sequence of the DNA ATCC Accession Numbers given in
CC the specification, or comprising a sequence with at least 80% identity
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC sequences fully defined in the specification. Also included are the PRO
CC proteins (or their extracellular domains with or without their associated
CC extracellular domains), expression vectors, host cells, PRO chimeric
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC sample, methods of linking a bioactive molecule to a cell expressing a
CC polypeptide and methods of modulating at least one biological activity of
CC a cell expressing the polypeptide. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC or inducing pancreatic beta-cell precursor differentiation. In
CC particular, these are useful for detecting or treating tumours and
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC may also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence represents a PRO protein.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. NO. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLILLYCEATWRSGSNTLNGYFVLSRNKENHSQPTOSLSLSDVTPKAVKTT 60
Db 1 MTFFLSLLILLYCEATWRSGSNTLNGYFVLSRNKENHSQPTOSLSLSDVTPKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAEAWGRGVKKNT 90
Db 61 GKGVKGRNLDRLGLILGAEAWGRGVKKNT 90

RESULT 37
ADA47852

ID ADA47852 standard; protein; 90 AA.

XX ADA47852;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073215-A1.
XX
PD 17-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140925.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00891962.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-644801/61.
XX N-PSDB; ADA47851.
DR
XX
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLGRNKNHSHQTSLSDSVTPTKAVKTT 60
 DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLGRNKNHSHQTSLSDSVTPTKAVKTT 60
 QY 61 GKGVGRNLDRLGLILGAEAWGRGVKKNKT 90
 DB 61 GKGVGRNLDRLGLILGAEAWGRGVKKNKT 90

RESULT 38

ADA21574

ID ADA21574 standard; protein; 90 AA.

XX ADA21574;

XX ADA21574;

DT 20-NOV-2003 (first entry)

XX Human secreted/transmembrane polypeptide PRO1159.

XX human; tumour; cancer; colorectal cancer; gene therapy;
 KW chondrocyte differentiation; VEGF inhibition;
 KW vascular endothelial growth factor; Alzheimer's disease;
 KW Parkinson's disease; atherosclerosis; cystic fibrosis;
 KW multiple sclerosis; ovarian cancer; tissue typing.

XX Homo sapiens.

XX US2003054404-A1.

XX 20-MAR-2003.

XX 15-NOV-2001; 2001US-00997601.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 11-JUN-1998; 98US-0088876P.
 PR 12-JUN-1998; 98US-0089105P.
 PR 16-JUN-1998; 98US-0089440P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 18-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 24-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 25-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.
 PR 01-JUL-1998; 98US-0091360P.
 PR 01-JUL-1998; 98US-0091544P.
 PR 02-JUL-1998; 98US-0091478P.
 PR 02-JUL-1998; 98US-0091519P.
 PR 02-JUL-1998; 98US-0091626P.
 PR 02-JUL-1998; 98US-0091628P.
 PR 02-JUL-1998; 98US-0091633P.
 PR 02-JUL-1998; 98US-0091646P.

```
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-014037P.
PR 07-JUL-1999; 98US-014048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0158663P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0123957P.
PR 23-JUN-1999; 98US-014037P.
PR 07-JUL-1999; 98US-014048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0149396P.
PR 15-SEP-1999; 98US-0158663P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFELSLILLIVCEAIWRNSGSGNTLENGVFLSRKKNHSHQPTOSSEDSVTPTKAVKTT 60
Db 1 MTFELSLILLIVCEAIWRNSGSGNTLENGVFLSRKKNHSHQPTOSSEDSVTPTKAVKTT 60
Qy 61 KGIVKGRNLDRLGLILCAEAWGSGVKNT 90
Db 61 KGIVKGRNLDRLGLILCAEAWGSGVKNT 90
RESULT 39
ADAL0361
ID ADAL0361 standard; protein; 90 AA.
AC ADAL0361;
XX
XX
XX 06-NOV-2003 (first entry)
DT Human secreted/transmembrane protein, PRO1159.
DE PRO; secreted protein; transmembrane protein; human; septic shock;
KW immunogen.
XX
XX Homo sapiens.
OS
XX
XX US2003059831-A1.
XX
XX 27-MAR-2003.
XX
XX 19-NOV-2001; 2001US-00989729.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065188P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
```


PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-695926/66.
DR N-PSDB; ADA67646.

XX Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.

XX Claim 12; Fig 474; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumor in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or l-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCAIWRNSGSGTLENGYFLSRNKENHSQPTQSSLEDSTPTKAVKTT 60
Db 1 MTFPLSLLLLVCAIWRNSGSGTLENGYFLSRNKENHSQPTQSSLEDSTPTKAVKTT 60

Qy 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 41

ADB30654
ID ADB30654 standard; protein; 90 AA.

XX AC ADB30654;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003068794-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123155.

XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 27-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005041.
PR 02-MAR-2000; 2000WO-US005057.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023338.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017032.
PR 01-JUN-2001; 2001WO-US017035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019632.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908927.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood MT, Zhang Z;
XX WPI; 2003-708391/67.
DR N-PSDB; ADB30653.
XX New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO

PT polypeptide, and as therapeutic agents e.g. vaccines.
XX Claim 12; Fig 474; 660pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX Sequence 90 AA;
SQ Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFJSLILLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60
DB 1 MTFFJSLILLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSLSDSVTPKAVKTT 60
QY 61 GKGIVKGRNLDNRGLIIGAEAWGRGVKNT 90
DB 61 GKGIVKGRNLDNRGLIIGAEAWGRGVKNT 90
RESULT 42
ADA85950
ID ADA85950 standard; protein; 90 AA.
XX ADA85950;
AC ADA85950;
XX 20-NOV-2003 (first entry)
DT 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1159.
XX Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS

XX US2003082693-A1.
 XX 01-MAY-2003.
 XX 22-APR-2002; 2002US-00127843.
 XX 05-JUN-2000; 2000US-0209832P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786907/74.
 XX N-PSDB; ADA85949.
 XX New PRO nucleic acid, useful for preparing a composition for treating
 XX e.g., tumor or for tissue typing.
 XX Claim 12; Fig 474; 637pp; English.
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 XX transmembrane) polypeptides (I). (I) is useful for stimulating the
 XX release of TNF-alpha from human blood, for modulating the uptake of
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
 XX stimulating the proliferation or differentiation of chondrocyte cells,
 XX for stimulating the proliferation of or gene expression in pericyte
 XX cells, for stimulating the release of proteoglycans from cartilage, for
 XX stimulating the proliferation of inner ear utricular supporting cells,
 XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
 XX the release of a cytokine from PMMC cells, for inhibiting the binding of
 XX A-peptide to factor VITR, for inhibiting the differentiation of adipocyte
 XX cells, for stimulating proliferation of endothelial cells, for detecting
 XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
 XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 XX are useful for isolating genomic and cDNA nucleotide sequences or
 XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 XX in assays to identify other proteins or molecules involved in binding
 XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 XX and gene mapping, in generation of antisense RNA and DNA, in the
 XX preparation of PRO polypeptide, for generating transgenic animals or
 XX knockout animals which in turn are useful in the development and
 XX screening of therapeutically useful reagents, in gene therapy, for
 XX chromosome identification, as chromosome marker, and for generating
 XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 XX detecting its expression in specific cells, tissues or serum, and for
 XX affinity purification of PRO from recombinant cell culture or natural
 XX sources. (I) and (II) are useful for tissue typing. This is the amino
 XX acid sequence of a novel human secreted and transmembrane PRO
 XX polypeptide.

XX SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLNGYFLGRNKNHSPQTSSEDSVTPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLNGYFLGRNKNHSPQTSSEDSVTPTKAVKTT 60
 QY 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90
 Db 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 43
 ADA17905
 ID ADA17905 standard; protein; 90 AA.

XX AC ADA17905;
 XX 20-NOV-2003 (first entry)
 XX DT Human Prol159 polypeptide.
 XX DE Human; PRO polypeptide; secreted protein; transmembrane protein;
 XX KW transgenic; tumour; cytosstatic.
 XX OS Homo sapiens.
 XX EN US2003054987-A1.
 XX PD 20-MAR-2003.
 XX PF 14-NOV-2001; 2001US-00990443.
 XX PR 16-JUN-1997; 97US-0049787P.
 XX PR 17-OCT-1997; 97US-0062250P.
 XX PR 05-NOV-1997; 97WO-US020069.
 XX PR 12-NOV-1997; 97US-0065186P.
 XX PR 13-NOV-1997; 97US-0065311P.
 XX PR 24-NOV-1997; 97US-0066770P.
 XX PR 25-FEB-1998; 98US-0075945P.
 XX PR 20-MAR-1998; 98US-0078910P.
 XX PR 28-APR-1998; 98US-0083322P.
 XX PR 07-MAY-1998; 98US-0084600P.
 XX PR 28-MAY-1998; 98US-0087106P.
 XX PR 02-JUN-1998; 98US-0087607P.
 XX PR 02-JUN-1998; 98US-0087609P.
 XX PR 03-JUN-1998; 98US-0087759P.
 XX PR 03-JUN-1998; 98US-0087827P.
 XX PR 04-JUN-1998; 98US-0088021P.
 XX PR 04-JUN-1998; 98US-0088025P.
 XX PR 04-JUN-1998; 98US-0088026P.
 XX PR 04-JUN-1998; 98US-0088028P.
 XX PR 04-JUN-1998; 98US-0088029P.
 XX PR 04-JUN-1998; 98US-0088030P.
 XX PR 04-JUN-1998; 98US-0088033P.
 XX PR 04-JUN-1998; 98US-0088126P.
 XX PR 05-JUN-1998; 98US-0088167P.
 XX PR 05-JUN-1998; 98US-0088202P.
 XX PR 05-JUN-1998; 98US-0088212P.
 XX PR 05-JUN-1998; 98US-0088217P.
 XX PR 09-JUN-1998; 98US-0088655P.
 XX PR 10-JUN-1998; 98US-0088734P.
 XX PR 10-JUN-1998; 98US-0088738P.
 XX PR 10-JUN-1998; 98US-0088742P.
 XX PR 10-JUN-1998; 98US-0088810P.
 XX PR 10-JUN-1998; 98US-0088824P.
 XX PR 10-JUN-1998; 98US-0088826P.
 XX PR 11-JUN-1998; 98US-0088858P.
 XX PR 11-JUN-1998; 98US-0088861P.
 XX PR 11-JUN-1998; 98US-0088876P.
 XX PR 12-JUN-1998; 98US-0089105P.
 XX PR 16-JUN-1998; 98US-0089440P.
 XX PR 16-JUN-1998; 98US-0089512P.
 XX PR 16-JUN-1998; 98US-0089514P.
 XX PR 17-JUN-1998; 98US-0089532P.
 XX PR 17-JUN-1998; 98US-0089538P.
 XX PR 17-JUN-1998; 98US-0089598P.
 XX PR 17-JUN-1998; 98US-0089599P.
 XX PR 17-JUN-1998; 98US-0089600P.
 XX PR 17-JUN-1998; 98US-0089653P.
 XX PR 18-JUN-1998; 98US-0089801P.
 XX PR 18-JUN-1998; 98US-0089907P.
 XX PR 18-JUN-1998; 98US-0089908P.
 XX PR 19-JUN-1998; 98US-0089947P.
 XX PR 19-JUN-1998; 98US-0089948P.
 XX PR 19-JUN-1998; 98US-0089952P.
 XX PR 22-JUN-1998; 98US-0090246P.
 XX PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 10-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0096929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 17-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.

PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113298P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007177.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 23-JUN-2000; 2000US-0215264.
PR 28-JUL-2000; 2000US-021637P.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US022031.
PR 24-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEATWRNSGNTLNGVFLSRNKNHSGPTQSSLEDSVTPTKAVTT 60
Db 1 MTFFLSLLLLVCEATWRNSGNTLNGVFLSRNKNHSGPTQSSLEDSVTPTKAVTT 60
Qy 61 GKGIKGRNLDLSRGLIIGAFAWGRGVKNT 90
Db 61 GKGIKGRNLDLSRGLIIGAFAWGRGVKNT 90

RESULT 44

ADA97162
ID ADA97162 standard; protein; 90 AA.
XX
AC ADA97162;
XX

20-NOV-2003 (first entry)

Human PRO polypeptide #237.

Human; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.

US2003082705-A1.

01-MAY-2003.

24-APR-2002; 2002US-00131829.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GENTECH) GENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755112/71.

N-PSDB; ADA97161.

New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from

CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFELSLLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFELSLLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKIVKGRNLDRLGLGAEAWGRGVKNT 90

Db 61 GKIVKGRNLDRLGLGAEAWGRGVKNT 90

RESULT 45

ADA79466

ID ADA79466 standard; protein; 90 AA.

XX AC ADA79466;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082763-A1.

XX 01-MAY-2003.

XX 17-APR-2002; 2002US-00124818.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019177.

XX 17-SEP-1998; 98WO-US019330.

XX 07-OCT-1998; 98WO-US019437.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US0005028.

XX 10-MAR-1999; 99WO-US0005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 22-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US005319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020231.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-0074259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001US-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755116/71.
 DR N-PSDB; ADA79465.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 in detection and treatment of cancer and in modulating the uptake of
 glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
 PT
 XX
 PS Claim 12; Fig 474; 659pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHNSQPTOSLSDSVTPTKAVKTT 60
 Db 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHNSQPTOSLSDSVTPTKAVKTT 60
 QY 61 KGKIVKGRNLDRLGLILGAEGWGRVKNT 90
 Db 61 KGKIVKGRNLDRLGLILGAEGWGRVKNT 90
 RESULT 46
 ADA87605
 ID ADA87605 standard; protein; 90 AA.
 XX
 AC ADA87605;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003087345-A1.
 XX
 XX 08-MAY-2003.
 XX
 XX 16-APR-2002; 2002US-001233907.
 XX
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022291.
 PR 29-OCT-1998; 98WO-US022292.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 03-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski R, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786937/74.
 DR N-PSDB; ADA87604.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX
 XX Claim 12; Fig 474; 638pp; English.
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQPTQSSLEDSVPTTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQPTQSSLEDSVPTTKAVKTT 60
Qy 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 47
ADA16807
ID ADA16807 standard; protein; 90 AA.
XX ADB16807;
AC ADB16807;
XX 20-NOV-2003 (first entry)
DT Human PRO polypeptide #237.
DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2003087349-A1.
XX 08-MAY-2003.
XX 19-APR-2002; 2002US-00125928.
XX 19-JUN-1998; 98US-0089947P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

WPI; 2003-786940/74.
N-PSDB; ADB16806.
New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide, and for manufacturing a medicament for diagnosing or treating tumor.
Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQPTQSSLEDSVPTTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNKHSQPTQSSLEDSVPTTKAVKTT 60
Qy 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 48
ADA28013
ID ADA28013 standard; protein; 90 AA.
XX ADA28013;
AC ADA28013;
XX 20-NOV-2003 (first entry)
DT Human secreted/transmembrane protein PRO1159.
DE PRO; secreted protein; transmembrane protein;
XX hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte cell;
KW chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation;
KW cardiac insufficiency disorder; wound; cancerous tumour;
KW retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;
KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;
KW cartilage disorder; sports injury; arthritis; cancer; human.
XX Homo sapiens.
OS
XX
XX US2003054359-A1.
XX PD
XX PD 20-MAR-2003.
XX PF
XX PF 14-NOV-2001; 2001US-00990726.
XX
XX 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
XX 05-NOV-1997; 97WO-US020069.
XX 12-NOV-1997; 97US-0065186P.
XX 13-NOV-1997; 97US-0065311P.
XX 24-NOV-1997; 97US-0066770P.
XX 25-FEB-1998; 98US-0075945P.
XX 20-MAR-1998; 98US-0078910P.
XX 28-APR-1998; 98US-0083322P.
XX 07-MAY-1998; 98US-0084600P.
XX 28-MAY-1998; 98US-0087106P.
XX 02-JUN-1998; 98US-0087607P.
XX 02-JUN-1998; 98US-0087609P.
XX 02-JUN-1998; 98US-0087759P.
XX 03-JUN-1998; 98US-0087827P.
XX 04-JUN-1998; 98US-0088021P.
XX 04-JUN-1998; 98US-0088025P.
XX 04-JUN-1998; 98US-0088026P.
XX 04-JUN-1998; 98US-0088028P.
XX 04-JUN-1998; 98US-0088029P.
XX 04-JUN-1998; 98US-0088030P.
XX 04-JUN-1998; 98US-0088326P.
XX 05-JUN-1998; 98US-0088167P.
XX 05-JUN-1998; 98US-0088202P.
XX 05-JUN-1998; 98US-0088212P.
XX 05-JUN-1998; 98US-0088217P.
XX 09-JUN-1998; 98US-0088655P.
XX 10-JUN-1998; 98US-0088734P.
XX 10-JUN-1998; 98US-0088738P.
XX 10-JUN-1998; 98US-0088742P.
XX 10-JUN-1998; 98US-0088810P.
XX 10-JUN-1998; 98US-0088824P.
XX 10-JUN-1998; 98US-0088826P.
XX 11-JUN-1998; 98US-0088858P.
XX 11-JUN-1998; 98US-0088861P.
XX 11-JUN-1998; 98US-0088876P.
XX 12-JUN-1998; 98US-0089105P.
XX 16-JUN-1998; 98US-0089440P.
XX 16-JUN-1998; 98US-0089512P.
XX 16-JUN-1998; 98US-0089514P.
XX 17-JUN-1998; 98US-0089532P.
XX 17-JUN-1998; 98US-0089538P.
XX 17-JUN-1998; 98US-0089598P.
XX 17-JUN-1998; 98US-0089599P.
XX 17-JUN-1998; 98US-0089600P.
XX 17-JUN-1998; 98US-0089653P.
XX 18-JUN-1998; 98US-0089801P.
XX 18-JUN-1998; 98US-0089907P.
XX 18-JUN-1998; 98US-0089908P.
XX 19-JUN-1998; 98US-0089947P.
XX 19-JUN-1998; 98US-0089948P.
XX 19-JUN-1998; 98US-0089952P.
XX 22-JUN-1998; 98US-0090246P.
XX 22-JUN-1998; 98US-0090252P.
XX 22-JUN-1998; 98US-0090254P.
XX 23-JUN-1998; 98US-0090349P.
XX 23-JUN-1998; 98US-0090355P.
XX 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.

```

PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
QY 61 GKGVKGRNLDGRGLILGAEAMGRGVKNT 90
DB 61 GKGVKGRNLDGRGLILGAEAMGRGVKNT 90

RESULT 49
ADA91899
ID ADA91899 standard; protein; 90 AA.
AC ADA91899;
XX
XX
XX 20-NOV-2003 (first entry)
XX
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX

```

```

OS Homo sapiens.
XX
XX US2003082694-A1.
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127845.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786908/74.
XX N-PSDB; ADA91898.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX or a composition for treating e.g., tumor or for tissue typing.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This is the amino
XX acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.
XX
XX Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 6; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
XX DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTPKAVKTT 60
XX QY 61 GKGVKGRNLDGRGLILGAEAMGRGVKNT 90
XX DB 61 GKGVKGRNLDGRGLILGAEAMGRGVKNT 90
XX
XX RESULT 50
XX ADB14962

```

ID ADB14962 standard; protein; 90 AA.
XX ADB14962;
XX
DT 20-NOV-2003 (first entry)
XX Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; r-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127822.
XX
XX 17-JUN-1998; 98US-0089532P.
XX 02-JUN-1999; 99WO-US012252.
XX 25-AUG-1999; 99WO-US0380137.
XX 30-NOV-1999; 99WO-US028313.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Baresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786942/74.
XX N-PSDB; ADB14961.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or r-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPTKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPTKAVKTT 60
QY 61 KGIVKGRNLDLSRGLILGAEGWGRGVKNT 90
DB 61 KGIVKGRNLDLSRGLILGAEGWGRGVKNT 90
RESULT 51
ADBI8923
ID ADB18923 standard; protein; 90 AA.
AC ADB18923;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
XX 15-APR-2002; 2002US-00123292.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 20-NOV-1998; 98WO-US022992.
XX 01-DEC-1998; 98WO-US024855.
XX 05-JAN-1999; 98WO-US025108.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000355.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 08-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 23-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 08-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-695954/66.
DR N-PSDB; ADB18922.
XX
XX New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PI diagnosis and treatment of cancer.
XX
XX Claim 12; Fig 474; 638pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRKKNHSGPTOSLSDSVPTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRKKNHSGPTOSLSDSVPTKAVKTT 60
Oy 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90
RESULT 52
ADA94138
ID ADA94138 standard; protein; 90 AA.
XX AC ADA94138;
XX
XX 20-NOV-2003 (first entry)
XX DE Human PRO polypeptide #237.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
OS Homo sapiens.
XX
XX US2003077722-A1.
XX
XX 24-APR-2003.
XX
XX 03-MAY-2002; 2002US-00137872.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755077/71.
 DR N-PSDB; ADA94137.
 XX
 PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
 PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
 PT breast, prostate, rectal, cervical and/or liver tumors.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human macrovascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SX Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLEDSVPTKAVKTT 60
 Db 1 MTFEFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQTSLSLEDSVPTKAVKTT 60
 QY 61 GKGIKGRNLDGRGLTILGAEAGRGVKKNT 90
 Db 61 GKGIKGRNLDGRGLTILGAEAGRGVKKNT 90
 RESULT 53
 ADB20034
 ID ADB20034 standard; protein; 90 AA.
 XX
 AC ADB20034;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1159.
 XX
 KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 OS Homo sapiens.
 XX
 PN US2003082691-A1.
 XX
 XX 01-MAY-2003.
 PD
 XX
 XX 22-APR-2002; 2002US-00127838.
 XX
 XX 17-NOV-1998; 98US-0108802P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-755108/71.
 DR N-PSDB; ADB20033.
 XX
 PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.
 XX
 XX Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMVC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping. In generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SX Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60
 DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60
 QY 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90
 DB 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90

RESULT 54
 ADB13346
 ID ADB13346 standard; protein; 90 AA.
 AC ADB13346;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #237.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; PFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX
 PN US2003082710-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 16-MAY-2002; 2002US-00147484.
 XX
 PP 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786913/74.
 DR N-PSDB; ADB13345.
 XX
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT preparing a composition for treating e.g., tumor, or for tissue typing.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.9e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60
 DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSPQTSSLEDSVTPTKAVKTT 60
 QY 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90
 DB 61 GKGIVKGRNLDNRGLILGAEAAGRGVKNT 90

RESULT 55

ABO43385
 ID ABO43385 standard; protein; 90 AA.
 XX
 AC ABO43385;
 XX

DT 26-SEP-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

KW Human; secreted and transmembrane protein; PRO; gene therapy;
 KW chromosome identification; tissue typing.

OS Homo sapiens.

PN US2003044945-A1.

PD 06-MAR-2003.

PF 10-MAY-2002; 2002US-00142419.

PP 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US022992.

PR 01-DEC-1998; 98WO-US024855.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

```
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005941.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006684.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 30-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 03-MAR-2001; 2001WO-US006666.
PR 14-MAR-2001; 2001US-00809889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.

PA (GETH ) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-492275/46.
XX N-PSDB; ACD98660.
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
XX Claim 12; Fig 474; 660pp; English.
XX The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
XX Sequence 90 AA;
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
Db 1 MTFPLSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
Db 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
RESULT 56
IDA94593
ID ADA94593 standard; protein; 90 AA.
XX ADA94593;
AC ADA94593;
XX
XX 20-NOV-2003 (first entry)
XX Human secreted/transmembrane protein PRO1159.
XX PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
XX rod photoreceptor cell.
OS Homo sapiens.
XX
XX US2003059832-A1.
PN
```


PR	12-MAR-1999;	99US-0121957P.	PD	10-APR-2003.
PR	02-JUN-1999;	99WO-US012252.	XX	
PR	23-JUN-1999;	99US-0141037P.	PF	07-MAY-2002; 2002US-00140928.
PR	07-JUL-1999;	99US-0143048P.	XX	
PR	20-JUL-1999;	99US-0144758P.	PR	31-MAR-1997; 97WO-US005230.
PR	26-JUL-1999;	99US-0145698P.	PR	12-JUN-1998; 98WO-US012456.
PR	28-JUL-1999;	99US-0146222P.	PR	14-JUL-1998; 98WO-US014552.
PR	17-AUG-1999;	99US-0149396P.	PR	28-AUG-1998; 98WO-US017888.
PR	15-SEP-1999;	99WO-US021090.	PR	10-SEP-1998; 98WO-US018824.
PR	15-SEP-1999;	99WO-US021547.	PR	14-SEP-1998; 98WO-US019093.
PR	08-OCT-1999;	99US-0158663P.	PR	14-SEP-1998; 98WO-US019094.
PR	30-NOV-1999;	99WO-US028313.	PR	16-SEP-1998; 98WO-US019177.
PR	01-DEC-1999;	99WO-US028301.	PR	16-SEP-1998; 98WO-US019330.
PR	01-DEC-1999;	99WO-US028634.	PR	17-SEP-1998; 98WO-US019437.
PR	16-DEC-1999;	99WO-US030095.	PR	29-OCT-1998; 98WO-US021141.
PR	20-DEC-1999;	99WO-US030095.	PR	29-OCT-1998; 98WO-US022991.
PR	05-JAN-2000;	2000WO-US000219.	PR	29-OCT-1998; 98WO-US022992.
PR	06-JAN-2000;	2000WO-US000376.	PR	29-OCT-1998; 98WO-US024855.
PR	11-FEB-2000;	2000WO-US003565.	PR	01-DEC-1998; 98WO-US025108.
PR	18-FEB-2000;	2000WO-US004341.	PR	05-JAN-1999; 99WO-US000106.
PR	22-FEB-2000;	2000WO-US004414.	PR	08-MAR-1999; 99WO-US005028.
PR	24-FEB-2000;	2000WO-US004914.	PR	10-MAR-1999; 99WO-US005190.
PR	01-MAR-2000;	2000WO-US005004.	PR	20-APR-1999; 99WO-US008615.
PR	02-MAR-2000;	2000WO-US005601.	PR	14-MAY-1999; 99WO-US010733.
PR	02-MAR-2000;	2000WO-US005746.	PR	14-MAY-1999; 99WO-US012252.
PR	02-MAR-2000;	2000WO-US005841.	PR	01-SEP-1999; 99WO-US020111.
PR	10-MAR-2000;	2000WO-US006319.	PR	08-SEP-1999; 99WO-US020594.
PR	15-MAR-2000;	2000WO-US006884.	PR	08-SEP-1999; 99WO-US020944.
PR	20-MAR-2000;	2000WO-US007377.	PR	13-SEP-1999; 99WO-US020944.
PR	21-MAR-2000;	2000WO-US007532.	PR	15-SEP-1999; 99WO-US021090.
PR	30-MAR-2000;	2000WO-US008439.	PR	15-SEP-1999; 99WO-US021547.
PR	30-MAR-2000;	2000WO-US013705.	PR	03-OCT-1999; 99WO-US023089.
PR	17-MAY-2000;	2000WO-US013705.	PR	23-NOV-1999; 99WO-US028214.
PR	22-MAY-2000;	2000WO-US014042.	PR	23-NOV-1999; 99WO-US028313.
PR	30-MAY-2000;	2000WO-US014941.	PR	30-NOV-1999; 99WO-US028409.
PR	02-JUN-2000;	2000WO-US015264.	PR	01-DEC-1999; 99WO-US028301.
PR	23-JUN-2000;	2000US-0213637P.	PR	01-DEC-1999; 99WO-US028634.
Query Match 100.0%; Score 462; DB 6; Length 90;			PR	02-DEC-1999; 99WO-US028551.
Best Local Similarity 100.0%; Pred. No. 9.8e-49;			PR	02-DEC-1999; 99WO-US028564.
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			PR	02-DEC-1999; 99WO-US028565.
Qy	1	MTFFLSLLLLVCAIWRNSGSGNTLENGVFLSRNKENHSGTOSSEDSVTPKAVKTT 60	PR	16-DEC-1999; 99WO-US030095.
Db	1	MTFFLSLLLLVCAIWRNSGSGNTLENGVFLSRNKENHSGTOSSEDSVTPKAVKTT 60	PR	20-DEC-1999; 99WO-US030911.
Qy	61	GKGIKGRNLDRLGILGAEGWGRGVKNT 90	PR	20-DEC-1999; 99WO-US030999.
Db	61	GKGIKGRNLDRLGILGAEGWGRGVKNT 90	PR	22-DEC-1999; 99WO-US030720.
RESULT 57			PR	30-DEC-1999; 99WO-US031243.
ID	ADA74600		PR	30-DEC-1999; 99WO-US031274.
XX	ADA74600 standard; protein; 90 AA.		PR	05-JAN-2000; 2000WO-US000219.
AC	ADA74600;		PR	06-JAN-2000; 2000WO-US000277.
XX	20-NOV-2003 (first entry)		PR	06-JAN-2000; 2000WO-US003376.
DT	Human PRO polypeptide #237.		PR	11-FEB-2000; 2000WO-US003565.
DE	Human; PRO; secreted polypeptide; transmembrane polypeptide;		PR	18-FEB-2000; 2000WO-US004341.
XX	Human; PRO; secreted polypeptide; transmembrane polypeptide;		PR	18-FEB-2000; 2000WO-US004342.
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		PR	22-FEB-2000; 2000WO-US004414.
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		PR	24-FEB-2000; 2000WO-US004914.
KW	liver; microvascular endothelial cell; glucose; FFA;		PR	01-MAR-2000; 2000WO-US005004.
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		PR	02-MAR-2000; 2000WO-US005601.
KW	inner ear utricular supporting cell; T-lymphocyte cell;		PR	02-MAR-2000; 2000WO-US005746.
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		PR	02-MAR-2000; 2000WO-US005841.
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		PR	10-MAR-2000; 2000WO-US006319.
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		PR	15-MAR-2000; 2000WO-US006884.
XX	immune system cell infiltration.		PR	20-MAR-2000; 2000WO-US007377.
XX	Homo sapiens.		PR	30-MAR-2000; 2000WO-US008439.
OS	US2003068798-A1.		PR	15-MAY-2000; 2000WO-US013358.
XX			PR	17-MAY-2000; 2000WO-US013705.
PN			PR	22-MAY-2000; 2000WO-US014042.
XX			PR	30-MAY-2000; 2000WO-US014941.
XX			PR	02-JUN-2000; 2000WO-US015264.
XX			PR	23-JUN-2000; 2000US-0213637P.

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKHNSQTOSSLEDSVTPKAVKIT 60
DB 1 MTFLLSLLLVCEAIWRNSGNTLENGYFLSRNKHNSQTOSSLEDSVTPKAVKIT 60

QY 61 CGKIVKGRNLDRLGILGAEAWGRGVKNT 90
DB 61 CGKIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 58
ADB24833
ID ADB24833 standard; protein; 90 AA.
XX
AC ADB24833;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; gliucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625490/59.
XX N-PSDB; ADB24833.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumors.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and

PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00870392.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625490/59.
XX N-PSDB; ADA74599.
XX
XX Novel secreted and transmembrane PRO polypeptides and polynucleotides
XX encoding them, useful for treating bone disorders, arthritis, heart
XX attack, injuries, tumors, and stimulating release of Tumor Necrosis
XX Factor-alpha from human blood.
XX
XX Claim 12; Fig 474; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGI V KGRNLD S RGLILGAEAWGRGVKNT 90

DB 61 GKGI V KGRNLD S RGLILGAEAWGRGVKNT 90

RESULT 59
ADA82357

ID ADA82357 standard; protein; 90 AA.

XX AC ADA82357;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082701-A1.

XX

PD 01-MAY-2003.

XX 23-APR-2002; 2002US-00128686.

XX 31-AUG-1998; 98US-0098525P.

XX 16-SEP-1998; 98US-0100634P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US015264.

PR 01-DEC-2000; 2000WO-US032678.

PR 15-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755110/71.

DR N-PSDB; ADA82356.

XX PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

PS Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

DB 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFUSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGI V KGRNLD S RGLILGAEAWGRGVKNT 90

Wed Jun 2 08:28:01 2004

us-09-989-293a-377.jun1.rag

61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db

RESULT 60

ADA75320

ID ADA75320 standard; protein; 90 AA.

XX

AC ADA75320;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

XX US2003073216-A1.

PN

XX 17-APR-2003.

PD

30-MAY-2002; 2002US-00160498.

PF

31-MAR-1997; 97WO-US005230.

XX

PR 12-JUN-1996; 98WO-US02456.

PR

PR 14-JUL-1998; 98WO-US014552.

PR

PR 28-AUG-1998; 98WO-US017888.

PR

PR 10-SEP-1998; 98WO-US018824.

PR

PR 14-SEP-1998; 98WO-US019093.

PR

PR 14-SEP-1998; 98WO-US019094.

PR

PR 14-SEP-1998; 98WO-US019177.

PR

PR 16-SEP-1998; 98WO-US019330.

PR

PR 17-SEP-1998; 98WO-US019437.

PR

PR 07-OCT-1998; 98WO-US021141.

PR

PR 29-OCT-1998; 98WO-US022991.

PR

PR 29-OCT-1998; 98WO-US024855.

PR

PR 20-NOV-1998; 98WO-US025108.

PR

PR 01-DEC-1998; 98WO-US005028.

PR

PR 05-JAN-1999; 98WO-US008615.

PR

PR 10-MAR-1999; 98WO-US005190.

PR

PR 20-APR-1999; 98WO-US010733.

PR

PR 14-MAY-1999; 98WO-US012252.

PR

PR 02-JUN-1999; 98WO-US020111.

PR

PR 01-SEP-1999; 98WO-US020594.

PR

PR 13-SEP-1999; 98WO-US020944.

PR

PR 15-SEP-1999; 98WO-US021090.

PR

PR 15-SEP-1999; 98WO-US021547.

PR

PR 05-OCT-1999; 98WO-US023089.

PR 29-NOV-1999; 98WO-US028214.

PR 30-NOV-1999; 98WO-US028313.

PR 30-NOV-1999; 98WO-US028409.

PR 01-DEC-1999; 98WO-US028301.

PR 01-DEC-1999; 98WO-US028634.

PR 02-DEC-1999; 98WO-US028551.

PR 02-DEC-1999; 98WO-US028564.

PR 02-DEC-1999; 98WO-US028565.

PR 16-DEC-1999; 98WO-US030095.

PR 20-DEC-1999; 98WO-US030911.

PR 20-DEC-1999; 98WO-US030999.

PR 22-DEC-1999; 98WO-US030720.

PR 30-DEC-1999; 98WO-US031243.

PR 30-DEC-1999; 98WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017803.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-765392/72.

N-PSDB; ADA75319.

New secreted and transmembrane PRO polypeptides useful for stimulating
 the release of tumor necrosis factor alpha in human blood and detecting
 the presence of tumor in a mammal.

Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQTSLSLSDSVTPTKAVKTT 60
Db 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQTSLSLSDSVTPTKAVKTT 60
QY 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90
Db 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90

RESULT 61
ADA85398
ID ADA85398 standard; protein; 90 AA.
AC
XX ADA85398;
XX
XX 20-NOV-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
OS
XX
XX US2003082695-A1.
PN
XX

PD 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127846.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786909/74.
DR N-PSDB; ADA85397.
XX
XX New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT composition for treating e.g. tumor by gene therapy, or for tissue
PT typing.
XX
XX Claim 12; Fig 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the release of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQTSLSLSDSVTPTKAVKTT 60
Db 1 MTFLLSLLLVCEAIWRSNGSNTLENGYFLSRKNHNSQTSLSLSDSVTPTKAVKTT 60
QY 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90
Db 61 KGKIVKGRNLSRGLILGAEGWGRGVKNT 90

RESULT 62
ADA84846
ID ADA84846 standard; protein; 90 AA.
XX
XX ADA84846;
AC

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082708-A1.

XX PD 01-MAY-2003.

XX PF 15-MAY-2002; 2002US-00146729.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-786911/74.

XX DR N-PSDB; ADA64845.

XX PT New PRO nucleic acid, useful for preparing a composition for treating

XX PT e.g. tumor or for tissue typing.

XX PS Claim 12; Fig 474; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PMBC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO

XX CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49; Mismatches 0; Indels 0; Gaps 0;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEAIWRNSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60

DB 1 MTFPLSLILLVCEAIWRNSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60

QY 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90

DB 61 KGKIVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 63

ADB30102

ID ADB30102 standard; protein; 90 AA.

XX AC ADB30102;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX KW liver; microvascular endothelial cell; glucose; FFA;

XX KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX KW inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;

XX KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003073214-A1.

XX PD 17-APR-2003.

XX PF 17-APR-2002; 2002US-00124822.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US0005028.

XX PR 10-MAR-1999; 99WO-US0005190.

XX PR 20-APR-1999; 99WO-US000615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 05-OCT-1999; 99WO-US021547.

XX PR 29-NOV-1999; 99WO-US023089.

XX PR 30-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-1999; 99WO-US028409.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

QY 61 KGKIVKGRNLDRLGLILGAENWGRGVKNT 90
DB 61 KGKIVKGRNLDRLGLILGAENWGRGVKNT 90

RESULT 65

ADA75872
ID ADA75872 standard; protein; 90 AA.

AC ADA75872;

DT 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082703-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128691.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765414/72.

DR N-PSDB; ADA75871.

XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

QY 61 KGKIVKGRNLDRLGLILGAENWGRGVKNT 90
DB 61 KGKIVKGRNLDRLGLILGAENWGRGVKNT 90

RESULT 66

ADA38818
ID ADA38818 standard; protein; 90 AA.

XX ADA38818;

XX 20-NOV-2003 (first entry)

XX Human secreted/transmembrane protein PRO1159.

XX PRO; secreted protein; transmembrane protein; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer.

XX Homo sapiens.

XX US2003059780-A1.

XX

PD 27-MAR-2003.
XX 14-NOV-2001; 2001US-00991854.
PF 16-JUN-1997; 97US-0049787P.
XX 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97MO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088036P.
PR 04-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089514P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-009339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874593.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-644800/61.
DR N-PSDB; ADA47096.

PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 12; Fig 474; 638pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49; Mismatches 0; Gaps 0;
Matches 90; Conservative 0; Indels 0;

Oy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSKENHSGPTQSSLEDSVTPKAVKTT 60
|||
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSKENHSGPTQSSLEDSVTPKAVKTT 60

Oy 61 GKGIKGRNLDNRGLILGAEGWGVKKNT 90
|||
Db 61 GKGIKGRNLDNRGLILGAEGWGVKKNT 90

RESULT 68

ADB25393

ID ADB25393 standard; protein; 90 AA.

XX AC ADB25393;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide SEQ ID NO 474.

XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX US2003077715-A1.

XX PD 24-APR-2003.

XX PF 23-APR-2002; 2002US-00128693.

XX PR 31-AUG-1998; 98US-0098525P.

XX PR 16-SEP-1998; 98US-0100634P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 02-JUN-2000; 2000WO-US015264.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755070/71.

DR N-PSDB; ADB25392.

XX New isolated, secreted and transmembrane PRO nucleic acids, useful for
 PT the diagnosis, prevention and/or treatment of tumors, such as lung,
 PT colon, breast, prostate, rectal, cervical and/or liver tumors.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEATWRNSGSGNTLENGYFLSRNKNHSQPTOSLSLEDSVPTKAVKTT 60

DB 1 MTFPLSLILLVCEATWRNSGSGNTLENGYFLSRNKNHSQPTOSLSLEDSVPTKAVKTT 60

QY 61 GKGVKGRNLDRLGLIIGAEAWGRGVKKN 90

DB 61 GKGVKGRNLDRLGLIIGAEAWGRGVKKN 90

RESULT 69

ADA93569

ID ADA93569 standard; protein; 90 AA.

AC ADA93569;

XX 20-NOV-2003 (first entry)

DT Human PRO polypeptide #237.

DE Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

PN US2003077721-A1.

PD 24-APR-2003.

PF 24-APR-2002; 2002US-00131837.

XX 09-DEC-1999; 93US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-755076/71.

DR N-PSDB; ADA93568.

XX New PRO nucleic acid, useful for recombinantly producing a PRO

PT polypeptide and for manufacturing a medicament for diagnosing or treating

PT tumor.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC the proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLILLVCEATWRNSGSGNTLENGYFLSRNKNHSQPTOSLSLEDSVPTKAVKTT 60

DB 1 MTFPLSLILLVCEATWRNSGSGNTLENGYFLSRNKNHSQPTOSLSLEDSVPTKAVKTT 60

Db 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 KGKIVGRNLDLSRGLILGAPAWGKVKNT 90
Db 61 KGKIVGRNLDLSRGLILGAPAWGKVKNT 90
RESULT 70
ADB26919
ID ADB26919 standard; protein; 90 AA.
AC ADB26919;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003092147-A1.
PN
PD 15-MAY-2003.
XX
XX 11-APR-2002; 2002US-00121051.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014341.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 08-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777249/73.
DR N-PSDE; ADB26918.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper-

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032878.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006666.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00860216.
PR 18-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-786990/74.
DR N-PSDB; ADB31205.
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX Claim 12; Fig 474; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60
|||
Db 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKTT 60
|||
Qy 61 GKGIVKGRNLDNRGLILGAEGWGVKNT 90
|||
Db 61 GKGIVKGRNLDNRGLILGAEGWGVKNT 90
|||

RESULT 72

ADA92939
ID ADA92939 standard; protein; 90 AA.
XX
AC ADA92939;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX

KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.

OS Homo sapiens.

PN US2003060407-A1.

XX 27-MAR-2003.

PD 14-NOV-2001; 2001US-00990440.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066770P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 07-MAY-1998; 98US-0083322P.

XX 28-MAY-1998; 98US-0084600P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

XX 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090822P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-011326P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98WO-US012252.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 28-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149396P.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 16-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.

```
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9. Be-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLILLVCBAIWRNSGNTLENGYFLSRNKENHNSOPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFPLSLLILLVCBAIWRNSGNTLENGYFLSRNKENHNSOPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIKVGKRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIKVGKRNLDNRGLILGAEAWGRGVKNT 90

RESULT 73
ID ADA61134 standard; protein; 90 AA.
XX ADA61134;
XX
XX
XX 20-NOV-2003 (first entry)
XX Homo sapiens.
XX
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX Glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX
XX Novel.
XX OS human.
XX OS secreted.
XX OS and.
XX OS transmembrane.
XX OS protein.
XX OS PRO1159.
XX
XX US2003049817-A1.
XX
XX 13-MAR-2003.
XX
XX 10-MAY-2002; 2002US-00142423.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018834.
XX 14-SEP-1998; 98WO-US019033.
XX 14-SEP-1998; 98WO-US019094.
XX 16-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 11-FEB-2000; 2000WO-US000376.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US022031.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 08-NOV-2000; 2000WO-US030952.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-MAR-2001; 2001US-00802706.
XX 09-MAR-2001; 2001US-00806666.
XX 14-MAR-2001; 2001US-00806689.
XX 22-MAR-2001; 2001US-00816744.
XX 05-APR-2001; 2001US-00828366.
XX 10-MAY-2001; 2001US-00854280.
XX 10-MAY-2001; 2001US-00854280.
XX 18-MAY-2001; 2001US-00860216.
XX 25-MAY-2001; 2001US-00866028.
XX 25-MAY-2001; 2001US-00866034.
XX 25-MAY-2001; 2001US-00866034.
XX 25-MAY-2001; 2001US-00866034.
XX 01-JUN-2001; 2001US-00872035.
XX 01-JUN-2001; 2001US-00872035.
XX 05-JUN-2001; 2001US-00874503.
XX 14-JUN-2001; 2001US-00882636.
XX 19-JUN-2001; 2001US-00886342.
```

20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 10-MAR-2009; 2000WO-US006319.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-695993/66.
 N-PSDB; ADA61133.
 New secreted and transmembrane PRO polypeptide and nucleic acid, useful
 for manufacturing a medicament for diagnosing or treating tumor.
 Claim 12; Fig 474; 659pp; English.
 The invention describes 305 nucleic acids encoding PRO (secreted and
 transmembrane) polypeptides (I). (I) is useful for stimulating the
 release of TNF-alpha from human blood, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating the proliferation or differentiation of chondrocyte cells,
 for stimulating the proliferation of or gene expression in pericyte
 cells, for stimulating the release of proteoglycans from cartilage, for
 stimulating the proliferation of inner ear utricular supporting cells,
 for stimulating the proliferation of T-lymphocyte cells, for stimulating
 the release of a cytokine from PBMC cells, for inhibiting the binding of
 a peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 cells, for stimulating proliferation of endothelial cells, for detecting
 the presence of tumour in a mammal. The tumour is lung, colon, breast,
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 are useful for isolating genomic and cDNA nucleotide sequences or
 antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 in assays to identify other proteins or molecules involved in binding
 interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 and gene mapping, in generation of antisense RNA and DNA, in the
 preparation of PRO polypeptide, for generating transgenic animals or
 knockout animals which in turn are useful in the development and
 screening of therapeutically useful reagents, in gene therapy, for
 chromosome identification, as chromosome marker, and for generating
 probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 detecting its expression in specific cells, tissues or serum, and for
 affinity purification of PRO from recombinant cell culture or natural
 sources. (I) and (II) are useful for tissue typing. This is the amino
 acid sequence of a novel human secreted and transmembrane PRO
 polypeptide.
 Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSSLEDSVTPTKAVKTT 60
 QY 61 GKGVKGRNLDRLGLIIGAGWGRGVKNT 90
 Db 61 GKGVKGRNLDRLGLIIGAGWGRGVKNT 90
 RESULT 74
 ADB24281

ID ADB24281 standard; protein; 90 AA.
 AC ADB24281;
 XX 20-NOV-2003 (first entry)
 DT Human PRO polypeptide SEQ ID NO 474.
 DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS US2003077714-A1.
 PN 24-APR-2003.
 PD 22-APR-2002; 2002US-00127901.
 XX 17-JUN-1998; 98US-0089599P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755069/71.
 DR N-PSDB; ADB24280.
 DR New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX Claim 12; Fig 474; 637pp; English.
 PS The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

QY 61 KGKIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 75

ADA96610
 ID ADA96610 standard; protein; 90 AA.

XX AC ADA96610;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003082690-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127837.

XX PR 01-SEP-1998; 98US-0098750P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 08-NOV-2000; 2000WO-US030952.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;

XX Gerriksen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-755107/71.

XX DR N-PSDB; ADA96609.

PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQPTQSSLEDSVPTKAVKTT 60

QY 61 KGKIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 76

ADA81182
 ID ADA81182 standard; protein; 90 AA.

XX AC ADA81182;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082702-A1.

XX 01-MAY-2003.

XX 23-APR-2002; 2002US-00128690.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerlitsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-755111/71.

XX N-PSDB; ADA81181.

XX New PRO nucleic acid, useful for preparing a composition for treating

XX e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

XX Query Match 100.0%; Score 462; DB 6; Length 90;

XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;

XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLLLLLLVCRAIWRNSGSGTLENGVFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60

Db 1 MTFPLLLLLLVCRAIWRNSGSGTLENGVFLSRNKENHSQPTQSSLEDSTVPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKKNT 90

Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKKNT 90

RESULT 77

ADA96058

ID ADA96058 standard; protein; 90 AA.

XX AC ADA96058;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003082759-A1.

XX 01-MAY-2003.

PF 11-APR-2002; 2002US-00121040.

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755114/71.
DR N-PSDB; ADA96057.
XX New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.

XX

PS Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-43;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWFSNCSGNTLENGYFLSRKNKHSQPTOSSLEDSVTPTKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWFSNCSGNTLENGYFLSRKNKHSQPTOSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 78

ADB26367
ID ADB26367 standard; protein; 90 AA.

XX ADB26367;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX

OS	Homo sapiens.
XX	US2003082760-A1.
PPN	01-MAY-2003.
PD	12-APR-2002; 2002US-00121056.
PF	31-MAR-1997; 97WO-US005230.
XX	PR 12-JUN-1998; 98WO-US012456.
PR	PR 14-JUL-1998; 98WO-US014552.
PR	PR 28-AUG-1998; 98WO-US017888.
PR	PR 10-SEP-1998; 98WO-US018824.
PR	PR 14-SEP-1998; 98WO-US019093.
PR	PR 14-SEP-1998; 98WO-US019094.
PR	PR 14-SEP-1998; 98WO-US019177.
PR	PR 16-SEP-1998; 98WO-US019330.
PR	PR 17-SEP-1998; 98WO-US019437.
PR	PR 07-OCT-1998; 98WO-US021141.
PR	PR 29-OCT-1998; 98WO-US022992.
PR	PR 29-OCT-1998; 98WO-US022991.
PR	PR 20-NOV-1998; 98WO-US024855.
PR	PR 01-DEC-1998; 98WO-US025108.
PR	PR 05-JAN-1999; 99WO-US000106.
PR	PR 08-MAR-1999; 99WO-US005028.
PR	PR 10-MAR-1999; 99WO-US005190.
PR	PR 20-APR-1999; 99WO-US008615.
PR	PR 14-MAY-1999; 99WO-US010733.
PR	PR 02-JUN-1999; 99WO-US012252.
PR	PR 01-SEP-1999; 99WO-US020111.
PR	PR 08-SEP-1999; 99WO-US020594.
PR	PR 13-SEP-1999; 99WO-US020944.
PR	PR 15-SEP-1999; 99WO-US021090.
PR	PR 15-SEP-1999; 99WO-US021547.
PR	PR 05-OCT-1999; 99WO-US023089.
PR	PR 29-NOV-1999; 99WO-US028214.
PR	PR 30-NOV-1999; 99WO-US028313.
PR	PR 30-NOV-1999; 99WO-US028409.
PR	PR 01-DEC-1999; 99WO-US028301.
PR	PR 01-DEC-1999; 99WO-US028634.
PR	PR 02-DEC-1999; 99WO-US028551.
PR	PR 02-DEC-1999; 99WO-US028564.
PR	PR 02-DEC-1999; 99WO-US028565.
PR	PR 16-DEC-1999; 99WO-US030095.
PR	PR 20-DEC-1999; 99WO-US030911.
PR	PR 20-DEC-1999; 99WO-US030999.
PR	PR 22-DEC-1999; 99WO-US030720.
PR	PR 30-DEC-1999; 99WO-US031243.
PR	PR 30-DEC-1999; 99WO-US031274.
PR	PR 05-JAN-2000; 2000WO-US000219.
PR	PR 06-JAN-2000; 2000WO-US000277.
PR	PR 11-FEB-2000; 2000WO-US000376.
PR	PR 18-FEB-2000; 2000WO-US003565.
PR	PR 18-FEB-2000; 2000WO-US004341.
PR	PR 18-FEB-2000; 2000WO-US004342.
PR	PR 22-FEB-2000; 2000WO-US004414.
PR	PR 24-FEB-2000; 2000WO-US004914.
PR	PR 24-FEB-2000; 2000WO-US005094.
PR	PR 01-MAR-2000; 2000WO-US005601.
PR	PR 02-MAR-2000; 2000WO-US005746.
PR	PR 02-MAR-2000; 2000WO-US005841.
PR	PR 10-MAR-2000; 2000WO-US006319.
PR	PR 15-MAR-2000; 2000WO-US006884.
PR	PR 20-MAR-2000; 2000WO-US007377.
PR	PR 21-MAR-2000; 2000WO-US007532.
PR	PR 30-MAR-2000; 2000WO-US008439.
PR	PR 17-MAY-2000; 2000WO-US013705.
PR	PR 22-MAY-2000; 2000WO-US014042.
PR	PR 30-MAY-2000; 2000WO-US014941.
PR	PR 02-JUN-2000; 2000WO-US015264.
PR	PR 28-JUL-2000; 2000WO-US020710.
PR	PR 11-AUG-2000; 2000WO-US022031.
PR	PR 23-AUG-2000; 2000WO-US023522.
PR	24-AUG-2000; 2000WO-US023328.
PR	PR 08-NOV-2000; 2000WO-US0310952.
PR	PR 10-NOV-2000; 2000WO-US030873.
PR	PR 01-DEC-2000; 2000WO-US032678.
PR	PR 20-DEC-2000; 2000US-00747259.
PR	PR 20-DEC-2000; 2000WO-US034956.
PR	PR 28-FEB-2001; 2001US-00796498.
PR	PR 28-FEB-2001; 2001WO-US006520.
PR	PR 01-MAR-2001; 2001WO-US006666.
PR	PR 09-MAR-2001; 2001US-00802706.
PR	PR 14-MAR-2001; 2001US-00808689.
PR	PR 22-MAR-2001; 2001US-00816744.
PR	PR 05-APR-2001; 2001US-00828366.
PR	PR 10-MAY-2001; 2001US-00854208.
PR	PR 10-MAY-2001; 2001US-00854280.
PR	PR 18-MAY-2001; 2001US-00860216.
PR	PR 25-MAY-2001; 2001US-00866028.
PR	PR 25-MAY-2001; 2001US-00866034.
PR	PR 25-MAY-2001; 2001WO-US017092.
PR	PR 01-JUN-2001; 2001US-00872035.
PR	PR 01-JUN-2001; 2001WO-US017800.
PR	PR 05-JUN-2001; 2001US-00874503.
PR	PR 14-JUN-2001; 2001US-00882636.
PR	PR 19-JUN-2001; 2001US-00886342.
PR	PR 20-JUN-2001; 2001WO-US019692.
PR	PR 21-JUN-2001; 2001US-00887879.
PR	PR 22-JUN-2001; 2001WO-US020116.
PR	PR 29-JUN-2001; 2001WO-US021066.
PR	PR 09-JUL-2001; 2001WO-US021735.
PR	PR 18-JUL-2001; 2001US-00908827.
PR	PR 06-AUG-2001; 2001US-00924419.
PR	PR 09-AUG-2001; 2001US-00927796.
PR	PR 16-AUG-2001; 2001US-00931836.
PR	PR 19-DEC-2001; 2001US-00028072.
XX	(GETH) GENENTECH INC.
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E,

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen MF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786920/74.
DR N-PSDB; ADB21851.
XX
XX New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 12; Fig 474; 639pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC cells, for stimulating the proliferation of inner ear utricular supporting cells,
CC stimulating the proliferation of T-lymphocyte cells, for stimulating
CC for stimulating the proliferation of BMC cells, for inhibiting the binding of
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1 MTFFLSLLLLVCEAIWRNSGNSNTLENGYFLSRNKENHSQPTQSSLSDSVTPKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNSNTLENGYFLSRNKENHSQPTQSSLSDSVTPKAVKTT 60
Oy 61 KGKIVKGRNLSRGLILGAEWGRGVKNT 90
Db 61 KGKIVKGRNLSRGLILGAEWGRGVKNT 90
RESULT 80
ADA77631
ID ADA77631 standard; protein; 90 AA.
XX
XX ADA77631;
AC

XX
DT 20-NOV-2003 (first entry)
XX Human PRO polypeptide #237.
DE
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX US2003068797-A1.
PN
XX
XX 10-APR-2003.
PD
XX
XX 07-MAY-2002; 2002US-00140921.
PF
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 23-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030311.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.

PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-755065/71.
 DR N-PSDB; ADB18370.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
 PT in tissue typing, and in identifying chromosomes.
 XX
 XX Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MTFLLSLLLLVCEAIWRNSGNSLTENGYPFLSRNKHNSPTQSSLEDSTVTPKAVKTT 60
 Db 1 MTFLLSLLLLVCEAIWRNSGNSLTENGYPFLSRNKHNSPTQSSLEDSTVTPKAVKTT 60
 Qy 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90
 Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 82
 ADA87054

ID ADA87054 standard; protein; 90 AA.
 XX
 AC ADA87054;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1159.
 XX
 XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003082709-A1.
 PN
 XX
 XX 01-MAY-2003.
 PD
 XX
 XX 15-MAY-2002; 2002US-00146791.
 XF
 XX
 XX 17-AUG-1998; 98US-0096895P.
 PR
 XX 02-JUN-1999; 99WO-US012252.
 PR
 XX 25-AUG-1999; 99US-00380137.
 PR
 XX 30-MAR-2000; 2000WO-US008439.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 13-DEC-2001; 2001US-00028072.
 PR
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786912/74.
 DR N-PSDB; ADA87053.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT for preparing a composition for treating e.g., tumor, or for tissue
 PT typing.
 XX
 XX Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from FPMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (i) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (ii) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKIT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 83

ADA88157

ID ADA88157 standard; protein; 90 AA.

XX AC ADA88157;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082700-A1.

XX PD 01-MAY-2003.

XX PF 23-APR-2002; 2002US-00128684.

XX PR 05-JUN-2000; 2000US-0209832P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-786910/74.

DR N-PSDB; ADA88156.

XX New PRO nucleic acid, useful for preparing a composition for treating

PT e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRNSGSSNTLENGYFLSRNKENHSQPTOSLSLDSVTPTKAVKIT 60

Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 84

ADA46545

ID ADA46545 standard; protein; 90 AA.

XX AC ADA46545;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003054516-A1.

XX PD 20-MAR-2003.

XX PF 12-APR-2002; 2002US-00121050.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAY-1999; 99WO-US010733.
PR 01-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 03-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-521853/49.

N-PSDB; ADA46544.

New nucleic acid, useful for preparing a composition for treating
e.g., tumor.

Claim 12; Fig 474; 200pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumor is lung, colon, breast, prostate, rectal, cervical or liver tumor. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTOSLSDSVTPPKAVTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTOSLSDSVTPPKAVTT 60
Qy 61 GKGIKGRNLDNRGLILGAEWGVRKNT 90

61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90

Db RESULT 85
ID ADB28575 standard; protein; 90 AA.
AC ADB28575;
XX 20-NOV-2003 (first entry)
DT Human PRO polypeptide #237.
DE
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

PN US2003082699-A1.

PP 01-MAY-2003.

PF 22-APR-2002; 2002US-00127851.

PR 17-JUN-1998; 98US-0089599P.

PR 02-JUN-1998; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-NOV-1999; 99WO-US028313.

PR 30-MAR-2000; 2000WO-US008439.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-777202/73.

DR N-PSDB; ADB28574.

XX New PRO nucleic acid, useful for preparing a composition for treating

PT e.g., tumor or for tissue typing.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRKNSGNTLENGYFLSRKKNHSGPTQSSLEDSVTPPKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRKNSGNTLENGYFLSRKKNHSGPTQSSLEDSVTPPKAVKTT 60

Qy 61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90

Db 61 GKGIVKGRNLDRLGLLGAEGAWGRGVKNT 90

RESULT 86

ADB29127

ID ADB29127 standard; protein; 90 AA.

AC ADB29127;

XX 20-NOV-2003 (first entry)

DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082706-A1.

XX 01-MAY-2003.

XX 24-APR-2002; 2002US-00131836.

XX 09-DEC-1999; 99US-0170262P.

XX 10-NOV-2000; 2000WO-US010873.

XX 01-DEC-2000; 2000WO-US012678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E;

XX Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-777203/73.

XX N-PSDB; ADB29126.

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS
XX Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFPLSLLLLVCAIWRKNSGSSNTLENGYFLSRNKENHSQTSLSLSDSVTPTKAVKTT 60
Dy 1 MTFPLSLLLLVCAIWRKNSGSSNTLENGYFLSRNKENHSQTSLSLSDSVTPTKAVKTT 60
Qy 61 KGIVKGRNLDRLGILGAEAWGRGVKNT 90
Dy 61 KGIVKGRNLDRLGILGAEAWGRGVKNT 90
RESULT 87
ABO53223
ID ABO53223 standard; protein; 90 AA.
XX
AC ABO53223;
DT
DT 14-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein Prol159.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW adrenal cortical capillary endothelial cell; angiogenesis; wound healing;
KW diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; kidney mesangial cell proliferation;
KW kidney disorder; Berger disease; neuropathy; coeliac disease;
KW dermatitis herpetiformis; Crohn's disease; tumour; cancer.
XX
OS Homo sapiens.

XX
PN
XX
PD
XX
XX 06-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00998156.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 12-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093333P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 20-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.

PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MTFELSLLLLVCEAIWESNGSNTLENGYFLSRKNHNSOPTOSSEDSVTPKAVKTT 60

Db 1 MTFELSLLLLVCEAIWESNGSNTLENGYFLSRKNHNSOPTOSSEDSVTPKAVKTT 60

Oy 61 GKGIKGNLDSRGLILGAEAWGRGVKNT 90

Db 61 GKGIKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 88

ADA77079

ID ADA77079 standard; protein; 90 AA.

XX ADA77079;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

OS Homo sapiens.

XX US2003059909-A1.
PN 27-MAR-2003.
XX 10-MAY-2002, 2002US-00143032.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 27-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US007532.
PR 17-MAY-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806889.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-540684/51.

N-PSDB; ADA77078.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 12; Fig 474; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCAIWRNSGNTLENGYPLSRNKHNSQPTOSLSLDSVPTKAVKTT 60
Db 1 MTFPLSLLLLVCAIWRNSGNTLENGYPLSRNKHNSQPTOSLSLDSVPTKAVKTT 60
Qy 61 KGIVKGRNLDGRGILGAEGWGRGVKNT 90
Db 61 KGIVKGRNLDGRGILGAEGWGRGVKNT 90

RESULT 89

ADA22500

ID ADA22500 standard; protein; 90 AA.

XX AC ADA22500;

XX DT 20-NOV-2003 (first entry)

XX DE Human secreted/transmembrane polypeptide PRO1159.

XX KW human; tumour; cancer; colorectal cancer; gene therapy;

XX KW chondrocyte differentiation; VEGF inhibition;

XX KW vascular endothelial growth factor; Alzheimer's disease;

XX KW Parkinson's disease; atherosclerosis; cystic fibrosis;

XX KW multiple sclerosis; ovarian cancer; tissue typing.

XX OS Homo sapiens.

XX PN US2003040473-A1.

XX PD 27-FEB-2003.

XX PF 19-NOV-2001; 2001US-00989726.

XX 16-JUN-1997; 97US-0049787P.

XX 17-OCT-1997; 97US-0062250P.

XX 05-NOV-1997; 97WO-US020069.

XX 12-NOV-1997; 97US-0065186P.

XX 13-NOV-1997; 97US-0065311P.

XX 24-NOV-1997; 97US-0066700P.

XX 25-FEB-1998; 98US-0075945P.

XX 20-MAR-1998; 98US-0078910P.

XX 28-APR-1998; 98US-0083322P.

XX 07-MAY-1998; 98US-0084600P.

XX 28-MAY-1998; 98US-0087106P.

XX 02-JUN-1998; 98US-0087607P.

XX 02-JUN-1998; 98US-0087609P.

XX 02-JUN-1998; 98US-0087759P.

XX 03-JUN-1998; 98US-0087827P.

XX 04-JUN-1998; 98US-0088021P.

XX 04-JUN-1998; 98US-0088025P.

XX 04-JUN-1998; 98US-0088026P.

XX 04-JUN-1998; 98US-0088028P.

XX 04-JUN-1998; 98US-0088030P.

XX 04-JUN-1998; 98US-0088032P.

XX 04-JUN-1998; 98US-0088033P.

XX 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.

```
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 10-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637E.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 90
ADA88709
ID ADA88709 standard; protein; 90 AA.
AC ADA88709;
XX
XX 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003073213-A1.
XX
XX 17-APR-2003.
XX
XX 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
```


PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 23-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081656P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 22-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090538P.
PR 01-JUL-1998; 98US-0090863P.
PR 02-JUL-1998; 98US-0091360P.
PR 07-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 11-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0098536P.
PR 09-SEP-1998; 98US-0098598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115660P.
PR 12-JAN-1999; 99US-0115662P.
PR 12-JAN-1999; 99US-0115664P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFEFLSLLLLVCEATWRSNGSNTLENGYFSLRNKENHSQPTQSSLESVPTKAVKTT 60
DB 1 MTFEFLSLLLLVCEATWRSNGSNTLENGYFSLRNKENHSQPTQSSLESVPTKAVKTT 60

QY 61 GKGIKVRNLDNRGLILGAENGRGVKKNT 90
DB 61 GKGIKVRNLDNRGLILGAENGRGVKKNT 90

RESULT 93
ADB22404
ID ADB22404 standard; protein; 90 AA.
AC ADB22404;
XX
XX
XX 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO1159.
XX Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX US2003087344-A1.
XX
XX 08-MAY-2003.
XX
XX 16-APR-2002; 2002US-00123905.
XX
XX 18-JUN-1997; 97US-0049911P.
XX 26-AUG-1997; 97US-0056974P.
XX 17-SEP-1997; 97US-0059113P.
XX 17-SEP-1997; 97US-0059115P.
XX 17-SEP-1997; 97US-0059117P.
XX 17-SEP-1997; 97US-0059122P.
XX 18-SEP-1997; 97US-0059184P.
XX 18-SEP-1997; 97US-0059263P.
XX 19-SEP-1997; 97US-0059352P.
XX 19-SEP-1997; 97US-0059588P.
XX 24-SEP-1997; 97US-0059836P.
XX 17-OCT-1997; 97US-0062250P.
XX 17-OCT-1997; 97US-0062285P.
XX 17-OCT-1997; 97US-0062287P.
XX 17-OCT-1997; 97US-0063755P.
XX 24-OCT-1997; 97US-0062814P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063045P.
XX 24-OCT-1997; 97US-0063082P.
XX 24-OCT-1997; 97US-0063327P.
XX 27-OCT-1997; 97US-0063329P.
XX 28-OCT-1997; 97US-0063550P.
XX 28-OCT-1997; 97US-0063561P.
XX 29-OCT-1997; 97US-0063704P.
XX 29-OCT-1997; 97US-0063733P.
XX 29-OCT-1997; 97US-0063735P.
XX 29-OCT-1997; 97US-0063738P.
XX 03-NOV-1997; 97US-0064248P.
XX 07-NOV-1997; 97US-0064809P.
XX 12-NOV-1997; 97US-0065186P.
XX 17-NOV-1997; 97US-0065846P.
XX 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 12-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 26-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012455.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.

```
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106858P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108923P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113298P.
PR 22-DEC-1998; 98US-0113298P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 12-JAN-1999; 98US-0115549P.
PR 12-JAN-1999; 98US-0115557P.
PR 12-JAN-1999; 98US-0115560P.
PR 12-JAN-1999; 98US-0115562P.
PR 12-JAN-1999; 98US-0115564P.
PR 12-JAN-1999; 98US-0115630P.
PR 12-JAN-1999; 98US-0115705P.
PR 12-JAN-1999; 98US-0115733P.
PR 20-JAN-1999; 98US-0116533P.
PR 01-FEB-1999; 98US-0116210P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDNRGLLILGAEAWGRGVKKNT 90
Db 61 GKGIKGRNLDNRGLLILGAEAWGRGVKKNT 90
```

RESULT 94

```
ABO22593
ID ABO22593 standard; protein; 90 AA.
XX AC
XX ABO22593;
DT 04-SEP-2003 (first entry)
XX Human secreted/transmembrane protein PRO1159.
DE Human; PRO; secreted protein; transmembrane protein; antidiabetic;
XX cytosolic; antirheumatic; antiarthritic; antiulcer; neuroprotective;
KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
KW amyotrophic lateral sclerosis; inflammatory condition; septic shock.
XX
OS Homo sapiens.
PN US2003017982-A1.
PD 23-JAN-2003.
XX
PF 16-NOV-2001; 2001US-00990441.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088328P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
```

QY 1 MTFFLSLLLLVC EAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRNSGNTLNGVFLSNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDLSRLILGAEAWGRGVKKNT 90
Db 61 GKGIKGRNLDLSRLILGAEAWGRGVKKNT 90

RESULT 95
ADA06666
ID ADA06666 standard; protein; 90 AA.
XX ADA06666;
XX
DT 29-JAN-2004 (revised)
DT 06-NOV-2003 (first entry)
XX
XX Human secreted/transmembrane PRO polypeptide #118.
XX human; tissue typing; cardiac insufficiency disorder; angiogenesis;
KW wound healing; tumour; immune response; retinal disorder; retinal injury;
KW sight loss; age-related macular degeneration; AMD; kidney disorder;
KW mesangial cell function; Berger disease; nephropathy; dermatitis;
KW herpiform; Crohn's disease; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003049638-A1.
XX
PD 13-MAR-2003.
XX
PF 16-NOV-2001; 2001US-00991157.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088036P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088866P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.

RESULT 97

ADA67095

ID ADA67095 standard; protein; 90 AA.

XX ADA67095;

XX 20-NOV-2003 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; INF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

XX US2003068793-A1.

XX 10-APR-2003.

XX 15-APR-2002; 2002US-00123108.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 05-OCT-1999; 99WO-US021547.

PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015284.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-695925/66.

XX N-PSDB; ADA67094.

XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
 PT release of tumor necrosis factor-alpha from human blood and detecting the
 PT presence of a tumor in a mammal.

XX Claim 12; Fig 474; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Sequence 90 AA;
QY 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60
QY 61 KGKIVKGNLDSRGLILGAEAWGRVKNT 90
DB 61 KGKIVKGNLDSRGLILGAEAWGRVKNT 90

RESULT 98
ADB22956
ID ADB22956 standard; protein; 90 AA.
XX AC ADB22956;
XX AC ADB22956;
DI 20-NOV-2003 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.
XX US200307711-A1.
PN
XX

PD 24-APR-2003.
XX 22-APR-2002; 2002US-00127829.
XX 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755066/71.
DR N-PSDB; ADB22955.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, as diagnostic markers for the presence of a disease condition, or as therapeutic targets for treating tumors, diabetes, obesity or arthritis.
XX Claim 12; Fig 474; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDSVTPKAVKTT 60
QY 61 KGKIVKGNLDSRGLILGAEAWGRVKNT 90

||||| 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db

RESULT 99

ADB23729

ID ADB23729 standard; protein; 90 AA.

XX

AC ADB23729;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polypeptide SEQ ID NO 474.

XX

Human: PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX

OS Homo sapiens.

XX

US2003077712-A1.

PN

XX

24-APR-2003.

PD

22-APR-2002; 2002US-00127835.

PF

XX

20-OCT-1998; 98US-0104987P.

PR

XX

01-SEP-1999; 99WO-US020111.

PR

XX

18-OCT-1999; 99US-00403297.

PR

XX

18-FEB-2000; 2000WO-US004342.

PR

XX

01-DEC-2000; 2000WO-US032678.

PR

XX

19-DEC-2001; 2001US-00028072.

PR

XX

(GETH) GENENTECH INC.

PA

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems. PRO
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

SQ

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKNHSQPTQSSLEDSVPTTKAVKTT 60

Db

1 MTFFLSLLLLVCEAIWRSNGSNTLENGYFLSRNKNHSQPTQSSLEDSVPTTKAVKTT 60

QY

61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

Db

61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 100

ADA92451

ID ADA92451 standard; protein; 90 AA.

XX

AC ADA92451;

XX

DT 20-NOV-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1159.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

(GETH) GENENTECH INC.

XX

XX

XX

XX

XX

XX

XX

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-786915/74.
DR N-PSDB; ADA92450.

New isolated, secreted and transmembrane PRO nucleic acid, useful for the
diagnosis, prevention and/or treatment of tumors, such as lung, colon,
breast, prostate, rectal, cervical and/or liver tumors.

Claim 12; Fig 474; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of

PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60
 Db 1 MTFPLSLILLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60

Qy 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
 Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 101
 ADB15514
 ID ADB15514 standard; protein; 90 AA.
 XX
 AC ADB15514;
 XX
 XX 20-NOV-2003 (first entry)
 XX
 DE Human PRO polypeptide #237.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 OS Homo sapiens.
 XX

PN US2003087352-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127824.
 XX
 PR 17-AUG-1998; 98US-0096891P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786943/74.
 DR N-PSDB; ADB15513.
 XX
 PT New PRO nucleic acid, useful for producing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLILLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60
 Db 1 MTFPLSLILLVCEAIWRSNGSGNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60

Qy 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
 Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90

|||||
61 GKGIKGRNLDNRGLILGAEAGRGVKNT 90

Db
RESULT 102
ADB38766
ID ADB38766 standard; protein; 90 AA.
XX
AC ADB38766;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003082766-A1.
PN
XX
PD 01-MAY-2003.
XX
XX 30-MAY-2002; 2002US-00158782.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019130.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021157.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786921/74.
XX N-PSDB; ADB38765.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, detecting the presence of tumor in a mammal, or
XX modulating the uptake of glucose or free fatty acid by skeletal muscle
XX cells or adipocyte cells.
XX
XX Claim 12; Fig 474; 660pp; English.
PR

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as a therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSGPTQSSLEDVTPPKAVKTT 60
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSGPTQSSLEDVTPPKAVKTT 60

Qy 61 KGKIVGRNLDRLGILGAEAWGRGVKNT 90
 Db 61 KGKIVGRNLDRLGILGAEAWGRGVKNT 90

RESULT 103
 ADB96385
 ID ADB96385 standard; protein; 90 AA.
 XX AC ADB96385;
 XX DT 04-DEC-2003 (first entry)
 XX DE Human PRO polypeptide #118.
 XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
 KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
 KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
 KW polycystic kidney disease; renal tumour; antidiabetic; antianemic;
 KW cytostatic; cardiac; vulnery; antiinflammatory; anorectic.
 XX OS Homo sapiens.
 XX EN US2003054403-A1.
 XX PD 20-MAR-2003.
 XX PF 15-NOV-2001; 2001US-00997559.
 XX PR 16-JUN-1997; 97US-0049787P.
 PR 17-OCT-1997; 97US-0062250P.
 PR 05-NOV-1997; 97WO-0020069.
 PR

PR 12-NOV-1997; 97US-0065186P.
 PR 13-NOV-1997; 97US-0065311P.
 PR 24-NOV-1997; 97US-0066770P.
 PR 25-FEB-1998; 98US-0075945P.
 PR 20-MAR-1998; 98US-0078910P.
 PR 28-APR-1998; 98US-0083322P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 02-JUN-1998; 98US-0087609P.
 PR 02-JUN-1998; 98US-0087759P.
 PR 03-JUN-1998; 98US-0087827P.
 PR 04-JUN-1998; 98US-0088021P.
 PR 04-JUN-1998; 98US-0088025P.
 PR 04-JUN-1998; 98US-0088026P.
 PR 04-JUN-1998; 98US-0088028P.
 PR 04-JUN-1998; 98US-0088029P.
 PR 04-JUN-1998; 98US-0088030P.
 PR 04-JUN-1998; 98US-0088033P.
 PR 04-JUN-1998; 98US-0088326P.
 PR 05-JUN-1998; 98US-0088167P.
 PR 05-JUN-1998; 98US-0088202P.
 PR 05-JUN-1998; 98US-0088212P.
 PR 05-JUN-1998; 98US-0088217P.
 PR 09-JUN-1998; 98US-0088655P.
 PR 10-JUN-1998; 98US-0088734P.
 PR 10-JUN-1998; 98US-0088738P.
 PR 10-JUN-1998; 98US-0088742P.
 PR 10-JUN-1998; 98US-0088810P.
 PR 10-JUN-1998; 98US-0088824P.
 PR 10-JUN-1998; 98US-0088826P.
 PR 11-JUN-1998; 98US-0088858P.
 PR 11-JUN-1998; 98US-0088861P.
 PR 12-JUN-1998; 98US-0088876P.
 PR 16-JUN-1998; 98US-0089400P.
 PR 16-JUN-1998; 98US-0089512P.
 PR 16-JUN-1998; 98US-0089514P.
 PR 17-JUN-1998; 98US-0089532P.
 PR 17-JUN-1998; 98US-0089538P.
 PR 17-JUN-1998; 98US-0089598P.
 PR 17-JUN-1998; 98US-0089599P.
 PR 17-JUN-1998; 98US-0089600P.
 PR 17-JUN-1998; 98US-0089653P.
 PR 18-JUN-1998; 98US-0089801P.
 PR 18-JUN-1998; 98US-0089907P.
 PR 18-JUN-1998; 98US-0089908P.
 PR 19-JUN-1998; 98US-0089947P.
 PR 19-JUN-1998; 98US-0089948P.
 PR 19-JUN-1998; 98US-0089952P.
 PR 22-JUN-1998; 98US-0090246P.
 PR 22-JUN-1998; 98US-0090252P.
 PR 22-JUN-1998; 98US-0090254P.
 PR 23-JUN-1998; 98US-0090349P.
 PR 23-JUN-1998; 98US-0090355P.
 PR 24-JUN-1998; 98US-0090429P.
 PR 24-JUN-1998; 98US-0090431P.
 PR 24-JUN-1998; 98US-0090435P.
 PR 24-JUN-1998; 98US-0090444P.
 PR 24-JUN-1998; 98US-0090445P.
 PR 24-JUN-1998; 98US-0090472P.
 PR 24-JUN-1998; 98US-0090535P.
 PR 24-JUN-1998; 98US-0090540P.
 PR 24-JUN-1998; 98US-0090542P.
 PR 25-JUN-1998; 98US-0090557P.
 PR 25-JUN-1998; 98US-0090676P.
 PR 25-JUN-1998; 98US-0090678P.
 PR 25-JUN-1998; 98US-0090690P.
 PR 25-JUN-1998; 98US-0090694P.
 PR 25-JUN-1998; 98US-0090695P.
 PR 25-JUN-1998; 98US-0090696P.
 PR 26-JUN-1998; 98US-0090862P.
 PR 26-JUN-1998; 98US-0090863P.

```
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0101943P.
PR 01-DEC-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 12-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98WO-US012252.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0143048P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149356P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTQSLEDVPTTKAVKIT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSOPTQSLEDVPTTKAVKIT 60

Qy 61 GKGIVKGRNLDNRGLILGAEWGRGVKNT 90
Db 61 GKGIVKGRNLDNRGLILGAEWGRGVKNT 90

RESULT 104
ADB38214
ID ADB38214 standard; protein; 90 AA.
XX
AC ADB38214;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003087347-A1.
XX
PN
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125921.
XX
PR 17-AUG-1998; 98US-0096791P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
```


PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786938/74.
 DR N-PSDB; ADB38213.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 XX Claim 12; Fig 474; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumor. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.
 XX
 XX Sequence 90 AA;
 SQ
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFISRNKHNHSQPTQSSLEDVPTTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFISRNKHNHSQPTQSSLEDVPTTKAVKTT 60
 QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90
 Db 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90
 RESULT 105
 ADB66686
 ID ADB66686 standard; protein; 90 AA.
 XX
 AC ADB66686;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO1159.
 XX

KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 OS
 XX US2003082689-A1.
 DN
 XX 01-MAY-2003.
 PD
 XX 22-APR-2002; 2002US-00127831.
 PF
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US023023.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 08-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnovers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-786905/74.

N-PSDB; ADB66685.

New PRO nucleic acid, useful for preparing a composition for treating
 e.g. tumor or for tissue typing.

Claim 12; Fig 474; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMBC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLGLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDVPTTKAVKTT 60
 |||||
 Db 1 MTFFLSLGLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDVPTTKAVKTT 60
 |||||
 QY 61 GKGIVKGRNLDGRGLLILGAEAWGRGVKKNT 90
 |||||
 Db 61 GKGIVKGRNLDGRGLLILGAEAWGRGVKKNT 90
 |||||

RESULT 106

ADB89766
 ID ADB89766 standard; protein; 90 AA.

XX AC ADB89766;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX US2003082698-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127850.

XX PR 20-AUG-1998; 98US-0097218P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnovers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX

DR WPI; 2003-743896/70.
DR N-PSDB; ADB89765.
XX New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT of cancer.
XX
XX
PS Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60
Db 1 MTFLLSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSQPTSSLEDSTPTKAVKTT 60

Qy 61 GKGIVKGRNLSRGLILGAEGWGRGVKNT 90
Db 61 GKGIVKGRNLSRGLILGAEGWGRGVKNT 90

RESULT 107
ADB90498
ID ADB90498 standard; protein; 90 AA.
XX
AC ADB90498;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003082762-A1.
XX
XX 01-MAY-2003.
XX
XX 15-APR-2002; 2002US-00123235.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022033.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 04-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001WO-US006666.
 PR 14-MAR-2001; 2001US-00802706.
 PR 22-MAR-2001; 2001US-00808689.
 PR 05-APR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001US-00196992.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908927.
 PR 08-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-743899/70.
 N-PSDB; ADB90497.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, and in the detection and treatment of tumor in a mammal.

Claim 12; Fig 474; 649pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumor in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Fred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEALWRSNLSGNTLENGYFLSRNKNHSQPTQSLSLDSVPTTKAVKTT 60
 DB 1 MTFFLSLLLLVCEALWRSNLSGNTLENGYFLSRNKNHSQPTQSLSLDSVPTTKAVKTT 60
 QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
 DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 108

ADB39599

ID ADB39599 standard; protein; 90 AA.

XX AC ADB39599;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX KW Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082764-A1.

XX PD 01-MAY-2003.

XX PF 03-MAY-2002; 2002US-00137868.

XX PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.

Sequence 90 AA;

RESULT 109
ADB47222

ID ADB47222 standard; protein; 90 AA.
XX
AC ADB47222;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082687-A1.
XX
PD 01-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125930.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000MO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786904/74.
DR N-PSDB; ADB47221.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 12; Fig 474; 627pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This is the amino
XX acid sequence of a novel human secreted and transmembrane PRO
XX polypeptide.

XX Sequence 90 AA;
XX
XX Query Match 100.0%; Score 462; DB 7; Length 90;
XX Best Local Similarity 100.0%; Pred. No. 9.8e-49;
XX Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 MTFFLSLLLLVCEAIWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRSNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
QY 61 GKGIYKGRNLDGRGLILGAEAMGRGVKKNT 90
DB 61 GKGIYKGRNLDGRGLILGAEAMGRGVKKNT 90
XX
RESULT 110
ADB86829
ID ADB86829 standard; protein; 90 AA.
XX
AC ADB86829;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003082697-A1.
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127849.
XX
XX 20-OCT-1998; 98US-0104987P.
XX 01-SEP-1999; 99MO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 18-FEB-2000; 2000MO-US004342.
XX 01-DEC-2000; 2000MO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-743895/70.
XX N-PSDB; ADB86828.
XX
XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis
XX and treatment of cancer.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSTQSSLEDSVTPTKAVKTT 60
 Db 1 MTFLLSLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSTQSSLEDSVTPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90
 Db 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90

RESULT 111

ID ADB77434 standard; protein; 90 AA.

AC ADB77434;

DT 04-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRL159.

XX Human; secreted and transmembrane protein; PRO;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082696-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127848.

XX 03-NOV-1998; 98US-0106934P.

XX 26-JUL-1999; 99US-0145698P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

PR 05-JAN-2000; 2000WO-US000219.
 PR 18-FEB-2000; 2000WO-US0004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-755109/71.
 DR N-PSDB; ADB77433.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 PT tumor or for tissue typing.

PS Claim 12; Fig 474; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This is the amino
 CC acid sequence of a novel human secreted and transmembrane PRO
 CC polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSTQSSLEDSVTPTKAVKTT 60
 Db 1 MTFLLSLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSTQSSLEDSVTPTKAVKTT 60

Qy 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90
 Db 61 KGKIVKGNLDSRGLILGAEGWGRGVKNT 90

RESULT 112

ID ADB34591 standard; protein; 90 AA.

XX ADB34591;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX US200307717-17-A1.
 XX 24-APR-2003.
 XX 24-APR-2002; 2002US-00131818.
 XX 07-OCT-1998; 98US-0103328P.
 XX 01-SEP-1999; 99WO-US020111.
 XX 18-OCT-1999; 99US-00403297.
 XX 30-NOV-1999; 99WO-US028313.
 XX 18-FEB-2000; 2000WO-US004342.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755072/71.
 XX N-PSDB; ADB34590.
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX Claim 12; Fig 474; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWFSNCSNTLENGYFLSRNKNHSQPTQSSLSDSVTPTRAVKIT 60
 Db 1 MTFPLSLLLLVCEAIWFSNCSNTLENGYFLSRNKNHSQPTQSSLSDSVTPTRAVKIT 60
 QY 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90
 Db 61 GKGIKGRNLDLSRGLILGAEAWGRGVKNT 90
 RESULT 113
 ADB35695
 ID ADB35695 standard; protein; 90 AA.
 XX ADB35695;
 XX 04-DEC-2003 (first entry)
 XX Human PRO polypeptide SEQ ID NO 474.
 XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 XX OS
 XX US200307719-A1.
 XX 24-APR-2003.
 XX 24-APR-2002; 2002US-00131824.
 XX 09-FEB-1999; 99US-0119341P.
 XX 01-DEC-1999; 99WO-US028634.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen WB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755074/71.
 XX N-PSDB; ADB35694.
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX Claim 12; Fig 474; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which

CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60
 Db 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Qy 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

Db 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

RESULT 114
 ADB34039

ID ADB34039 standard; protein; 90 AA.

AC ADB34039;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 XX liver; microvascular endothelial cell; glucose; FFA;
 XX skeletal muscle cell; adipocyte cell; pericyte cell;
 XX inner ear utricular supporting cell; T-lymphocyte cell;
 XX endothelial cell tube formation; bone disorder; cartilage disorder;
 XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 XX immune system cell infiltration.

XX Homo sapiens.

XX US2003077716-A1.

XX 24-APR-2003.

PF 24-APR-2002; 2002US-00131813.

XX 07-OCT-1998; 98US-0103315P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-755071/71.

XX N-PSDB; ADB34038.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 XX in gene therapy, in chromosome and gene mapping, as chromosome markers,
 XX in tissue typing, and in identifying chromosomes.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
 XX stimulating differentiation of adipocyte cells, for stimulating
 XX the proliferation of or gene expression in pericyte cells, for stimulating
 XX cells, for inducing endothelial cell tube formation and for treating
 XX various bone and/or cartilage disorders such as sports injuries and
 XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
 XX from cartilage are useful for treating sports-related joint problems,
 XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 XX polypeptides are also useful for treating various mammalian haemoglobin-
 XX associated disorders such as various thalassaemias and conditions which
 XX may benefit from enhanced local immune system cell infiltration. This
 XX sequence represents a human PRO polypeptide of the invention. Note: The
 XX sequence data for this patent is also available in electronic format from
 XX USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFFLSLLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Qy 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

Db 61 GKGVKGRNLDRLGLILGAFAWGRGVKNT 90

RESULT 115

ADB35143

ID ADB35143 standard; protein; 90 AA.

XX ADB35143;

AC ADB35143;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX

XX Homo sapiens.

XX OS

XX PN

XX PD

XX 24-APR-2003.

XX 24-APR-2002; 2002US-00131823.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 03-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755073/71.
 N-PSDB; ADB35142.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 12; Fig 474; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-44;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTVPTKAVKTT 60
DB 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTVPTKAVKTT 60
QY 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90
DB 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

RESULT 116

ADB36247

XX ADB36247

XX ADB36247;

XX 04-DEC-2003 (first entry)

XX Human PRO polypeptide SEQ ID NO 474.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077720-A1.

PN

XX PD

XX 24-APR-2003.

XX 24-APR-2002; 2002US-00131830.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755075/71.

XX N-PSDB; ADB36246.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumours,
XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
XX tumours.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-44;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTVPTKAVKTT 60

DB 1 MTFLLSLLLVCCEAIWRSNGSNTLENGYFLSRKNHNSQPTQSSLEDSTVPTKAVKTT 60

QY 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

DB 61 KGKIVKGNLDSRGLILGAEAWGRGVKNT 90

```
RESULT 117
ADB46642
ID ADB46642 standard; protein; 90 AA.
XX
AC ADB46642;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003082692-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127842.
XX
PR 03-MAR-2000; 2000US-0187202P.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR N-PSDB; ADB46641.
XX
PF 2003-786906/74.
XX
DR N-PSDB; ADB46641.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMC cells for inhibiting the binding of
CC A-peptide to factor viiia, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
```

```
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;
XX
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIRWSNCGSNTLENGYFLSRNKENHSQPTQSSLEDVTPTKAVKIT 60
Db 1 MTFFLSLLLLVCEAIRWSNCGSNTLENGYFLSRNKENHSQPTQSSLEDVTPTKAVKIT 60
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90
Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90
RESULT 118
ADC57857
ID ADC57857 standard; protein; 90 AA.
XX
AC ADC57857;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnarary; antinflammatory; anorectic.
XX
OS Homo sapiens.
XX
US2003027754-A1.
XX
PF 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990438.
XX
PR 16-JUN-1997; 97US-0049787P.
XX
PR 17-OCT-1997; 97US-0062250P.
XX
PR 05-NOV-1997; 97WO-US020069.
XX
PR 12-NOV-1997; 97US-0065186P.
XX
PR 13-NOV-1997; 97US-0065311P.
XX
PR 24-NOV-1997; 97US-0066770P.
XX
PR 25-FEB-1998; 98US-0075945P.
XX
PR 20-MAR-1998; 98US-0078310P.
XX
PR 28-APR-1998; 98US-0083322P.
XX
PR 07-MAY-1998; 98US-0084600P.
XX
PR 28-MAY-1998; 98US-0087106P.
XX
PR 02-JUN-1998; 98US-0087607P.
XX
PR 02-JUN-1998; 98US-0087609P.
XX
PR 02-JUN-1998; 98US-0087759P.
XX
PR 03-JUN-1998; 98US-0087827P.
XX
PR 04-JUN-1998; 98US-0088021P.
XX
PR 04-JUN-1998; 98US-0088025P.
XX
PR 04-JUN-1998; 98US-0088026P.
XX
PR 04-JUN-1998; 98US-0088028P.
XX
PR 04-JUN-1998; 98US-0088029P.
XX
PR 04-JUN-1998; 98US-0088030P.
XX
PR 04-JUN-1998; 98US-0088033P.
XX
PR 05-JUN-1998; 98US-0088167P.
XX
PR 05-JUN-1998; 98US-0088202P.
XX
PR 05-JUN-1998; 98US-0088212P.
XX
PR 05-JUN-1998; 98US-0088217P.
XX
PR 09-JUN-1998; 98US-0088655P.
XX
PR 10-JUN-1998; 98US-0088734P.
XX
PR 10-JUN-1998; 98US-0088738P.
XX
PR 10-JUN-1998; 98US-0088742P.
```

PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089807P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090352P.
PR 22-JUN-1998; 98US-0090354P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090836P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091636P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 20-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019431.
PR 01-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

```
PR 23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
QY 61 GKGIVKGRNLDGRGLILGAEANGRGVKKNT 90
Db 61 GKGIVKGRNLDGRGLILGAEANGRGVKKNT 90

RESULT 119
ADC55221
ID ADC55221 standard; protein; 90 AA.
XX AC ADC55221;
XX DT 18-DEC-2003 (first entry)
XX DE Human PRO polypeptide #118.
XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalasassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnary; antiinflammatory; anorectic.
XX OS Homo sapiens.
XX PN US2003045463-A1.
XX PD 06-MAR-2003.
XX PF 16-NOV-2001; 2001US-00990437.
XX PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-009057P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 20-JUL-1998; 98US-0092472P.
PR 30-JUL-1998; 98US-0093339P.
PR 04-AUG-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
```

```
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 23-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000US-0213637P.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLLVCETAIWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCETAIWRNSGNTLENGYFSLRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGVKGRNLDSEGLILGAEAWGRGVKKNT 90
Db 61 GKGVKGRNLDSEGLILGAEAWGRGVKKNT 90

RESULT 120
ADCL12088
ID ADC12088 standard; protein; 90 AA.
XX
AC ADC12088;
XX
AC ADC12088;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
US2003049681-A1.
XX
PD 13-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997514.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
```


PR 17-AUG-1998; 98US-00968997P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 20-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99WO-US012357P.
PR 02-JUN-1999; 99WO-US012352.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143848P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028331.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLNGYFLSRNKNHSQPTQSSLEDSTVPTKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLNGYFLSRNKNHSQPTQSSLEDSTVPTKAVKTT 60

QY 61 GKGIYKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIYKGRNLDNRGLILGAEAWGRGVKNT 90
RESULT 122
ADC07565
ID ADC07565 standard; protein; 90 AA.
XX
AC ADC07565;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
DE PRO; secreted protein; transmembrane protein;
XX hypertrophy of neonatal heart; angiogenesis;
XX vascular endothelial growth factor; VEGF-stimulated proliferation;
XX endothelial cell; T-lymphocyte proliferation; retinal neuron;
XX c-fos induction; adipocyte cell; chondrocyte differentiation;
XX pancreatic beta-cell precursor differentiation; gene therapy; tumour;
XX cancer; human; colon cancer; lung cancer; breast cancer;
XX rod photoreceptor cell.
OS Homo sapiens.
XX
PN US2003068647-A1.
XX
PD 10-APR-2003.
XX
PF 15-NOV-2001; 2001US-00997542.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.

Db 61 GKGVKGRNLSRGLILGAENGRGVKKT 90

RESULT 123

ADCL1555

ID ADCL1555 standard; protein; 90 AA.

XX

AC ADCL1555;

DT 18-DEC-2003 (first entry)

DE Human secreted/transmembrane protein PRO159.

XX

KW PRO; secreted protein; transmembrane protein;

KW hypertrophy of neonatal heart; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW c-fos induction; adipocyte cell; chondrocyte differentiation;

KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;

KW cancer; human; colon cancer; lung cancer; breast cancer;

KW rod photoreceptor cell.

OS Homo sapiens.

XX

XX US2003069403-A1.

XX

PD 10-APR-2003.

XX

XX 14-NOV-2001; 2001US-00993748.

XX

PR 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.

PR 02-JUN-1998; 98US-0087607P.

PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.

PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.

PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.

PR 04-JUN-1998; 98US-0088029P.

PR 04-JUN-1998; 98US-0088030P.

PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.

PR 05-JUN-1998; 98US-0088212P.

PR 05-JUN-1998; 98US-0088217P.

PR 09-JUN-1998; 98US-0088655P.

PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.

PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.

PR 10-JUN-1998; 98US-0088824P.

PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.

PR 11-JUN-1998; 98US-0088861P.

PR 11-JUN-1998; 98US-0088876P.

PR 12-JUN-1998; 98US-00889105P.

PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.

PR 16-JUN-1998; 98US-0089514P.

PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.

PR 17-JUN-1998; 98US-0089598P.

PR 17-JUN-1998; 98US-0089599P.

PR 17-JUN-1998; 98US-0089600P.

PR 17-JUN-1998; 98US-0089653P.

PR 18-JUN-1998; 98US-0089801P.

PR 18-JUN-1998; 98US-0089907P.

PR 18-JUN-1998; 98US-0089908P.

PR 19-JUN-1998; 98US-0089947P.

PR 19-JUN-1998; 98US-0089948P.

PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.

PR 23-JUN-1998; 98US-0090349P.

PR 23-JUN-1998; 98US-0090355P.

PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090431P.

PR 24-JUN-1998; 98US-0090435P.

PR 24-JUN-1998; 98US-0090444P.

PR 24-JUN-1998; 98US-0090445P.

PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.

PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.

PR 24-JUN-1998; 98US-0090557P.

PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.

PR 25-JUN-1998; 98US-0090690P.

PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.

PR 26-JUN-1998; 98US-0090862P.

PR 26-JUN-1998; 98US-0090863P.

PR 01-JUL-1998; 98US-0091360P.

PR 01-JUL-1998; 98US-0091544P.

PR 02-JUL-1998; 98US-0091478P.

PR 02-JUL-1998; 98US-0091519P.

PR 02-JUL-1998; 98US-0091626P.

PR 02-JUL-1998; 98US-0091628P.

PR 02-JUL-1998; 98US-0091633P.

PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.

PR 07-JUL-1998; 98US-0091978P.

PR 07-JUL-1998; 98US-0091982P.

PR 09-JUL-1998; 98US-0092182P.

PR 10-JUL-1998; 98US-0092472P.

PR 20-JUL-1998; 98US-0093339P.

PR 30-JUL-1998; 98US-0094651P.

PR 04-AUG-1998; 98US-0095282P.

PR 04-AUG-1998; 98US-0095285P.

PR 04-AUG-1998; 98US-0095301P.

PR 04-AUG-1998; 98US-0095302P.

PR 04-AUG-1998; 98US-0095310P.

PR 04-AUG-1998; 98US-0095321P.

PR 04-AUG-1998; 98US-0095325P.

PR 10-AUG-1998; 98US-0095916P.

PR 10-AUG-1998; 98US-0095929P.

PR 11-AUG-1998; 98US-0096012P.

PR 11-AUG-1998; 98US-0096143P.

PR 12-AUG-1998; 98US-0096146P.

PR 17-AUG-1998; 98US-0096329P.

PR 17-AUG-1998; 98US-0096757P.

PR 17-AUG-1998; 98US-0096766P.

PR 17-AUG-1998; 98US-0096768P.

PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.

PR 17-AUG-1998; 98US-0096867P.

PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096894P.

PR 17-AUG-1998; 98US-0096895P.

PR 17-AUG-1998; 98US-0096897P.

PR 18-AUG-1998; 98US-0096949P.

PR 18-AUG-1998; 98US-0096950P.

CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
 DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
 QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90
 DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 125
 ADC72062
 ID ADC72062 standard; protein; 90 AA.
 AC ADC72062;
 DT 18-DEC-2003 (first entry)
 DE Novel human secreted and transmembrane protein PRO1159.
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003092107-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131828.

XX 07-OCT-1998; 98US-0103315P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-801172/75.
 DR N-PSDB; ADC72061.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating the proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
 DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
 QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90
 DB 61 GKGIKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 126

ADC60041

ID ADC60041 standard; protein; 90 AA.

XX AC ADC60041;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003092105-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131821.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH.) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801170/75.

XX N-PSDB; ADC60040.

XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDLSRGLJLILGAEGWGVKKNT 90

Db 61 GKGIVKGRNLDLSRGLJLILGAEGWGVKKNT 90

RESULT 127
IDC53048

ID ADC53048 standard; protein; 90 AA.

XX ADC53048;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.

XX Homo sapiens.

XX US2003087365-A1.

XX 08-MAY-2003.

XX 23-APR-2002; 2002US-00128689.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX WPI; 2003-801151/75.
 DR N-PSDB; ADC57401.
 XX
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 XX
 XX Claim 1; SEQ ID NO 474; 637pp; English.
 XX
 XX This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophins and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is the amino acid sequence of a human PRO protein of the
 CC invention.
 XX
 XX Sequence 90 AA;
 SQ
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCAIRWNSGNSLTENGFLSRNKENHSQTOSLSLDSVTPKAVKTT 60
 DB 1 MTFPLSLLLLVCAIRWNSGNSLTENGFLSRNKENHSQTOSLSLDSVTPKAVKTT 60
 QY 61 KGKIVKGRNLDRLGILLGAEGWGRVKKNT 90
 DB 61 KGKIVKGRNLDRLGILLGAEGWGRVKKNT 90
 RESULT 129
 ADC60593
 ID ADC60593 standard; protein; 90 AA.
 XX
 AC ADC60593;
 XX
 XX 18-DEC-2003 (first entry)
 XX
 XX Novel human secreted and transmembrane protein PRO1159.
 XX
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; RFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.
 OS
 XX US2003087367-A1.
 PN
 XX 08-MAY-2003.
 PD
 XX 24-APR-2002; 2002US-00131825.
 PF
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-DEC-2000; 2000WO-US034956.
 PR 20-FEB-2001; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001WO-US006566.
 PR 01-MAR-2001; 2001US-00802706.
 PR 12-MAR-2001; 2001US-00806889.
 PR 14-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 25-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908927.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX NPI; 2003-801152/75.
 DR N-PSDB; ADC60592.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.

PS Claim 12; Fig 474; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for

CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKT 60
 DB |||||
 QY 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKHHSQPTQSSLEDSVTPTKAVKT 60
 DB |||||
 QY 61 GKGIKGRNLDRLGLILGAWGRGVKNT 90
 DB |||||
 QY 61 GKGIKGRNLDRLGLILGAWGRGVKNT 90

RESULT 130

ADCS1068

ID ADCS1068 standard; protein; 90 AA.

XX AC ADCS1068;
 XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1159.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW Glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003087361-A1.

XX PD 08-MAY-2003.

XX PF 22-APR-2002; 2002US-00127841.

XX PR 09-SEP-1998; 98US-0099536P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX NPI; 2003-801152/75.
 DR N-PSDB; ADC51067.

Db 61 GKGIVGRNLDRLGLILGAEAWGRGVKNT 90
|||||

RESULT 132

ID ADC54693 standard; protein; 90 AA.

XX ADC54693;

DT 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

PN US2003087363-A1.

XX 08-MAY-2003.

PF 23-APR-2002; 2002US-00128687.

XX 10-SEP-1998; 98US-0099816P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801148/75.

DR N-PSDB; ADC54692.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 1; SEQ ID NO 474; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophic factors and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLILLVCEAIWRSNCSNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
Db |||||||

QY 61 GKGIVGRNLDRLGLILGAEAWGRGVKNT 90
Db |||||||

RESULT 133

ADC53654

ID ADC53654 standard; protein; 90 AA.

XX ADC53654;

DT 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

XX US2003087364-A1.

XX 08-MAY-2003.

XX 23-APR-2002; 2002US-00128688.

XX 09-FEB-1999; 99US-0119341P.

PR 01-DEC-1999; 99WO-US028634.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801149/75.

DR N-PSDB; ADC53653.

XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.

XX Claim 1; SEQ ID NO 474; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neurotrophic factors and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a

CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is the amino acid sequence of a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVPTKAVKTT 60
 QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90
 Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90
 RESULT 134
 ID ADC59177 standard; protein; 90 AA.
 AC ADC59177;
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein Seq ID474.
 DE human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuro peptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 XX
 OS Homo sapiens.
 PN US2003087359-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127834.
 XX
 PR 17-SEP-1998; 98US-0100710p.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-801144/75.
 DR N-PSDB; ADC59176.
 XX
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 1; SEQ ID NO 474; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,

CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is the amino acid sequence of a human PRO protein of the
 CC invention.
 XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVPTKAVKTT 60
 QY 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90
 Db 61 GKGIVKGRNLDRLGILGAEAWGRGVKNT 90

RESULT 135
 ADC56055
 ID ADC56055 standard; protein; 90 AA.
 AC ADC56055;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein Seq ID474.
 DE human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuro peptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 XX
 OS Homo sapiens.
 PN US2003087360-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127836.
 XX
 PR 17-NOV-1998; 98US-0108802P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-801145/75.
 DR N-PSDB; ADC56054.
 XX
 PT New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.

XX PS Claim 1; SEQ ID NO 474; 637pp; English.

XX CC This invention relates to novel nucleic acids encoding human PRO secreted

XX CC and transmembrane proteins. Extracellular proteins play important roles

XX CC in the formation, differentiation and maintenance of multicellular

XX CC organisms. The fate of many individual cells (for example proliferation,

XX CC migration or differentiation) is typically governed by information

XX CC received from other cells and the immediate environment. The information

XX CC is often transmitted by secreted polypeptides (for example mitogenic

XX CC factors, survival factors, cytotoxic factors, differentiation factors,

XX CC neurotrophins and hormones) which are received and interpreted by diverse

XX CC cell receptors or membrane bound proteins. These membrane bound proteins

XX CC as in the blocking of receptor-ligand interactions. The current invention

XX CC provides the amino acid sequences of novel human membrane bound receptors

XX CC and proteins, along with the cDNA sequences encoding them. The novel

XX CC proteins of the invention may have cytostatic activities through the

XX CC stimulation of chondrocytes. The nucleic acids of the invention may be

XX CC useful for the manufacture of a medicament for diagnosing or treating a

XX CC tumour in a mammal. In addition, they may be useful for measuring or

XX CC detecting the expression of a tumour associated gene. The present

XX CC sequence is the amino acid sequence of a human PRO protein of the

XX CC invention.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 136

ADCS58625

ID ADCS58625 standard; protein; 90 AA.

AC ADCS58625;

XX 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein Seq ID474.

XX human; PRO; membrane bound protein; membrane bound receptor;

XX cell proliferation; cell migration; cell differentiation;

XX mitogenic factor; survival factor; cytotoxic factor;

XX differentiation factor; neurotrophin; hormone; cell receptor;

XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.

XX Homo sapiens.

XX US2003087346-A1.

XX 08-MAY-2003.

XX 17-APR-2002; 2002US-00124815.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-801137/75.

XX N-PSDB; ADCS58624.

XX PT Isolated nucleic acid for use in industrial applications has at least 80

XX PT percent nucleic acid sequence identity to nucleotide sequence that

XX PT encodes amino acid sequence selected from amino acid sequence group.

XX PS Claim 1; SEQ ID NO 474; 637pp; English.

XX CC This invention relates to novel nucleic acids encoding human PRO secreted

XX CC and transmembrane proteins. Extracellular proteins play important roles

XX CC in the formation, differentiation and maintenance of multicellular

XX CC organisms. The fate of many individual cells (for example proliferation,

XX CC migration or differentiation) is typically governed by information

XX CC received from other cells and the immediate environment. The information

XX CC is often transmitted by secreted polypeptides (for example mitogenic

XX CC factors, survival factors, cytotoxic factors, differentiation factors,

XX CC neurotrophins and hormones) which are received and interpreted by diverse

XX CC cell receptors or membrane bound proteins. These membrane bound proteins

XX CC as in the blocking of receptor-ligand interactions. The current invention

XX CC provides the amino acid sequences of novel human membrane bound receptors

XX CC and proteins, along with the cDNA sequences encoding them. The novel

XX CC proteins of the invention may have cytostatic activities through the

XX CC stimulation of chondrocytes. The nucleic acids of the invention may be

XX CC useful for the manufacture of a medicament for diagnosing or treating a

XX CC tumour in a mammal. In addition, they may be useful for measuring or

XX CC detecting the expression of a tumour associated gene. The present

XX CC sequence is the amino acid sequence of a human PRO protein of the

XX CC invention.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 137

ADCL4677

ID ADCL4677 standard; protein; 90 AA.

XX ADCL4677;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

XX human; secreted and transmembrane protein; PRO; neurotrophic;

XX neuroprotective; antiparkinsonian; cytostatic; gene therapy;

XX chromosome mapping; gene mapping; transgenic animal; knock-out animal;

XX neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.

XX Homo sapiens.

XX US2003082546-A1.

XX 01-MAY-2003.

XX 28-AUG-2001; 2001US-00941992.

XX 06-NOV-1996; 96US-00743698.

XX 16-JUN-1997; 97US-0049787P.

XX 16-JUN-1997; 97US-00876698.

PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97US-00965056.
PR 12-NOV-1997; 97WO-US020069.
PR 13-NOV-1997; 97US-0065186P.
PR 24-NOV-1997; 97US-0065311P.
PR 25-FEB-1998; 98US-0075945P.
PR 28-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 28-MAY-1998; 98US-0084600P.
PR 02-JUN-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088023P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088213P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 17-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089589P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 22-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 25-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.

PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091636P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 09-JUL-1998; 98US-0091982P.
PR 10-JUL-1998; 98US-0092182P.
PR 20-JUL-1998; 98US-0092472P.
PR 30-JUL-1998; 98US-0093339P.
PR 04-AUG-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 10-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097022P.
PR 20-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098014P.
PR 16-SEP-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 07-OCT-1998; 98WO-US019437.
PR 06-NOV-1998; 98US-00168978.
PR 01-DEC-1998; 98US-00187368.
PR 07-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 98US-0113296P.
PR 20-FEB-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.

```

PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 09-MAR-1999; 99US-00254460.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-APR-1999; 99US-00284291.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 18-OCT-1999; 99US-00403296.
PR 12-NOV-1999; 99US-00423844.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 05-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004341.
PR 22-FEB-2000; 2000WO-US0004414.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAWRNSGNTLENGYFLSRNKNHSQPTOSLSDSVPTKAVKTT 60
Db 1 MTFPLSLLLLVCEAWRNSGNTLENGYFLSRNKNHSQPTOSLSDSVPTKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEGWGVKKNT 90
Db 61 GKGIKGRNLDRLGLILGAEGWGVKKNT 90

RESULT 138
ADD08209
ID ADD08209 standard; protein; 90 AA.
AC
XX
XX
DT
DT
XX
XX
DE 01-JAN-2004 (first entry)
XX
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;
KW antiparkinsonian.
OS
XX Homo sapiens.
XX
FN US2003068623-A1.
XX

```

```

PD 10-APR-2003.
XX
XX
XX 14-NOV-2001; 2001US-00993469.
XX
PR 15-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089103P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.

```


PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 13-SEP-1999; 98WO-US020594.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US021089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 16-DEC-1999; 98WO-US028565.
PR 20-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-JUL-2000; 2000WO-US020710.
PR 28-AUG-2000; 2000WO-US020731.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801169/75.

N-PSDB; ADD03298.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 12; Fig 474; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

SQ

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNCGSNTLENGYFLSRKNHQSPTQSSLEDSVPTPKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRSNCGSNTLENGYFLSRKNHQSPTQSSLEDSVPTPKAVKTT 60

QY 61 KGKIVKGNLDSRGLILGAEWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEWGRGVKNT 90

RESULT 140

ID ADC90291 standard; protein; 90 AA.

XX

AC ADC90291;

DT 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO1159.

DE Human; secreted and transmembrane protein; PRO;

KW tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS

XX US2003087348-A1.

PN

XX 08-MAY-2003.

PD

XX 19-APR-2002; 2002US-00125923.

PF

XX 05-JUN-2000; 2000US-0209832P.

PR

XX 01-DEC-2000; 2000WO-US032678.

PR

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

PA

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tomas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786939/74.

DR N-PSDB; ADC90290.

DR

XX New PRO nucleic acid, useful for manufacturing a medicament for

PT diagnosing or treating tumor.

XX

XX Claim 12; SEQ ID NO 474; 637pp; English.

XX

XX The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation or gene expression in pericyte

CC cells, for stimulating the release of or gene expression in pericyte

CC cells, for stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino

CC acid sequence of a novel human secreted and transmembrane PRO

XX polypeptide.

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNCGSNTLENGYFLSRKNHQSPTQSSLEDSVPTPKAVKTT 60

Db 1 MTFFLSLLLLVCEAIWRSNCGSNTLENGYFLSRKNHQSPTQSSLEDSVPTPKAVKTT 60

QY 61 KGKIVKGNLDSRGLILGAEWGRGVKNT 90

Db 61 KGKIVKGNLDSRGLILGAEWGRGVKNT 90

RESULT 141

ID ADC82034

XX ADC82034 standard; protein; 90 AA.

XX

AC ADC82034;

DT 01-JAN-2004 (first entry)

XX Human PRO polypeptide #118.

DE

XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; antidiabetic; antianemic;

KW cytosstatic; cardiant; vulnerrary; antiinflammatory; anorectic.

XX

OS Homo sapiens.

XX

XX US2003083461-A1.

PN

XX 01-MAY-2003.

XX

XX 14-NOV-2001; 2001US-00992521.

XX

XX 16-JUN-1997; 97US-0049787P.

XX

XX 17-OCT-1997; 97US-0062250P.

XX

XX 05-NOV-1997; 97WO-US020069.

XX

XX 12-NOV-1997; 97US-0065186P.

XX

XX 24-NOV-1997; 97US-0065311P.

XX

XX 25-FEB-1998; 98US-0066770P.

XX

XX 20-MAR-1998; 98US-0075945P.

XX

XX 28-APR-1998; 98US-0078310P.

XX

XX 07-MAY-1998; 98US-0083322P.

XX

XX 28-MAY-1998; 98US-0084600P.

XX

XX 02-JUN-1998; 98US-0087106P.

XX

XX 02-JUN-1998; 98US-0087609P.

XX

XX 02-JUN-1998; 98US-0087759P.

XX

XX 03-JUN-1998; 98US-0087827P.

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006984.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPTKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPTKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAEGWGVKNT 90
DB 61 GKGVKGRNLDRLGLILGAEGWGVKNT 90

RESULT 142

ADC69710
ID ADC69710 standard; protein; 90 AA.

XX AC ADC69710;

DT 01-JAN-2004 (first entry)

DE Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003194770-A1.

PD 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152375.

XX 03-MAR-2000; 2000US-0187202P.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-844453/78.

XX N-PSDB; ADC69709.

XX

PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

PS Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX the proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPTKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSOPTOSSLEDSVTPTKAVKTT 60

QY 61 GKGVKGRNLDRLGLILGAEGWGVKNT 90

DB 61 GKGVKGRNLDRLGLILGAEGWGVKNT 90

RESULT 143

ADC48599

ID ADC48599 standard; protein; 90 AA.

XX AC ADC48599;

XX 01-JAN-2004 (first entry)

DT Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194773-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152391.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844455/78.
DR N-PSDB; ADC48598.
XX
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLYCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
DB |||||
1 MTFFLSLLLLYCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTTKAVKTT 60
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKNT 90
DB |||||
61 GKGIVKGRNLDNRGLILGAEAWGRGVKKNT 90
RESULT 144
ADD10128
ID ADD10128 standard; protein; 90 AA.
XX
AC ADD10128;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX US2003194776-A1.
XX
PD 16-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-852596/79.
DR N-PSDB; ADD10127.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFLLSLLLVCEAIWNSGNSNLENGYFLSRKNHNSQPTQSSLEDSVTPKAVKTT 60
Db 1 MTFLLSLLLVCEAIWNSGNSNLENGYFLSRKNHNSQPTQSSLEDSVTPKAVKTT 60
Qy 61 KGIVKGRNLSRGILLGAEGWGRGVKNT 90
Db 61 KGIVKGRNLSRGILLGAEGWGRGVKNT 90

RESULT 145

ADD07676

ID ADD07676 standard; protein; 90 AA.

XX

AC ADD07676;

XX

DT 01-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO1159.

XX

KW Human; secreted protein; transmembrane protein; PRO;

KW neonatal heart hypertrophy; angiogenesis;

KW vascular endothelial growth factor; VEGF-stimulated proliferation;

KW endothelial cell; T-lymphocyte proliferation; retinal neuron;

KW rod photoreceptor cell; c-fos induction; adipocyte;

KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;

KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

KW polycystic kidney disease; renal tumour; neurodegenerative disorder;

KW Parkinson's disease; Alzheimer's disease; gene therapy;

KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;

KW antidiabetic; antianaemic; cytostatic; neuroprotective;

KW antiparkinsonian.

XX

OS Homo sapiens.

XX

XX US2002193299-A1.

XX

PD 19-DEC-2002.

XX

XX 19-NOV-2001; 2001US-00989735.

XX

XX 16-JUN-1997; 97US-0045787P.

PR

PR 17-OCT-1997; 97US-0062250P.

PR

PR 05-NOV-1997; 97WO-US020069.

PR

PR 12-NOV-1997; 97US-0065186P.

PR

PR 13-NOV-1997; 97US-0065311P.

PR

PR 24-NOV-1997; 97US-0066770P.

PR

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 02-JUN-1999; 98WO-US012252.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US007377.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
XX WPI; 2003-657230/62.
XX N-PSDB; ADD07675.
XX
XX Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and
PT are thus therapeutically useful e.g. for enhancing immune response.
XX
XX Claim 12; SEQ ID NO 377; 659pp; English.
XX
XX The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of
CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
|||||

Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90
|||||
Db 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90
|||||
RESULT 146
ADD04703
ID ADD04703 standard; protein; 90 AA.
XX
AC ADD04703;
XX
DT 01-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
OS
XX US2003087354-A1.
XX
PD 08-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127827.
XX
XX 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801139/75.
XX N-PSDB; ADD04702.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems. articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFELSLILLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDRLGLIIGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDRLGLIIGAEAWGRGVKNT 90

RESULT 147

ADC82567

ID ADC82567 standard; protein; 90 AA.

XX AC ADC82567;

XX DT 01-JAN-2004 (first entry)

XX DE Human PRO polypeptide #118.

XX KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;

XX KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;

XX KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;

XX KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;

XX KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.

XX OS Homo sapiens.

XX PN US2003059833-A1.

XX PD 27-MAR-2003.

XX PF 15-NOV-2001; 2001US-00997440.

XX PR 16-JUN-1997; 97US-0049787F.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 05-NOV-1997; 97WO-US020069.

XX PR 12-NOV-1997; 97US-0065186P.

XX PR 13-NOV-1997; 97US-0065311P.

XX PR 24-NOV-1997; 97US-0066770P.

XX PR 25-FEB-1998; 98US-0075945P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 28-APR-1998; 98US-0083322P.

XX PR 07-MAY-1998; 98US-0084600P.

XX PR 28-MAY-1998; 98US-0087106P.

XX PR 02-JUN-1998; 98US-0087607P.

XX PR 02-JUN-1998; 98US-0087609P.

PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088467P.
PR 05-JUN-1998; 98US-0088820P.
PR 05-JUN-1998; 98US-0088821P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 23-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.

```
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095918P.
PR 10-AUG-1998; 98US-0095923P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096113P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096146P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100859P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 22-DEC-1998; 98US-0100858P.
PR 05-JAN-1999; 98US-0100858P.
PR 20-FEB-1999; 98US-0100858P.
PR 08-MAR-1999; 98US-0100858P.
PR 12-MAR-1999; 98US-0100858P.
PR 02-JUN-1999; 98US-0100858P.
PR 23-JUN-1999; 98US-0100858P.
PR 07-JUL-1999; 98US-0100858P.
PR 20-JUL-1999; 98US-0100858P.
PR 26-JUL-1999; 98US-0100858P.
PR 28-JUL-1999; 98US-0100858P.
PR 17-AUG-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 08-OCT-1999; 98US-0100858P.
PR 30-NOV-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 16-DEC-1999; 98US-0100858P.
PR 05-JAN-2000; 98US-0100858P.
PR 06-JAN-2000; 98US-0100858P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095918P.
PR 10-AUG-1998; 98US-0095923P.
PR 10-AUG-1998; 98US-0095929P.
PR 11-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096113P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096146P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100859P.
PR 07-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 22-DEC-1998; 98US-0100858P.
PR 05-JAN-1999; 98US-0100858P.
PR 20-FEB-1999; 98US-0100858P.
PR 08-MAR-1999; 98US-0100858P.
PR 12-MAR-1999; 98US-0100858P.
PR 02-JUN-1999; 98US-0100858P.
PR 23-JUN-1999; 98US-0100858P.
PR 07-JUL-1999; 98US-0100858P.
PR 20-JUL-1999; 98US-0100858P.
PR 26-JUL-1999; 98US-0100858P.
PR 28-JUL-1999; 98US-0100858P.
PR 17-AUG-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 15-SEP-1999; 98US-0100858P.
PR 08-OCT-1999; 98US-0100858P.
PR 30-NOV-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 01-DEC-1999; 98US-0100858P.
PR 16-DEC-1999; 98US-0100858P.
PR 05-JAN-2000; 98US-0100858P.
PR 06-JAN-2000; 98US-0100858P.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013358.
PR 22-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKHHSQPTOSLSDSVTPKAVKTT 60
Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGVFLSRNKHHSQPTOSLSDSVTPKAVKTT 60
QY 61 GKGVKGRNLDRLGLGAEAWGRGVKNT 90
Db 61 GKGVKGRNLDRLGLGAEAWGRGVKNT 90
RESULT 148
ADC80659
ID ADC80659 standard; protein; 90 AA.
AC ADC80659;
XX
DT 01-JAN-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; thalassaemia;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
FN US2003092103-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131815.
XX
PR 22-DEC-1998; 98US-0113511P.
PR 01-DEC-1999; 98US-0113511P.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US0032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH ) GENENTECH INC.
XX
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
```

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801166/75.
 DR N-PSDB; ADC80658.
 DR
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polypeptide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;

 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

 QY 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90
 Db 61 GKGIVKGRNLDRLGLILGAEAWGRGVKNT 90

 RESULT 149
 ADD11166
 ID ADD11166 standard; protein; 90 AA.
 AC ADD11166;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human PRO polypeptide #237.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; FFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003194774-A1.
 XX
 XX 16-OCT-2003.
 XX
 PF 21-MAY-2002; 2002US-00152399.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENEINTECH INC.
 XX
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-852594/79.
 DR N-PSDB; ADD11165.
 DR
 XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 PT for detecting a tumor, stimulating the proliferation or differentiation
 PT of chondrocyte cells and stimulating the release of tumor necrosis factor
 PT alpha.
 XX
 PS Claim 12; SEQ ID NO 474; 637pp; English.

 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 cells, for stimulating differentiation of adipocyte cells, for
 stimulating proliferation of or gene expression in pericyte cells, for
 stimulating the proliferation of inner ear utricular supporting cells or
 T-lymphocyte cells, for inducing endothelial cell tube formation and for
 treating various bone and/or cartilage disorders such as sports injuries
 and arthritis. PRO polypeptides which stimulate the release of
 proteoglycans from cartilage are useful for treating sports-related joint
 problems, articular cartilage defects, osteoarthritis and rheumatoid
 arthritis. PRO polypeptides are also useful for treating various
 mammalian haemoglobin-associated disorders such as various thalassaemias
 and conditions which may benefit from enhanced local immune system cell
 infiltration. This sequence represents a human PRO polypeptide of the
 invention. Note: The sequence data for this patent is also available in
 electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 90 AA;

```
Query Match      100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKN 90
DB 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKN 90

RESULT 150
ADC48047
ID ADC48047 standard; protein; 90 AA.
XX
AC ADC48047;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194771-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152377.
XX
PR 09-DEC-1999; 99US-0170262P.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Gurney SL, Smith V;
PI Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844454/78.
XX
DR N-PSDB; ADC48046.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and stimulating the proliferation of endothelial cells.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
```

```
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumors, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match      100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKN 90
DB 61 GKGIVKGRNLDNRGLILGAEAWGRGVKKN 90

RESULT 151
ADD08747
ID ADD08747 standard; protein; 90 AA.
XX
AC ADD08747;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; neurotropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2003073090-A1.
XX
PD 17-APR-2003.
XX
PF 16-NOV-2001; 2001US-00990439.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
```



```

PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US000431.
PR 22-FEB-2000; 2000WO-US000414.
PR 24-FEB-2000; 2000WO-US0004914.
PR 24-FEB-2000; 2000WO-US0005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US0006319.
PR 15-MAR-2000; 2000WO-US0006884.
PR 20-MAR-2000; 2000WO-US0007377.
PR 30-MAR-2000; 2000WO-US0008439.
PR 15-MAY-2000; 2000WO-US013358.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSHQTSLSLEDSVTPKAVKTT 60
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSHQTSLSLEDSVTPKAVKTT 60

QY 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90
DB 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90

RESULT 152
ADC80107
ID ADC80107 standard; protein; 90 AA.
XX
AC ADC80107;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087358-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127833.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US0004342.
PR 08-NOV-2000; 2000WO-US010952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX

```

```

PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801143/75.
DR N-PSDB; ADC80106.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSHQTSLSLEDSVTPKAVKTT 60
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKNHSHQTSLSLEDSVTPKAVKTT 60

QY 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90
DB 61 GKGVKGRNLDNRGLILGAEGWGVKKNT 90

RESULT 153
ADD06996
ID ADD06996 standard; protein; 90 AA.
XX
AC ADD06996;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX

```

KW	Human; secreted protein; transmembrane protein; PRO;	PR	16-SEP-1998;	98WO-US019330.
KW	neonatal heart hypertrophy; angiogenesis;	PR	17-SEP-1998;	98WO-US019437.
KW	vascular endothelial growth factor; VEGF-stimulated proliferation;	PR	07-OCT-1998;	98WO-US021141.
KW	endothelial cell; T-lymphocyte proliferation; retinal neuron;	PR	01-DEC-1998;	98WO-US025108.
KW	rod photoreceptor cell; c-fos induction; adipocyte;	PR	05-JAN-1999;	99WO-US000106.
KW	chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;	PR	08-MAR-1999;	99WO-US005028.
KW	breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;	PR	02-JUN-1999;	99WO-US012252.
KW	insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;	PR	15-SEP-1999;	99WO-US021547.
KW	thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;	PR	15-SEP-1999;	99WO-US028313.
KW	polycystic kidney disease; renal tumour; neurodegenerative disorder;	PR	01-DEC-1999;	99WO-US028301.
KW	Parkinson's disease; Alzheimer's disease; gene therapy;	PR	01-DEC-1999;	99WO-US028634.
KW	chromosome mapping; gene mapping; transgenic animal; knock-out animal;	PR	16-DEC-1999;	99WO-US030095.
KW	antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;	PR	20-DEC-1999;	99WO-US030911.
KW	antiparkinsonian.	PR	05-JAN-2000;	2000WO-US000219.
OS		PR	06-JAN-2000;	2000WO-US000376.
OS	Homo sapiens.	PR	11-FEB-2000;	2000WO-US003565.
XX		PR	11-FEB-2000;	2000WO-US003565.
XX		PR	18-FEB-2000;	2000WO-US004341.
XX		PR	22-FEB-2000;	2000WO-US004414.
PD		PR	24-FEB-2000;	2000WO-US004914.
XX		PR	24-FEB-2000;	2000WO-US005004.
XX		PR	02-MAR-2000;	2000WO-US005841.
XX		PR	10-MAR-2000;	2000WO-US006319.
XX		PR	15-MAR-2000;	2000WO-US006684.
XX		PR	20-MAR-2000;	2000WO-US007377.
PR		PR	30-MAR-2000;	2000WO-US008439.
PR		PR	15-MAY-2000;	2000WO-US013358.
PR		PR	17-MAY-2000;	2000WO-US013705.
PR		PR	22-MAY-2000;	2000WO-US014042.
PR		PR	30-MAY-2000;	2000WO-US014941.
PR		PR	02-JUN-2000;	2000WO-US015264.
PR		PR	28-JUL-2000;	2000WO-US020710.
PR		PR	11-AUG-2000;	2000WO-US022031.
PR		PR	23-AUG-2000;	2000WO-US023522.
PR		PR	24-AUG-2000;	2000WO-US023328.
PR		PR	08-NOV-2000;	2000WO-US030952.
PR		PR	01-DEC-2000;	2000WO-US032678.
PR		PR	28-FEB-2001;	2001WO-US006520.
PR		PR	01-JUN-2001;	2001WO-US017800.
PR		PR	20-JUN-2001;	2001WO-US019692.
PR		PR	29-JUN-2001;	2001WO-US021066.
PR		PR	09-JUL-2001;	2001WO-US021735.
PR		PR	28-AUG-2001;	2001US-00941992.
XX		PA		(GETH) GENENTECH INC.
XX		PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;	
XX		PI	Ferrara N, Fong S, Gerber H, Gerechtson ME, Goddard A, Godowski PJ;	
PI		PI	Grimaldi JC, Gurney AL, Kujavski LJ, Napier MA, Pan J, Paoni NF;	
PI		PI	Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;	
PI		PI	Zhang Z;	
XX		XX	WPI; 2003-657231/62.	
DR		DR	N-PSDB; ADD06995.	
XX		XX		
PT		PT	Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346	
PT		PT	and PRO1375, which stimulate proliferation of stimulated T-lymphocytes	
XX		XX	and are thus therapeutically useful for enhancing immune response.	
XX		XX	Claim 12; SEQ ID NO 377; 653pp; English.	
XX		XX	The invention relates to human secreted and transmembrane PRO	
CC		CC	polypeptides and the polynucleotides encoding them. The PRO polypeptides	
CC		CC	or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors	
CC		CC	or bioreactors. They are useful for stimulating hypertrophy of neonatal	
CC		CC	heart, promoting angiogenesis, inhibiting vascular endothelial growth	
CC		CC	factor (VEGF)-stimulated proliferation of endothelial cells, modulating	
CC		CC	the proliferation of stimulated T-lymphocytes, enhancing the survival or	
CC		CC	proliferation of retinal neurons or rod photoreceptor cells, inducing c-	
CC		CC	fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,	
CC		CC	inducing proliferation and/or re-differentiation of chondrocytes, or	
CC		CC	inducing pancreatic beta-cell precursor differentiation into mature	
CC		CC	pancreatic beta-cells. They may therefore be useful in the treatment of	
CC		CC		

CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
QY 61 GKGIKVRNLDLSRGLILGAEGWGRGVKNT 90
DB 61 GKGIKVRNLDLSRGLILGAEGWGRGVKNT 90

RESULT 154

ID ADD09576 standard; protein; 90 AA.

AC ADD09576;

XX 01-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003194775-A1.

XX 16-OCT-2003.

XX 28-MAY-2002; 2002US-00156848.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-852595/79.
DR N-PSDB; ADD09575.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha from blood and stimulating the release of proteoglycans from
PT cartilage.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
DB 1 MTFLLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
QY 61 GKGIKVRNLDLSRGLILGAEGWGRGVKNT 90
DB 61 GKGIKVRNLDLSRGLILGAEGWGRGVKNT 90

RESULT 155

AD83243

ID ADC83243 standard; protein; 90 AA.

XX AC ADC83243;

XX 01-JAN-2004 (first entry)

XX Human PRO polypeptide #118.

XX Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;

insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytotatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
XX Homo sapiens.
OS
XX US2003059783-A1.
PN
XX 27-MAR-2003.
PD
XX
XX 15-NOV-2001; 2001US-00997683.
XX
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US202069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089533P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089601P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090515P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090895P.
PR 25-JUN-1998; 98US-0090896P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0092182P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 12-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.

of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems. PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 158
ADD53168

ID ADD53168 standard; protein; 90 AA.

AC ADD53168;

XX 15-JAN-2004 (first entry)

DT Human PRO polypeptide #237.

DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003194792-A1.

PN 16-OCT-2003.

XX 15-APR-2002; 2002US-00123156.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018624.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 157

ADD52428

ID ADD52428 standard; protein; 90 AA.

AC ADD52428;

XX 15-JAN-2004 (first entry)

DT Human PRO polypeptide #237.

DE Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003194769-A1.

PN 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152374.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-852593/79.

XX N-PSDB; ADD52427.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX acids useful for detection of tumors, modulating the uptake of glucose

XX or free fatty acids and stimulating the release of proteoglycans from

XX cartilage.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation

PR 29-OCT-1998; 98WO-US022992.
PR 30-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-852599/79.
DR N-PSDB; ADD53167.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLESDVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGVFLSRNKENHSQPTQSSLESDVTPTKAVKTT 60

CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFFLSLLLLVCEAIWESNGSNTLENGYFLSRNKNHSPTQSSLEDSVTPKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWESNGSNTLENGYFLSRNKNHSPTQSSLEDSVTPKAVKTT 60
Qy 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
RESULT 160
ADD55350
ID ADD55350 standard; protein; 90 AA.
XX
AC ADD55350;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiac; vulnary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003077593-A1.
XX
PD 24-APR-2003.
XX
PF 19-NOV-2001; 2001US-00989328.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087105P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.

Qy 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
Db 61 GKGIVKGNLDSRGLILGAEAWGRGVKNT 90
RESULT 159
ADD53720
ID ADD53720 standard; protein; 90 AA.
XX
AC ADD53720;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203437-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146728.
XX
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUN-1999; 99WO-US012252.
PR 01-DEC-2000; 2000US-00380137.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2003-875644/81.
DR N-PSDB; ADD53719.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
FS Claim 12; SEQ ID NO 474; 659pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the

PR	15-MAY-2000;	2000WO-US013358.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	23-JUN-2000;	2000US-0213637P.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	11-AUG-2000;	2000WO-US022031.	
PR	23-AUG-2000;	2000WO-US023522.	

Query Match	100.0%;	Score 462;	DB 7;	Length 90;
Best Local Similarity	100.0%;	Pred. No. 9,8e-49;		
Matches 90;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	1	MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSPTOSSLEDSVTPTKAVKTT	60
Db	1	MTFFLSLLLLLVCEAIWRNSGSGNTLENGYFLSRKNKHNHSPTOSSLEDSVTPTKAVKTT	60
Qy	61	GKGIWKGRLNDSRGLILGAEAWGRGVKXNT	90
Db	61	GKGIWKGRLNDSRGLILGAEAWGRGVKXNT	90

RESULT 161	
ADD56308	
ID	ADD56308 standard; protein; 90 AA.
XX	ADD56308;
XX	15-JAN-2004 (first entry)
XX	Human PRO polypeptide #118.
XX	Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW	insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW	thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW	polycystic kidney disease; renal tumour; antidiabetic; antinaemic;
KW	cystostatic; cardiast; vulnary; antiinflammatory; anorectic.
XX	Homo sapiens.
XX	US2003077594-A1.
XX	24-APR-2003.
XX	14-NOV-2001; 2001US-00993583.
XX	16-JUN-1997; 97US-0049787P.
PR	17-OCT-1997; 97US-0062250P.
PR	05-NOV-1997; 97WO-US020069.
PR	12-NOV-1997; 97US-0065186P.
PR	13-NOV-1997; 97US-0065311P.
PR	24-NOV-1997; 97US-0066770P.
PR	25-FEB-1998; 98US-0075345P.
PR	20-MAR-1998; 98US-0078910P.
PR	28-APR-1998; 98US-0083322P.
PR	07-MAY-1998; 98US-0084600P.
PR	28-MAY-1998; 98US-0087106P.
PR	02-JUN-1998; 98US-0087607P.
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1998; 98US-0087759P.
PR	03-JUN-1998; 98US-0087827P.
PR	04-JUN-1998; 98US-0088021P.
PR	04-JUN-1998; 98US-0088025P.
PR	04-JUN-1998; 98US-0088026P.
PR	04-JUN-1998; 98US-0088028P.
PR	04-JUN-1998; 98US-0088029P.
PR	04-JUN-1998; 98US-0088030P.
PR	04-JUN-1998; 98US-0088033P.
PR	04-JUN-1998; 98US-0088326P.
PR	05-JUN-1998; 98US-0088167P.
PR	05-JUN-1998; 98US-0088202P.
PR	05-JUN-1998; 98US-0088212P.

```

PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100633P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 01-OCT-1998; 98US-0100858P.
PR 01-DEC-1998; 98US-0100858P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 98US-0113296P.
PR 08-MAR-1999; 98US-0123957P.
PR 08-MAR-1999; 98US-0123957P.
PR 02-JUN-1999; 98US-0140377P.
PR 23-JUN-1999; 98US-0140377P.
PR 07-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0144758P.
PR 28-JUL-1999; 98US-0146222P.
PR 17-AUG-1999; 98US-0149386P.
PR 17-AUG-1999; 98US-0149386P.
PR 15-SEP-1999; 98US-0158663P.
PR 15-SEP-1999; 98US-0158663P.
PR 08-OCT-1999; 98US-0158663P.
PR 30-NOV-1999; 98US-0158663P.
PR 01-DEC-1999; 98US-0158663P.
PR 16-DEC-1999; 98US-0158663P.
PR 20-DEC-1999; 98US-0158663P.
PR 05-JAN-2000; 98US-0158663P.
PR 06-JAN-2000; 98US-0158663P.
PR 11-FEB-2000; 98US-0158663P.
PR 18-FEB-2000; 98US-0158663P.
PR 22-FEB-2000; 98US-0158663P.
PR 24-FEB-2000; 98US-0158663P.
PR 24-FEB-2000; 98US-0158663P.
PR 02-MAR-2000; 98US-0158663P.
PR 10-MAR-2000; 98US-0158663P.
PR 15-MAR-2000; 98US-0158663P.
PR 20-MAR-2000; 98US-0158663P.
PR 30-MAR-2000; 98US-0158663P.
PR 15-MAY-2000; 98US-0158663P.
PR 17-MAY-2000; 98US-0158663P.
PR 22-MAY-2000; 98US-0158663P.
PR 30-MAY-2000; 98US-0158663P.

PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023323.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLILLVCEAIWFNSGNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60
   |||||
Db 1 MTFFLSLILLVCEAIWFNSGNTLENGYFLSRKNHNSOPTQSSLEDSVTPTKAVKTT 60
   |||||

QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
   |||||
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 162
ADD51876
ID ADD51876 standard; protein; 90 AA.
XX AC ADD51876;
XX DT 15-JAN-2004 (first entry)
XX DE Human PRO polypeptide #237.
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
   liver; microvascular endothelial cell; Glucose; FFA;
   skeletal muscle cell; adipocyte cell; pericyte cell;
   inner ear utricular supporting cell; T-lymphocyte cell;
   endothelial cell tube formation; bone disorder; cartilage disorder;
   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
   rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
   immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003194779-A1.
XX PD 16-OCT-2003.
XX PF 30-MAY-2002; 2002US-00160500.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
   WPI; 2003-852597/79.
XX DR N-PSDB; ADD51875.
XX PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
   for detecting the presence of a tumor, stimulating the release of tumor
   necrosis factor alpha from human blood and treating, e.g. organ failure.
XX PS Claim 12; Fig 474; 637pp; English.
XX CC The invention relates to isolated human PRO polypeptides (secreted and
   transmembrane polypeptides) and the polynucleotides encoding them. The
   invention also relates to an antibody which specifically binds to a PRO
   polypeptide, a method for stimulating the release of tumour necrosis
   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
```


CC	proliferation or differentiation of chondrocyte cells and a method for	PR	28-OCT-1998; 98US-0106030P.
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	PR	01-SEP-1999; 99WO-US020111.
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours).	PR	18-OCT-1999; 99US-00403297.
CC	polynucleotides are useful in molecular biology, including uses as	PR	18-FEB-2000; 2000WO-US004342.
CC	hybridisation probes, in chromosome and gene mapping, in generating	PR	24-AUG-2000; 2000WO-US023328.
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	PR	01-DEC-2000; 2000WO-US02678.
CC	be used in preparing PRO polypeptides by recombinant techniques and in	PR	19-DEC-2001; 2001US-00028072.
CC	generating either transgenic animals or knock-out animals which are	XX	
CC	useful in the development and screening of therapeutically useful	XX	(GETH) GENENTECH INC.
CC	reagents. The PRO polypeptides or antibodies are used in preparing a	XX	
CC	medicament for treating a condition responsive to the polypeptides or	PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	PI	Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
CC	of human microvascular endothelial cells, for modulating the uptake of	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	XX	WPI; 2003-875638/81.
CC	stimulating differentiation of adipocyte cells, for stimulating	DR	N-PSDB; ADD02674.
CC	proliferation of or gene expression in pericyte cells, for stimulating	DR	
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	XX	
CC	cells, for inducing endothelial cell tube formation and for treating	XX	
CC	various bone and/or cartilage disorders such as sports injuries and	PT	PRO4978, useful in molecular biology, chromosome and gene mapping, in
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans	PT	generating antisense RNA and DNA, and in gene therapy.
CC	from cartilage are useful for treating sports-related joint problems, PRO	XX	
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO	PS	Claim 12; Fig 474; 637pp; English.
CC	polypeptides are also useful for treating various mammalian haemoglobin-	XX	
CC	associated disorders such as various thalassaemias and conditions which	CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	may benefit from enhanced local immune system cell infiltration. This	CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	sequence represents a human PRO polypeptide of the invention. Note: The	CC	invention also relates to an antibody which specifically binds to a PRO
CC	sequence data for this patent is also available in electronic format from	CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	the USPTO website at seqdata.uspto.gov.	CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX		CC	proliferation or differentiation of chondrocyte cells and a method for
SQ	Sequence 90 AA;	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
	Query Match 100.0%; Score 462; DB 7; Length 90;	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
	Best Local Similarity 100.0%; Pred. No. 9.8e-49;	CC	polynucleotides are useful in molecular biology, including uses as
	Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	CC	hybridisation probes, in chromosome and gene mapping, in generating
		CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
		CC	be used in preparing PRO polypeptides by recombinant techniques and in
		CC	generating either transgenic animals or knock-out animals which are
		CC	useful in the development and screening of therapeutically useful
		CC	reagents. The PRO polypeptides or antibodies are used in preparing a
		CC	medicament for treating a condition responsive to the polypeptides or
		CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
		CC	of human microvascular endothelial cells, for modulating the uptake of
		CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
		CC	stimulating differentiation of adipocyte cells, for stimulating
		CC	proliferation of or gene expression in pericyte cells, for stimulating
		CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
		CC	cells, for inducing endothelial cell tube formation and for treating
		CC	various bone and/or cartilage disorders such as sports injuries and
		CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
		CC	from cartilage are useful for treating sports-related joint problems, PRO
		CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
		CC	polypeptides are also useful for treating various mammalian haemoglobin-
		CC	associated disorders such as various thalassaemias and conditions which
		CC	may benefit from enhanced local immune system cell infiltration. This
		CC	sequence represents a human PRO polypeptide of the invention. Note: The
		CC	sequence data for this patent is also available in electronic format from
		CC	the USPTO website at seqdata.uspto.gov.
		XX	
		SQ	Sequence 90 AA;
			Query Match 100.0%; Score 462; DB 7; Length 90;
			Best Local Similarity 100.0%; Pred. No. 9.8e-49;
			Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGPTQSSLEDSVTPKAVKTT 60		
DB	1 MTFPLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSGPTQSSLEDSVTPKAVKTT 60		
QY	61 KGKIVKGRNLDNRGLLILGAEAWGRGVKNT 90		
DB	61 KGKIVKGRNLDNRGLLILGAEAWGRGVKNT 90		
RESULT 163			
ADD02675			
ID	ADD02675 standard; protein; 90 AA.		
XX			
AC	ADD02675;		
XX			
DT	15-JAN-2004 (first entry)		
XX			
DE	Human PRO polypeptide #237.		
XX			
KW	Human; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003203431-A1.		
XX			
PD	30-OCT-2003.		
XX			
PF	24-APR-2002; 2002US-00131820.		
XX			

ADD02109
ID ADD02109 standard; protein; 90 AA.
XX
AC ADD02109;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003203430-A1.
XX
XX 30-OCT-2003.
XX
XX 23-APR-2002; 2002US-00128685.
XX
XX 11-AUG-1998; 98US-0096143P.
XX
XX 02-JUN-1999; 99WO-US012252.
XX
XX 30-MAR-2000; 2000US-00380137.
XX
XX 30-MAR-2000; 2000WO-US008439.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875637/81.
XX
XX N-PSDB; ADD02108.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFEFLSLILLVCEALWRSNSGNTLENGYFLSRKNHSHQPTQSSLEDVPTKAVKTT 60
DB 1 MTFEFLSLILLVCEALWRSNSGNTLENGYFLSRKNHSHQPTQSSLEDVPTKAVKTT 60
QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90
DB 61 GKGIKGRNLDGRGLILGAEAWGRGVKKNT 90
RESULT 165
ADD54291
ID ADD54291 standard; protein; 90 AA.
XX
AC ADD54291;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
XX Human; secreted and transmembrane protein; PRO;
KW tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
XX
XX US2003203432-A1.
XX
XX 30-OCT-2003.
XX
XX 10-MAY-2002; 2002US-00142886.
XX
XX 05-JUN-2000; 2000US-0209832P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875639/81.
XX
XX N-PSDB; ADD54290.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 12; SEQ ID NO 474; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and

transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSOPTQSSLEDVTPTKAVKTT 60
DB 1 MTFELSLLLLVCEAIWRSNGSNTLENGYFLSRNKENHSOPTQSSLEDVTPTKAVKTT 60

QY 61 KGKIVKGNLSDRGHILGAEWGRGVKNT 90
DB 61 KGKIVKGNLSDRGHILGAEWGRGVKNT 90

RESULT 166
ADD54746
ID ADD54746 standard; protein; 90 AA.
XX
AC ADD54746;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell; insulin deficiency; diabetes mellitus; haemoglobin-associated disorder; thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia; polycystic kidney disease; renal tumour; antidiabetic; antinaemic; cytostatic; cardiant; vulnary; antinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2002132253-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00991163.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088036P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 12-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;
PI Zhang Z;
XX WPI: 2003-695825/66.
DR N-PSDB; ADD54745.
XX New PRO polypeptides and nucleic acid molecules, useful in gene therapy,
FT or in diagnosing or treating inflammatory diseases, diabetes, cancer,
PT rheumatoid arthritis, ulcers, amyotrophic lateral sclerosis or septic
PT shock.
XX Claim 12; SEQ ID NO 377; 658pp; English.
XX The invention relates to human PRO polypeptides and the polynucleotides
CC encoding them. The sequences are useful for inducing differentiation of
CC pancreatic beta-cell precursor cells into mature pancreatic beta-cells,
CC and thus for treating various insulin deficient states in mammals,
CC including diabetes mellitus. The sequences are also useful for treating
CC mammalian haemoglobin-associated disorders e.g., various thalassemias,
CC renal dysplasia, polycystic kidney disease and renal tumours. The
CC polypeptides are useful for tissue typing, as molecular weight markers
CC for protein electrophoresis purposes, as therapeutic agents and as
CC hybridisation probes for isolating PRO cDNA from a cDNA library. The
CC polynucleotides are useful in gene therapy, as chromosome identification
CC recombinantly expressing molecular weight markers, in chromosome and gene
CC mapping, in the generation of anti-sense RNA and DNA and in preparation
CC of PRO polypeptides by recombinant techniques. This sequence represents a
CC human PRO polypeptide of the invention. Note: The sequence data for this
CC patent is also available in electronic format from USPTO at
XX seqdata.uspto.gov/sequence.html.
XX SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTFPLSLLLLLVCAIWRNSGSGTLENGYFLSRNKENHSOPTOSSLEDSVTPPKAVKTT 60
Db 1 MTFPLSLLLLLVCAIWRNSGSGTLENGYFLSRNKENHSOPTOSSLEDSVTPPKAVKTT 60
Qy 61 KGKIVKGNLDSRGLILGAEAWGRGVKQNT 90
Db 61 KGKIVKGNLDSRGLILGAEAWGRGVKQNT 90
RESULT 167
ADD92608
ID ADD92608 standard; protein; 90 AA.
XX
AC ADD92608;
29-JAN-2004 (first entry)
Human PRO polypeptide #237.
Human; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
immune system cell infiltration.
XX Homo sapiens.
XX US2003199030-A1.
XX 23-OCT-2003.
XX 28-MAY-2002; 2002US-00156841.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
XX WPI: 2003-900159/82.
DR N-PSDB; ADD92607.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 12; SEQ ID NO 474; 636pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting the uptake of
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalasassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSQTSLSLDSVTPTKAVKTT 60

Db 1 MTFFLSLLLVCEAIWRNSGNTLENGYFLSRKNKHSQTSLSLDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDGRGLILGAENGGRVKKNT 90

Db 61 GKGIVKGRNLDGRGLILGAENGGRVKKNT 90

RESULT 168

ADD91504
ID ADD91504 standard; protein; 90 AA.

XX AC

XX ADD91504;

XX DT 29-JAN-2004 (first entry)

XX DE

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; r-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS

XX Homo sapiens.

XX PN US2003199055-A1.

XX PD 23-OCT-2003.

XX PF 12-APR-2002; 2002US-00121063.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018224.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US019437.

PR 29-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 29-OCT-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 98WO-US000106.

PR 08-MAR-1999; 98WO-US005028.

PR 10-MAR-1999; 98WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 98WO-US008615.

PR 14-MAY-1999; 98WO-US010733.

PR 02-JUN-1999; 98WO-US012252.

PR 01-SEP-1999; 98WO-US020111.

PR 08-SEP-1999; 98WO-US020594.

PR 13-SEP-1999; 98WO-US020944.

PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 22-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 03-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900165/82.
DR N-PSDB; ADD91503.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 12; SEQ ID NO 474; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for treating
CC the proliferation of inner ear utricular supporting cells and for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFEFLSLLLVCEAIWRNSGNTLNGYFFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
DB 1 MTFEFLSLLLVCEAIWRNSGNTLNGYFFLSRNKENHSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGIKGRNLDSEGLILGAFAWGRGVKQNT 90
DB 61 GKGIKGRNLDSEGLILGAFAWGRGVKQNT 90
RESULT 169
AD804118
ID ADE04118 standard; protein; 90 AA.
XX
AC ADE04118;
XX
DT 29-JAN-2004 (first entry)

XX DE
XX Human PRO polypeptide #237.
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX US2003199057-A1.
XX
XX 23-OCT-2003.
XX
XX 15-APR-2002; 2002US-00123213.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028403.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US005884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023532.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030932.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00736498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-900167/82.
 DR N-PSDB; ADE04117.
 XX
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 XX Claim 12; Fig 474; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear uricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRSNSGNTLENGYFLSRNKNHSGPTQSSLEDSVPTKAVKTT 60
 DB 1 MTFFLSLLLLVCEAIWRSNSGNTLENGYFLSRNKNHSGPTQSSLEDSVPTKAVKTT 60
 QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90
 DB 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90

RESULT 170

ADE26900

ID ADE26900 standard; protein; 90 AA.

XX ADE26900;

DT 29-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO1159.

XX human; secreted and transmembrane protein; PRO; neotropic;
 KW neuroprotective; antiparkinsonian; cytosolic; gene therapy;
 KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
 KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.

OS Homo sapiens.

XX US2003087304-A1.

XX 08-MAY-2003.

PF 15-NOV-2001; 2001US-00997333.

XX 16-JUN-1997; 97US-0049787P.

PR 17-OCT-1997; 97US-0062250P.

PR 05-NOV-1997; 97WO-US020069.

PR 12-NOV-1997; 97US-0065186P.

PR 13-NOV-1997; 97US-0065311P.

PR 24-NOV-1997; 97US-0066770P.

PR 25-FEB-1998; 98US-0075945P.

PR 20-MAR-1998; 98US-0078910P.

PR 28-APR-1998; 98US-0083322P.

PR 07-MAY-1998; 98US-0084600P.

XX	WPI; 2003-899784/82.
DR	N-PSDB; ADE32414.
XX	
PT	Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT	useful for treating pericyte-associated tumors, diabetes and various bone
PT	and/or cartilage disorders, e.g. arthritis.
XX	
PPS	Claim 12; SEQ ID NO 474; 636pp; English.
XX	
CC	The invention describes 305 nucleic acids encoding PRO (secreted and
CC	transmembrane) polypeptides (I). (I) is useful for stimulating the
CC	release of TNF-alpha from human blood, for modulating the uptake of
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating the proliferation or differentiation of chondrocyte cells,
CC	for stimulating the proliferation of or gene expression in pericyte
CC	cells, for stimulating the release of proteoglycans from cartilage, for
CC	stimulating the proliferation of inner ear utricular supporting cells,
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC	the release of a cytokine from PBMC cells, for inhibiting the binding of
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC	cells, for stimulating proliferation of endothelial cells, for detecting
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC	are useful for isolating genomic and cDNA nucleotide sequences or
CC	antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC	in assays to identify other proteins or molecules involved in binding
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC	and gene mapping, in generation of antisense RNA and DNA, in the
CC	preparation of PRO polypeptide, for generating transgenic animals or
CC	knockout animals which in turn are useful in the development and
CC	screening of therapeutically useful reagents, in gene therapy, for
CC	chromosome identification, as chromosome marker, and for generating
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC	detecting its expression in specific cells, tissues or serum, and for
CC	affinity purification of PRO from recombinant cell culture or natural
CC	sources. (I) and (II) are useful for tissue typing. This is the amino
CC	acid sequence of a novel human secreted and transmembrane PRO
XX	polypeptide.
SQ	Sequence 90 AA;
	Query Match 100.0%; Score 462; DB 7; Length 90;
	Best Local Similarity 100.0%; Pred. No. 9.8e-49;
	Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDVSVPFKAVKTT 60
Db	1 MTFFLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTOSSLEDVSVPFKAVKTT 60
QY	61 KGKIVGRNLDSRGLILGAEWGRGVKKNT 90
Db	61 KGKIVGRNLDSRGLILGAEWGRGVKKNT 90
RESULT 172	
ADE22347	ID ADE22347 standard; protein; 90 AA.
XX	ADE22347;
XX	29-JAN-2004 (first entry)
DT	
XX	Human PRO polypeptide #237.
DE	
XX	Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

[illegible]

KM rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

OS Homo sapiens.

PN US2003199056-A1.

XX 23-OCT-2003.

DD 15-APR-2002; 2002US-00123212.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022951.

XX 29-OCT-1998; 98WO-US022952.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 98WO-US00106.

XX 08-MAR-1999; 98WO-US005028.

XX 10-MAR-1999; 98WO-US005190.

XX 10-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 09-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00806689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00308827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-900166/82.

DR N-PSDB; ADE22346.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, and

XX useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

PT Claim 12; Fig 474; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFSLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFSLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 173

ADD79571

ID ADD79571 standard; protein; 90 AA.

AC ADD79571;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

OS

XX US2003203428-A1.

XX

XX 30-OCT-2003.

XX

XX 22-APR-2002; 2002US-00127852.

XX

XX 09-DEC-1999; 99US-0170262P.

XX

XX 01-DEC-2000; 2000WO-US032678.

XX

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX

XX WPI; 2003-875635/81.

XX

XX N-PSDB; ADD79570.

XX

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver

PT tumors.

XX

PS Claim 12; Fig 474; 637pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from

CC the USPTO website at seqdata.uspto.gov.

XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFSLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

Db 1 MTFSLSLLLLVCEAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPKAVKTT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

Db 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 174

ADE42107

ID ADE42107 standard; protein; 90 AA.

XX

AC ADE42107;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003194772-A1.

XX 16-OCT-2003.

XX 21-MAY-2002; 2002US-00152386.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-899788/82.

XX N-PSDB; ADE42106.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

XX Claim 12; Fig 474; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor- α (TNF- α) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems.
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90
DB 61 GKGVKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 175

ADE17924

ID ADE17924 standard; protein; 90 AA.

XX AC ADE17924;

XX 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX Homo sapiens.

XX US2003199023-A1.

XX 23-OCT-2003.

XX 17-APR-2002; 2002US-00124821.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019177.

XX 17-SEP-1998; 98WO-US019330.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 01-DEC-1998; 98WO-US024855.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005199.

XX 20-APR-1999; 2000WO-US006319.

XX 14-MAY-1999; 99WO-US008615.

XX 02-JUN-1999; 99WO-US010733.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 02-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028584.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806869.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX
PA (GETH) GENENTECH INC.
XX Baker KP, Bresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TX, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900155/82.
DR N-PSDB; ADE17923.
DR Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
PT

XX Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USFTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDNRGLILGAEAWGRGVKNT 90
RESULT 176
ADD92056
ID ADD92056 standard; protein; 90 AA.
XX
XX ADD92056;
XX AC
XX 29-JAN-2004 (first entry)
XX DE
XX Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX

OS	Homo sapiens.	
XX	US2003199053-A1.	
XX	23-OCT-2003.	
XX	12-APR-2002; 2002US-00121053.	
XX	31-MAR-1997; 97WO-US005230.	24-AUG-2000; 2000WO-US023328.
PR	12-JUN-1998; 98WO-US012456.	08-NOV-2000; 2000WO-US030952.
PR	14-JUL-1998; 98WO-US014552.	10-NOV-2000; 2000WO-US030873.
PR	28-AUG-1998; 98WO-US017888.	01-DEC-2000; 2000WO-US032678.
PR	10-SEP-1998; 98WO-US018824.	20-DEC-2000; 2000US-00747259.
PR	14-SEP-1998; 98WO-US019093.	20-DEC-2000; 2000WO-US034956.
PR	14-SEP-1998; 98WO-US019094.	PR 28-FEB-2001; 2001US-00796498.
PR	14-SEP-1998; 98WO-US019177.	PR 28-FEB-2001; 2001WO-US006520.
PR	16-SEP-1998; 98WO-US019330.	PR 01-MAR-2001; 2001US-00066666.
PR	17-SEP-1998; 98WO-US019437.	PR 09-MAR-2001; 2001US-00802706.
PR	07-OCT-1998; 98WO-US021141.	PR 14-MAR-2001; 2001US-00808689.
PR	29-OCT-1998; 98WO-US022991.	PR 22-MAR-2001; 2001US-00816744.
PR	29-OCT-1998; 98WO-US022992.	PR 05-APR-2001; 2001US-00828366.
PR	20-NOV-1998; 98WO-US024855.	PR 10-MAY-2001; 2001US-00854208.
PR	01-DEC-1998; 98WO-US025108.	PR 10-MAY-2001; 2001US-00854280.
PR	05-JAN-1999; 98WO-US005028.	PR 18-MAY-2001; 2001US-00860216.
PR	08-MAR-1999; 98WO-US005190.	PR 25-MAY-2001; 2001US-00866028.
PR	10-MAR-1999; 2000WO-US006319.	PR 25-MAY-2001; 2001US-00866034.
PR	20-APR-1999; 99WO-US010733.	PR 25-MAY-2001; 2001WO-US017092.
PR	14-MAY-1999; 99WO-US012252.	PR 01-JUN-2001; 2001US-00872035.
PR	02-JUN-1999; 99WO-US020111.	PR 01-JUN-2001; 2001WO-US017800.
PR	08-SEP-1999; 99WO-US020594.	PR 05-JUN-2001; 2001US-00874503.
PR	13-SEP-1999; 99WO-US020944.	PR 14-JUN-2001; 2001US-00882636.
PR	15-SEP-1999; 99WO-US021090.	PR 19-JUN-2001; 2001US-00886342.
PR	15-SEP-1999; 99WO-US021547.	PR 20-JUN-2001; 2001WO-US019692.
PR	05-OCT-1999; 99WO-US023089.	PR 21-JUN-2001; 2001US-00887879.
PR	29-NOV-1999; 99WO-US028214.	PR 22-JUN-2001; 2001WO-US020116.
PR	30-NOV-1999; 99WO-US028313.	PR 29-JUN-2001; 2001WO-US021066.
PR	30-NOV-1999; 99WO-US028409.	PR 09-JUL-2001; 2001WO-US021735.
PR	01-DEC-1999; 99WO-US028301.	PR 18-JUL-2001; 2001US-00308827.
PR	01-DEC-1999; 99WO-US028634.	PR 06-AUG-2001; 2001US-00324419.
PR	02-DEC-1999; 99WO-US028551.	PR 09-AUG-2001; 2001US-00927795.
PR	02-DEC-1999; 99WO-US028564.	PR 16-AUG-2001; 2001US-00931836.
PR	16-DEC-1999; 99WO-US028565.	PR 19-DEC-2001; 2001US-00028072.
PR	20-DEC-1999; 99WO-US030095.	XX
PR	20-DEC-1999; 99WO-US030911.	PA (GETH) GENENTECH INC.
PR	20-DEC-1999; 99WO-US030999.	XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PR	22-DEC-1999; 99WO-US030720.	PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PR	30-DEC-1999; 99WO-US031243.	PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PR	30-DEC-1999; 99WO-US031274.	XX WPI; 2003-900164/82.
PR	05-JAN-2000; 2000WO-US000219.	DR N-PSDB; ADD92055.
PR	06-JAN-2000; 2000WO-US000277.	XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, (secreted and
PR	06-JAN-2000; 2000WO-US000376.	CC transmembrane polypeptides) and the polynucleotides encoding them. The
PR	11-FEB-2000; 2000WO-US003565.	CC invention also relates to an antibody which specifically binds to a PRO
PR	18-FEB-2000; 2000WO-US004341.	CC polypeptide, a method for stimulating the release of tumour necrosis
PR	22-FEB-2000; 2000WO-US004342.	CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR	24-FEB-2000; 2000WO-US004914.	CC proliferation or differentiation of chondrocyte cells and a method for
PR	24-FEB-2000; 2000WO-US005004.	CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, The
PR	01-MAR-2000; 2000WO-US005601.	CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR	02-MAR-2000; 2000WO-US005746.	CC polynucleotides are useful in molecular biology, including uses as
PR	02-MAR-2000; 2000WO-US005841.	CC hybridisation probes, in chromosome and gene mapping, in generating
PR	15-MAR-2000; 2000WO-US006884.	CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR	20-MAR-2000; 2000WO-US007377.	CC generating either transgenic animals or knock-out animals which are
PR	21-MAR-2000; 2000WO-US007532.	CC useful in the development and screening of therapeutically useful
PR	30-MAR-2000; 2000WO-US014042.	CC reagents. The PRO polypeptides or antibodies are used in preparing a
PR	02-JUN-2000; 2000WO-US015264.	CC medicament for treating a condition responsive to the polypeptides or
PR	28-JUL-2000; 2000WO-US020710.	CC antibodies, such as tumours, for stimulating and inhibiting proliferation
PR	11-AUG-2000; 2000WO-US022031.	CC of human microvascular endothelial cells, for modulating the uptake of
PR	23-AUG-2000; 2000WO-US023522.	CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
		CC stimulating differentiation of adipocyte cells, for stimulating
		CC proliferation of or gene expression in pericyte cells, for stimulating
		CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
		CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USFTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 177
ADE33519
ID ADE33519 standard; protein; 90 AA.

XX AC ADE33519;
XX DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1159.
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.
XX PN US2003194767-A1.
XX PD 16-OCT-2003.
XX PF 16-MAY-2002; 2002US-00147497.
XX PR 26-AUG-1998; 98US-0097951P.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 25-AUG-1999; 99US-00380137.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899786/82.
XX DR N-ESDB; ADE33518.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.

PS Claim 12; SEQ ID NO 474; 636pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amiro
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFLLSLLLLVCEAIWRNSGNTLNGVFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90
Db 61 GKGVKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 178
ADE34071
ID ADE34071 standard; protein; 90 AA.

XX AC ADE34071;
XX DT 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1159.
XX Human; secreted and transmembrane protein; PRO;
XX Tumour necrosis factor alpha release; TNF-alpha release;
XX glucose uptake modulator; FFA uptake modulator;
XX cell proliferation stimulator; cell differentiation stimulator;
XX cell differentiation inhibitor; cytokine release stimulator; tumour;
XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003194791-A1.
XX PD 16-OCT-2003.
XX PF 11-APR-2002; 2002US-00121046.

XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 24-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX WPI: 2003-899790/82.
DR N-PSDB; ADE34070.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBM cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This is the amino acid sequence of a novel human secreted and transmembrane PRO polypeptide.
XX

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-875867/81.
DR N-PSDB; ADD80122.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
XX Claim 12; Fig 474; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 60
QY 61 GKGIKVRNLDRLGLIGAEAWGRGVKNT 90
Db 61 GKGIKVRNLDRLGLIGAEAWGRGVKNT 90
RESULT 180
ADD93160
ID ADD93160 standard; protein; 90 AA.
XX
XX ADD93160;
XX
XX 29-JAN-2004 (first entry)
DT
XX Human PRO polypeptide #377.
DE
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX US2003194768-A1.
PN
XX
XX 16-OCT-2003.
PD
XX
XX 21-MAY-2002; 2002US-00152371.
PF
XX
XX 03-MAR-2000; 2000US-0187202P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
PR
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-899787/82.
DR N-PSDB; ADD93159.
DR
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
PT
XX
XX Claim 12; SEQ ID NO 474; 636pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60
DB 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 181
ADE19580
ID ADE19580 standard; protein; 90 AA.
XX
AC ADE19580;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199025-A1.
XX
PD 23-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152385.
XX
PR 03-MAR-2000; 2000US-0187202P.
XX
PR 10-NOV-2000; 2000WO-US030873.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPT; 2003-900156/82.
DR N-PSDB; ADE19579.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
FS Claim 12; SEQ ID NO 474; 648pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
USPTO at seqdata.uspto.gov/sequence.html.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60
DB 1 MTFPLSLLLVCEAIWRNSGNTLENGYFLSRNKNHSQPTQSSLEDSVTPKAVKT 60

QY 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90
DB 61 GKGIKGRNLDRLGLILGAEAWGRGVKNT 90

RESULT 182
ADE19028
ID ADE19028 standard; protein; 90 AA.
XX
AC ADE19028;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199026-A1.
XX
PD 23-OCT-2003.
XX
PF 20-MAY-2002; 2002US-00152393.
XX
PR 03-MAR-2000; 2000US-0187202P.
XX
PR 01-DEC-2000; 2000WO-US032678.
XX
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900157/82.
DR N-PSDB; ADE19027.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFEFLSLILLVCEATWRNSGNTLNGYFYSRNKENHSQPTOSLSDSVPTPKAVKT 60
DB 1 MTFEFLSLILLVCEATWRNSGNTLNGYFYSRNKENHSQPTOSLSDSVPTPKAVKT 60
QY 61 GKGVKGRNLDKRLILGAEAWGRGVKNT 90
DB 61 GKGVKGRNLDKRLILGAEAWGRGVKNT 90
RESULT 183
AD843224
ID ADE43224 standard; protein; 90 AA.
XX
AC ADE43224;
DT 29-JAN-2004 (first entry)
XX Human PRO polypeptide #237.
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003199033-A1.
XX
PD 23-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156845.
XX
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900162/82.
DR N-PSDB; ADE43223.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 12; Fig 474; 636pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 90 AA;
SQ

	Query Match	100.0%; Score 462; DB 7; Length 90;	
	Best Local Similarity	100.0%; Pred. No. 9.8e-49;	
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 MTFFLSLLILLVCEAIWRSGNSTLNGYFLSRNKHNSOPTOSSLEDSVTPTKAVKIT	60	
Dd	1 MTFFLSLLILLVCEAIWRSGNSTLNGYFLSRNKHNSOPTOSSLEDSVTPTKAVKIT	60	
QY	61 KGKIVKGRLNDRGLILGAEWGRGVKKNT	90	
Dd	61 KGKIVKGRLNDRGLILGAEWGRGVKKNT	90	
RESULT 184			
ADD96013			
ID	ADD96013 standard; protein; 90 AA.		
XX AC			
AC	ADD96013;		
DT DT	29-JAN-2004 (first entry)		
XX DE	Human PRO polypeptide #237.		
KW KW	Human; PRO; secreted polypeptide; transmembrane polypeptide;		
KW KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW KW	liver; microvascular endothelial cell; glucose; FFA;		
KW KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW KW	immune system cell infiltration.		
XX OS	Homo sapiens.		
XX FN	US2003199059-A1.		
XX PD	23-OCT-2003.		
XX PF	15-APR-2002; 2002US-00123322.		
PR PR	31-MAR-1997; 97WO-US005230.		
PR PR	12-JUN-1998; 98WO-US012456.		
PR PR	14-JUL-1998; 98WO-US014552.		
PR PR	28-AUG-1998; 98WO-US017888.		
PR PR	10-SEP-1998; 98WO-US019824.		
PR PR	14-SEP-1998; 98WO-US019093.		
PR PR	14-SEP-1998; 98WO-US019094.		
PR PR	16-SEP-1998; 98WO-US019177.		
PR PR	17-SEP-1998; 98WO-US019330.		
PR PR	07-OCT-1998; 98WO-US021141.		
PR PR	29-OCT-1998; 98WO-US022392.		
PR PR	20-NOV-1998; 98WO-US022392.		
PR PR	01-DEC-1998; 98WO-US025108.		
PR PR	05-JAN-1999; 99WO-US000106.		
PR PR	08-MAR-1999; 99WO-US005028.		
PR PR	10-MAR-1999; 99WO-US005190.		
PR PR	10-MAR-1999; 2000WO-US006319.		
PR PR	20-APR-1999; 99WO-US008615.		
PR PR	14-MAY-1999; 99WO-US010733.		
PR PR	02-JUN-1999; 99WO-US012252.		
PR PR	01-SEP-1999; 99WO-US020111.		
PR PR	08-SEP-1999; 99WO-US020594.		
PR PR	13-SEP-1999; 99WO-US020944.		
PR PR	15-SEP-1999; 99WO-US021050.		
PR PR	05-OCT-1999; 99WO-US021547.		
PR PR	29-NOV-1999; 99WO-US028214.		
PR PR	30-NOV-1999; 99WO-US028313.		
PR PR	30-NOV-1999; 99WO-US028409.		
PR PR	(GETH) GENENTECH INC.		
PI PI	Baker KF, Beresini M, Defor		
PI PI	Gerritsen ME, Goddard A, Go		

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900168/82.
DR N-PSDB; ADD96012.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 12; Fig 474; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at segdata.uspto.gov/sequence.html.
XX
XX Sequence 90 AA;
SQ
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSILLLLVCEATWRNSGNTLENGVFLSRNKHNSQPTQSSLEDSVPTKAVKTT 60
Db 1 MTFFLSILLLLVCEATWRNSGNTLENGVFLSRNKHNSQPTQSSLEDSVPTKAVKTT 60
QY 61 GKGVKGRNLDRLGLILGAPAWGVKKNT 90
Db 61 GKGVKGRNLDRLGLILGAPAWGVKKNT 90
RESULT 185
ADE22899
ID ADE22899 standard; protein; 90 AA.
XX
XX ADE22899;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polypeptide #237.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW

KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX OS
XX US2003199064-A1.
XX 23-OCT-2003.
XX
XX 19-APR-2002; 2002US-00125932.
31-MAR-1997; 97WO-US005230.
12-JUN-1998; 98WO-US012456.
14-JUL-1998; 98WO-US014552.
28-AUG-1998; 98WO-US017888.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US0005028.
10-MAR-1999; 99WO-US0005190.
10-MAR-1999; 2000WO-US006319.
20-APR-1999; 99WO-US008615.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
01-SEP-1999; 99WO-US020111.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028409.
01-DEC-1999; 99WO-US028301.
01-DEC-1999; 99WO-US028634.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028584.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
24-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
02-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
20-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US008566.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
23-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-900169/82.
N-PSDB; ADE22898.
Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
Claim 12; Fig 474; 638pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLESVPTTKAVKT 60
Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLESVPTTKAVKT 60
QY 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
Db 61 GKGIKGRNLDGRGLILGAEAWGRGVKNT 90
RESULT 186
ADD79017
ID ADD79017 standard; protein; 90 AA.
XX
AC ADD79017;
XX
XX 29-JAN-2004 (first entry)
DT
XX
DE Human PRO polypeptide #237.
XX
XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003203429-A1.
XX
XX 30-OCT-2003.
XX
XX 22-APR-2002; 2002US-00127900.
PF
XX
XX 05-JUN-2000; 2000US-0209832P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
PR
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSLSDSVTPTRAVKTT 60
Dd 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKHNSQPTQSLSDSVTPTRAVKTT 60
QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90
Dd 61 GKGIVKGRNLDGRGLILGAEAWGRGVKKNT 90

RESULT 190
ADD80675
ID ADD80675 standard; protein; 90 AA.
XX
AC ADD80675;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003207418-A1.
XX
PD 06-NOV-2003.
XX
PF 07-MAY-2002; 2002US-00140809.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022591.
PR 20-NOV-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US024855.
PR 05-JAN-1999; 98WO-US025108.
PR 08-MAR-1999; 99WO-US000106.
PR 10-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030939.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019632.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 N-PSDB; ADD80674.
 WPI; 2003-875868/81.
 New PRO nucleic acid, useful for manufacturing a medicament for
 diagnosing or treating tumor, for chromosome mapping or for tissue
 typing.
 Claim 12; Fig 474; 638pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format from
 the USPTO website at seqdata.uspto.gov.
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Rest Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLEDSVTPKAVKTT 60
 |||||
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNENHSQPTQSSLEDSVTPKAVKTT 60
 |||||
 QY 61 GKGVKGRNLDLSGLILGAEAWGRGVKNT 90
 |||||
 Db 61 GKGVKGRNLDLSGLILGAEAWGRGVKNT 90
 |||||

RESULT 191

ADD89703
 ID ADD89703 standard; protein; 90 AA.
 XX
 AC ADD89703;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human PRO polypeptide #237.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003199028-A1.
 XX
 PD 23-OCT-2003.
 XX
 PF 22-MAY-2002; 2002US-00153552.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2003-900158/82.
 N-PSDB; ADD89702.
 DR
 DR Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 useful for treating pericyte-associated tumors, diabetes and various bone
 and/or cartilage disorders, e.g. arthritis.
 PT
 PS Claim 12; Fig 474; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.
 XX
 SQ Sequence 90 AA;

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;
Matches 90; Conservative 0; Mismatches 0;

QY 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 192
ADE40987
ID ADE40987 standard; protein; 90 AA.
XX
AC ADE40987;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199031-A1.
XX
PD 23-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156842.
XX
PP 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900160/82.
DR N-PSDB; ADE40986.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 12; Fig 474; 637pp; English.
PS
PS The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, biology, including uses as
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49; Indels 0; Gaps 0;
Matches 90; Conservative 0; Mismatches 0;

QY 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFLLSLLLVCFAIWRNSGSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

QY 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90
DB 61 GKGIVKGRNLDGRGLILGAEAWGRGVKNT 90

RESULT 193
ADE40786
ID ADE40786 standard; protein; 90 AA.
XX
AC ADE40786;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199034-A1.
XX
PD 23-OCT-2003.

XX PF 28-MAY-2001; 2001US-00156846.
 XX AC 03-MAR-2000; 2000US-0187202P.
 XX PR 01-DEC-2000; 2000WO-US032678.
 XX PR 19-DEC-2001; 2001US-00028072.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900163/82.
 DR N-PSDB; ADE04785.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 12; Fig 474; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 7; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFSLLLLLVCEATWRNSGNTLENGYFLSRNKNHNSQPTQSSLEDSVTTKAVKTT 60
 DB |||||
 DB 1 MTFSLLLLLVCEATWRNSGNTLENGYFLSRNKNHNSQPTQSSLEDSVTTKAVKTT 60
 QY 61 GKGVKGRNLDLSRGLILGAEWGRVKKNT 90
 DB |||||
 DB 61 GKGVKGRNLDLSRGLILGAEWGRVKKNT 90

RESULT 194
 ADC81211

ID XX ADC81211 standard; protein; 90 AA.
 AC XX ADC81211;
 DT 15-JAN-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO1159.
 DE XX
 XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
 KW cell differentiation; skeletal muscle cell; adipocyte cell;
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 XX Homo sapiens.
 OS XX
 XX US20030921115-A1.
 PN XX
 XX 15-MAY-2003.
 PD XX
 XX 30-MAY-2002; 2002US-00158785.
 PF XX
 XX 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-020238/02.
 DR N-PSDB; ADC81210.
 XX
 XX New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.
 XX Claim 12; Fig 474; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells, for
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries

CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFPLSLLLLVCAIRWSNNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60
Dbb 1 MTFPLSLLLLVCAIRWSNNGSNTLENGYFLSRNKENHSOPTQSSLEDSVTPKAVKTT 60
QY 61 KGKIVKGRNLDNRGLILGAEAWGRGVKKNT 90
Dbb 61 KGKIVKGRNLDNRGLILGAEAWGRGVKKNT 90

RESULT 195

ADD76659
ID ADD76659 standard; protein; 90 AA.
XX
XX AC ADD76659;
XX
XX DT 29-JAN-2004 (first entry)
XX
XX DE Human PRO polypeptide #237.
XX
XX KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; macrovascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX OS Homo sapiens.
XX
XX PN US2003100087-A1.
XX
XX PD 29-MAY-2003.
XX
XX PF 16-APR-2002; 2002US-00123912.
XX
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 08-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 20-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.

29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GENTH) GENENTECH INC.
 Human; PRO; secreted polypeptide; transmembrane polypeptide;
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; FFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 immune system cell infiltration.
 Homo sapiens.
 OS
 XX
 XX
 US2003092113-A1.
 15-MAY-2003.
 16-MAY-2002; 2002US-00147523.
 09-DEC-1999; 99US-0170262P.
 01-DEC-2000; 2000WO-US032678.
 19-DEC-2001; 2001US-00028072.
 (GENTH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2004-020237/02.
 N-PSDB; ADD88022.
 New secreted and transmembrane nucleic acids and polypeptides, designated
 as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 cancer, cancer injury, infertility, birth defects, premature aging, AIDS, or
 Claim 12; Fig 474; 637pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polypeptide of the invention. Note: The
 sequence data for this patent is also available in electronic format from
 USPTO at seqdata.uspto.gov/sequence.html.
 USPTO at seqdata.uspto.gov/sequence.html.
 Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 8; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLILLVCEAIWRNSGSSNTLENGYFLSRKKNHSQPTQSSLEDSTVPTKAVKTT 60
 DB 1 MTFPLSLILLVCEAIWRNSGSSNTLENGYFLSRKKNHSQPTQSSLEDSTVPTKAVKTT 60
 QY 61 GKGIKVGRLDGRGLILGAEMGRGVKKT 90
 DB 61 GKGIKVGRLDGRGLILGAEMGRGVKKT 90
 RESULT 196

RESULT 196

CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;
 Query Match 100.0%; Score 462; DB 8; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9.8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60
 Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60
 QY 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90
 Db 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

RESULT 197

ADD86427

ID ADD86427 standard; protein; 90 AA.

XX

XX AC ADD86427;

XX

XX DT 29-JAN-2004 (first entry)

XX

XX DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX OS

XX XX US2003203440-A1.

XX

XX PD 30-OCT-2003.

XX

XX PF 29-MAY-2002; 2002US-00157798.

XX

XX XX 05-JUN-2000; 2000US-0209832P.

XX

XX PR 01-DEC-2000; 2000WO-US032678.

XX

XX PR 19-DEC-2001; 2001US-00028072.

XX

XX PA (GETH) GENENTECH INC.

XX

XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

XX XX WPI; 2004-021363/02.

XX

XX DR N-PSDB; ADD86426.

XX

XX XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

XX

XX PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

XX

XX PT generating antisense RNA and DNA, and in gene therapy.

XX

XX PS Claim 12; Fig 474; 637pp; English.

XX

XX CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

Db 1 MTFPLSLLLLVCEAIWRNSGNTLENGYFLSRKNHNSQTSLSLEDSVTPTKAVKTT 60

QY 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

Db 61 KGKIVKGRNLDGRGLILGAEGAWGRGVKNT 90

RESULT 198

ADE75875

ID ADE75875 standard; protein; 90 AA.

XX

XX AC ADE75875;

XX

XX DT 29-JAN-2004 (first entry)

XX

XX DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX OS

XX XX US2003211571-A1.

XX

XX PN

PD 13-NOV-2003.
XX 20-MAY-2002; 2002US-00152405.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR WPI; 2004-051576/05.
DR N-PSDB; ADE75874.
XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding
PT it, for use in gene therapy, as diagnostic markers for the presence of a
PT disease condition, or as therapeutic targets for treating tumors,
PT diabetes, or arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFLLSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
Dd 1 MTFLLSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
QY 61 GKGVKGRNLDRLGLILGAPAWGRVKNT 90
Dd 61 GKGVKGRNLDRLGLILGAPAWGRVKNT 90

RESULT 199
ADE23451
ID ADE23451 standard; protein; 90 AA.
XX
AC ADE23451;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003092108-A1.
XX
XX 15-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131835.
XX
XX 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-020234/02.
DR N-PSDB; ADE23450.
DR
XX New secreted and transmembrane nucleic acids and polypeptides, designated
XX as PRO, useful for treating inflammation, organ failure, atherosclerosis,
XX cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.
XX
XX Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;
Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9,8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTFLLSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
Dd 1 MTFLLSLLLVCEAIWRNSGNTLNGYFLSRNKENHSQPTQSSLEDSVTPTKAVKIT 60
QY 61 GKGVKGRNLDRLGLILGAPAWGRVKNT 90
Dd 61 GKGVKGRNLDRLGLILGAPAWGRVKNT 90

CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90
DB 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90

RESULT 200
ADE24003
ID ADE24003 standard; protein; 90 AA.

XX ADE24003;

DT 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003092110-A1.

XX 15-MAY-2003.

XX 03-MAY-2002; 2002US-00137864.

XX 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-020235/02.

XX N-PSDB; ADE24002.

XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
XX cancer.

XX Claim 12; Fig 474; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90
DB 61 GKGIVKGRNLDNRGLILGAEAWGRGVKXNT 90

RESULT 201

ADE24646

ID ADE24646 standard; protein; 90 AA.

XX ADE24646;

DT 29-JAN-2004 (first entry)

XX Human PRO polypeptide #237.

XX Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003092111-A1.

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ

Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFLLSLLLLVCAIRWSNGSGSTLENGYFLSRKNKHSQPTQSSLEDSVTPTKAVKTT 60
DB 1 MTFLLSLLLLVCAIRWSNGSGSTLENGYFLSRKNKHSQPTQSSLEDSVTPTKAVKTT 60
QY 61 GKGIVKGRNLDNRGLILGAERAWGRGVKNT 90
DB 61 GKGIVKGRNLDNRGLILGAERAWGRGVKNT 90

RESULT 203

AD89337

ID AD89337 standard; protein; 90 AA.

XX

AC AD89337;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polypeptide #237.

XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003199062-A1.

XX

XX 23-OCT-2003.

XX

PF 17-APR-2002; 2002US-00124823.

XX

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-041360/04.
 DR N-PSDB; ADE89336.
 XX
 XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
 PT attack, various coagulation disorders, tumors.
 XX
 XX Claim 12; SEQ ID NO 474; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 90 AA;
 SQ
 Query Match 100.0%; Score 462; DB 8; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVPTKAVKTT 60
 Db 1 MTFFLSLLLLVCEAIWRNSGNTLENGYFLSRNKENHSQPTQSSLEDVPTKAVKTT 60
 QY 61 GKGIKGRNLDGRGLILGAEMGRGVKNT 90
 Db 61 GKGIKGRNLDGRGLILGAEMGRGVKNT 90

RESULT 204

ADE18476
 ID ADE18476 standard; protein; 90 AA.
 XX
 AC ADE18476;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human PRO polypeptide #237.
 XX
 KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003194794-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 17-APR-2002; 2002US-00125805.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 20-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 2000WO-US006319.
 PR 14-MAY-1999; 99WO-US008615.
 PR 02-JUN-1999; 99WO-US010733.
 PR 01-SEP-1999; 99WO-US012252.
 PR 08-SEP-1999; 99WO-US020111.
 PR 13-SEP-1999; 99WO-US020594.
 PR 15-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 05-OCT-1999; 99WO-US021547.
 PR 29-NOV-1999; 99WO-US023089.
 PR 30-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 02-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 20-DEC-1999; 99WO-US030095.
 PR 22-DEC-1999; 99WO-US030911.
 PR 22-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000277.
 06-JAN-2000; 2000WO-US000376.
 11-FEB-2000; 2000WO-US000356S.
 18-FEB-2000; 2000WO-US004341.
 18-FEB-2000; 2000WO-US004342.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US004914.
 01-MAR-2000; 2000WO-US005004.
 02-MAR-2000; 2000WO-US005601.
 02-MAR-2000; 2000WO-US005746.
 02-MAR-2000; 2000WO-US005841.
 15-MAR-2000; 2000WO-US006884.
 20-MAR-2000; 2000WO-US007377.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUL-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034956.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 WPI; 2004-021079/02.
 N-ESDB; ADE18475.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PRO4978, for use in molecular biology, chromosome and gene mapping, in
 generating antisense RNA and DNA, and in gene therapy.

Claim 12; SEQ ID NO 474; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
 Best Local Similarity 100.0%; Pred. No. 9,8e-49;
 Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHNSQPTQSSLEDSVTPKAVKTT 60
 DB 1 MTFELSLLLLVCEAIWFSNGSNTLENGYFLSRKNKHNSQPTQSSLEDSVTPKAVKTT 60
 QY 61 KGIVKGRNLDNRGLILGAEGWGRGVKNT 90
 DB 61 KGIVKGRNLDNRGLILGAEGWGRGVKNT 90

RESULT 205

ADE88785
 ID ADE88785 standard; protein; 90 AA.

XX AC ADE88785;

XX DT 29-JAN-2004 (first entry)

XX DE Human PRO polypeptide #237.

XX KW Human; PRO: secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

XX XX US2003199054-A1.
 PN

XX PD 23-OCT-2003.
XX PF 12-APR-2002; 2002US-00121054.
XX PF 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
XX PR 14-JUL-1998; 98WO-US014552.
XX PR 28-AUG-1998; 98WO-US014588.
XX PR 10-SEP-1998; 98WO-US018824.
XX PR 14-SEP-1998; 98WO-US019093.
XX PR 14-SEP-1998; 98WO-US019094.
XX PR 14-SEP-1998; 98WO-US019177.
XX PR 16-SEP-1998; 98WO-US019330.
XX PR 17-SEP-1998; 98WO-US019437.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 29-OCT-1998; 98WO-US022991.
XX PR 29-OCT-1998; 98WO-US022992.
XX PR 01-DEC-1998; 98WO-US024855.
XX PR 03-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 10-MAR-1999; 99WO-US006319.
XX PR 14-MAY-1999; 99WO-US008615.
XX PR 01-JUN-1999; 99WO-US010733.
XX PR 01-SEP-1999; 99WO-US012252.
XX PR 08-SEP-1999; 99WO-US020111.
XX PR 13-SEP-1999; 99WO-US020594.
XX PR 15-SEP-1999; 99WO-US021090.
XX PR 05-OCT-1999; 99WO-US021547.
XX PR 29-NOV-1999; 99WO-US023089.
XX PR 30-NOV-1999; 99WO-US028214.
XX PR 01-DEC-1999; 99WO-US028313.
XX PR 01-DEC-1999; 99WO-US028409.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 02-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 02-DEC-1999; 99WO-US028565.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.
XX PR 22-DEC-1999; 99WO-US030720.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 05-JAN-2000; 99WO-US031274.
XX PR 06-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 11-FEB-2000; 2000WO-US000376.
XX PR 18-FEB-2000; 2000WO-US003565.
XX PR 22-FEB-2000; 2000WO-US004344.
XX PR 24-FEB-2000; 2000WO-US004414.
XX PR 24-FEB-2000; 2000WO-US004914.
XX PR 01-MAR-2000; 2000WO-US005004.
XX PR 01-MAR-2000; 2000WO-US005601.
XX PR 02-MAR-2000; 2000WO-US005745.
XX PR 15-MAR-2000; 2000WO-US005841.
XX PR 20-MAR-2000; 2000WO-US006884.
XX PR 21-MAR-2000; 2000WO-US007377.
XX PR 30-MAR-2000; 2000WO-US008439.
XX PR 17-MAY-2000; 2000WO-US013705.
XX PR 22-MAY-2000; 2000WO-US014042.
XX PR 02-JUN-2000; 2000WO-US014941.
XX PR 28-JUL-2000; 2000WO-US015264.
XX PR 11-AUG-2000; 2000WO-US020710.
XX PR 21-AUG-2000; 2000WO-US022031.
XX PR 24-AUG-2000; 2000WO-US023522.
XX PR 08-NOV-2000; 2000WO-US030952.
XX PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-0076498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX XX

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2004-041356/04.
N-PSDB; ADE88784.

Novel secreted and transmembrane polypeptides, PRO useful for treating bone disorders, arthritis, heart attack, injuries, tumors, and stimulating release of TNF-alpha from human blood.

Claim 12; SEQ ID NO 474; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;

Best Local Similarity 100.0%; Pred. No. 9.8e-49;

Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTFEFLSLLLVCEAIWRSNSGNTLENGYFYSRNKENHSQPTQSLEDVPTKAVKTT 60

Db 1 MTFEFLSLLLVCEAIWRSNSGNTLENGYFYSRNKENHSQPTQSLEDVPTKAVKTT 60

QY 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

Db 61 GKGIVKGRNLDNRGLILGAEAWGRGVKNT 90

RESULT 206

AAU19838

ID AAU19838 standard; protein; 222 AA.

XX

AC AAU19838;

XX

DT 04-DEC-2001 (first entry)

XX

XX Human novel extracellular matrix protein, Seq ID No 488.

XX

Human; secreted extracellular matrix protein; immunomodulatory; Anti-HIV;
anemic; antirheumatic; antisclerotic; cardiac; vascular;
cerebroprotective; thrombolytic; antimicrobial; ophthalmic; cytostatic;
anti-alzheimers; immune/autoimmune disease; HIV infection; anaemia;
human immunodeficiency virus; rheumatoid arthritis; multiple sclerosis;
cancer; hyperproliferative disorder; breast neoplasia; melanoma;
Sézary syndrome; Gaucher's disease; neurological diseases;
Alzheimer's disease; Parkinson's disease; cardiovascular disorder;
cardiac arrest; tachycardia; angina; infection; corneal infections;
wound healing; immunogen; gene therapy; antisense; food additive.

XX Homo sapiens.

XX

XX WO200155368-A1.

XX

PD 02-AUG-2001.

XX

XX 17-JAN-2001; 2001WO-US001348.

XX

XX 31-JAN-2000; 2000US-0179065P.

XX

XX 04-FEB-2000; 2000US-0180628P.

XX

XX 24-FEB-2000; 2000US-0184664P.

XX

XX 02-MAR-2000; 2000US-0186350P.

XX

XX 16-MAR-2000; 2000US-0189874P.

XX

XX 17-MAR-2000; 2000US-0190076P.

XX

XX 18-APR-2000; 2000US-0198123P.

XX

XX 19-MAY-2000; 2000US-0205515P.

XX

XX 07-JUN-2000; 2000US-0209467P.

XX

XX 28-JUN-2000; 2000US-0214886P.

XX

XX 30-JUN-2000; 2000US-0215135P.

XX

XX 07-JUL-2000; 2000US-0216647P.

XX

XX 07-JUL-2000; 2000US-0216880P.

PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225575P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226688P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235835P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.

